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VII. ABSTRACT 
Recently, microarrays of synthetic long sense-oriented oligonucleotides were 
introduced as an alternative expression profiling platform with distinct advantages to 
both cDNA arrays and commercial arrays produced by in situ synthesis of multiple 
short oligonucleotides per gene. However, gene expression analysis using 
microarrays of long oligonucleotides is limited in that it requires substantial amounts 
of RNA. The objective of this thesis was to develop protocols that allow for the 
analysis of gene expression even in minimal samples. Two different approaches 
were taken, one that amplifies the RNA target material before hybridization and 
another that amplifies the signal generated on the array. Most existing target 
amplification protocols linearly amplify mRNA by cDNA synthesis and in vitro 
transcription. Since orientation of the product is antisense (aRNA), it is inapplicable 
for dye-labeling by reverse transcription and hybridization to sense-oriented 
oligonucleotide arrays. Here, a novel protocol (TAcKLE) is introduced in which a 
combination of two reverse and one forward transcription reactions followed by dye-
incorporation using the Klenow fragment of E. coli DNA polymerase I generates 
fluorescent antisense cDNA. This protocol provides high fidelity and up to 105-fold 
amplification, starting from 2 ng total RNA. The generated data are highly 
reproducible and maintain relative gene expression levels between samples.  
Signal amplification is another option if only minimal amounts of sample material are 
available. Therefore, a method was evaluated that uses on-chip rolling circle 
replication of circularized oligonucleotides for the amplified detection of gene 
expression profiles. This principle should allow for a faster and cheaper experimental 
procedure, circumventing sequence-dependent amplification bias. The preliminary 
results provide evidence for the method’s applicability, but further experiments are 
required to reduce the required amount of starting material and to define a stable 
protocol. 
As the TAcKLE protocol performed particularly well, it was subsequently applied to 
evaluate the utility of spotted oligonucleotide microarrays compared to a widely-used 
and accepted commercial reference platform. There are numerous ways to perform 
global transcriptional profiling, among which microarray technology has certainly 
gained a premier position. The comparison of gene expression measurements 
obtained with different array-based approaches is therefore of substantial interest in 
order to clarify whether inter-platform differences may conceal biologically significant 
information. To address this concern, global gene expression was analyzed in a set 
of clinical head and neck squamous cell carcinoma samples, using both spotted 
oligonucleotide microarrays made from a large collection of 70-mer probes and 
commercial arrays produced by in situ synthesis of sets of multiple 25-mer 
oligonucleotides per gene. Expression measurements were compared for 4,425 
genes represented on both platforms, which revealed strong correlations between 
the corresponding data sets and similar profiles of relative gene expression. 
In conclusion, combining the TAcKLE protocol with spotted oligonucleotide arrays is 
an attractive alternative for transcriptional profiling of limited source material, offering 
a high potential for gene expression analysis in a multitude of disease situations. 
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VIII. ZUSAMMENFASSUNG 
Microarrays bestehend aus langen, sense-orientierten Oligunukleotiden sind seit 
kurzem als eine Alternative zu cDNA-Arrays und Arrays kurzer, in-situ-hergestellter 
Oligonukleotide erhältlich, welche deutliche Vorteile zu beiden anderen Systemen 
aufweisen. Das Spektrum wissenschaftlicher Fragestellungen, das mit Hilfe dieser 
neuartigen Microarray-Technologie bearbeitet werden kann, ist allerdings limitiert 
durch die großen RNA-Mengen, die für die Experimente benötigt werden. Ziel dieser 
Arbeit war die Entwicklung von Methoden, die das Erstellen von Genexpressions-
profilen auch bei Fragestellungen mit limitierter RNA-Menge erlauben. Es wurden 
hierzu zweierlei Ansätze gewählt, nämlich einerseits die Amplifikation des Ausgangs-
materials, und andererseits die Verstärkung des Signals direkt auf dem Array. 
Etablierte Amplifikationsprotokolle schreiben die zu analysierende mRNA zunächst in 
cDNA um und amplifizieren sie anschließend durch in-vitro-Transkription. Sie 
produzieren so allerdings RNA in antisense-Orientierung, die nach reverser 
Transkription in fluoreszenzmarkierte, sense-orientierte cDNA nicht auf sense-
orientierte Oligonukleotid-Sonden hybridisiert werden kann. Im Rahmen dieser Arbeit 
wurde daher ein neuartiges Protokoll (TAcKLE) entwickelt, in welchem eine 
Kombination von zwei reversen Transkriptionen, einer nicht-reversen Transkription 
und einer Markierungsreaktion mittels Klenow-Fragment fluoreszenzmarkierte cDNA 
in antisense-Orientierung erzeugt.  
Die mit diesem Protokoll generierten Daten sind reproduzierbar und geben relative 
Expressionsniveaus wahrheitsgemäß wieder. Der maximale Amplifikationsfaktor liegt 
bei 105, bei einer minimalen Ausgangsmenge von lediglich 2 ng gesamt-RNA. 
Eine weitere Option bei limitiertem Untersuchungsmaterial ist die Verstärkung des 
Signals, welches auf dem Array generiert wird. Im Rahmen dieser Arbeit wurde eine 
Methode erarbeitet, bei der diese Signalamplifikation durch in-situ-Replikation 
zirkulärer Oligonukleotide (rolling circle replication) auf dem Array erzielt wird. Dieses 
Prinzip ermöglicht eine schnellere und billigere Durchführung der Experimente und 
vermeidet sequenzbedingte Verzerrungen der Ergebnisse. Weiterführende Experi-
mente sind allerdings notwendig, um den Amplifikationsfaktor zu erhöhen und ein 
stabiles Protokoll zu etablieren.  
Da mit dem TAcKLE-Protokoll besonders gute Ergebnisse erzielt worden waren, 
wurde es im Anschluss verwendet, um die Nützlichkeit und Leistungsfähigkeit selbst 
hergestellter Oligonukleotid-Microarrays im Vergleich zu einem etablierten, 
kommerziellen System zu untersuchen. Es gibt verschiedenste Methoden für eine 
globale Expressionsanalyse, unter welchen die Microarray-Technologie sicherlich am 
häufigsten zum Einsatz kommt. Der Vergleich von Expressionsprofilen, die mit 
unterschiedlichen Varianten dieser Methodik erstellt wurden, sollte klären, ob 
plattformspezifische Unterschiede biologische Daten überlagern können. Es wurden 
diesbezüglich die Genexpressionsprofile von sechs HNSCC-Tumoren bestimmt, und 
zwar sowohl mittels selbst produzierter 70-mer Oligonukleotid-Microarrays, die pro 
Gen nur ein Sondenmolekül verwenden, als auch über kommerzielle, durch in-situ-
Synthese hergestellte Arrays, auf denen pro Gen mehrere 25-mer-Oligonukleotide 
aufgebracht sind. Die Expressionsdaten wurden verglichen für insgesamt 4.425 
Gene, die auf beiden Plattformen vertreten waren. Die Korrelationen unter den 
Datensätzen waren sehr gut, und es wurden mit beiden Ansätzen sehr ähnliche 
Genexpressionsprofile erhalten.  
Die Kombination aus TAcKLE-Protokoll und selbst produzierten 70-mer-Arrays ist 
somit eine attraktive Alternative für die Expressionsanalyse von limitiertem 
Probenmaterial, deren hohes Potential für die wissenschaftliche Untersuchung bei 
einer Vielzahl von Erkrankungen Verwendung finden kann. 
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1 Introduction 
 
The beginning is half the whole. 
ARISTOTELES 
 
The completion of the Human Genome Project (HGP) in April 2003 1-4 was a 
landmark event, making the genomic era a reality. Notably, the human genome 
seems to encode only 20,000 - 25,000 protein-coding genes, but the exact number is 
still a matter of investigation, as is the function of the majority of genes. Functional 
analysis of these genes is a scientific and technical challenge which requires the use 
of novel high-throughput methods. 
 
DNA microarray technology is a powerful approach for the parallel expression 
analysis of thousands of genes. It provides a comprehensive and accurate snapshot 
of gene expression in the analyzed samples and gave rise to the term and concept of 
the “transcriptome”, which denotes the entirety of transcripts present in a given 
sample at a given time. On average, a cell uses only about 5% of its genes at the 
same time, whereas the remaining 95% are repressed at the transcriptional or, less 
commonly, at the translational level 5. Transcriptome analysis by means of 
expression profiling on DNA microarrays can therefore provide an image of a cell’s 
differentiation state, its function and its phenotype. This can help to clarify a multitude 
of biological and medical questions, including cellular functions, biochemical reaction 
cascades or regulatory mechanisms.  
 
Many human diseases associate with abnormal changes in gene expression. 
Expression analysis of diseased cells or tissues can reveal pathomechanisms, open 
up new concepts for therapy, improve diagnosis and substantiate prognosis. 
Profound genetic reprogramming can, e.g., be found in cancer, which is responsible 
for one in eight cases of death worldwide 6.  
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1.1 Cancer Statistics 
 
Cancer is the second most frequent cause of death worldwide (12.6%) and is only 
exceeded by circulatory diseases 6. More people dye of cancer than of AIDS, malaria 
and tuberculosis taken together. On average, worldwide, there is about a 10% 
chance of getting a cancer before the age of 65 7. There were an estimated 10.1 
million new cases (incidence), 6.2 million deaths (mortality) (Fig. 1) and 22.4 million 
persons living with cancer (prevalence) in the year 2000 7. No attempt has been 
made to estimate the incidence or mortality of non-melanoma skin cancer due to the 
lack of reliable data, and these tumors are therefore excluded from average 
calculations.  
The estimate of the global cancer burden for the year 2000 7 presents an increase of 
around 22% in incidence and mortality since the previous comprehensive estimate 
for 1990; the prospected incidence for the year 2020 is 15.7 million new cases, which 
would mean an increase of 50% compared to the year 2000. This can in part be 
explained by an increased overall life expectancy and the constantly growing world 
population. 
 
 
 
 
Figure 1. Global cancer mortality 2000. The color coding indicates the respective percentage of cancer-related 
cases of death in the year 2000. In addition, the absolute numbers of deaths are given as totals for major regions of 
the world. The data were gathered from the Globocan 2000 database of the International Agency for Research on 
Cancer (IARC), which is part of the World Health Organization (WHO). The figure was originally taken and 
modified from the website of the Deutsche Krebshilfe e.V. (http://www.krebshilfe.de).  
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Lung cancer is the main cancer in the world today, both in terms of numbers of cases 
(1.2 million) or deaths (1.1 million), because of the high case fatality (ratio of 
mortality / incidence = 0.9) (Fig. 2). However, breast cancer, although it is the second 
most common cancer overall (1.05 million new cases) ranks much lower as the 5th 
most common cause of death by cancer because of the relatively favorable prognosis 
(ratio of mortality / incidence = 0.4). In terms of prevalence (the proportion of a 
population that has a disease at a given point in time; for cancer, the most common 
specification is 5-year prevalence, which denotes those cases neither dead nor 
considered cured until 5 years after the initial diagnosis), the most frequent cancers 
are breast (3.9 million cases), colorectal cancers (2.4 million) and prostate 
(1.6 million) 7.  
 
 
 
Figure 2. Global age-standardized incidence and mortality rates for the most frequent types of cancer in the year 
2002. The data were extracted online from the Globocan 2002 database at the CancerMondial website 
(http://www-dep.iarc.fr/) of the IARC. Regional statistics may exhibit considerable deviations from this 
generalized compilation. There is an increased incidence of breast and colorectal cancers in more developed 
countries as compared to less developed countries, whereas the latter have higher rates for liver, stomach and 
cervical cancers, partly due to the elevated risk of infections. 
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Statistics on German cancer mortality in the year 2000 (Fig. 3) confirm that primarily 
senior citizens are affected (Fig. 3A), the average age at diagnosis being 65-67 years. 
But whereas the worldwide summarized mortality rate increased considerably during 
the decade 1990-2000 7, the German rate revealed a downward-trend (Fig. 3B). 
Looking more closely at various common types of cancer, one can find that the 
prospects improved clearly for stomach cancer or male lung cancer, remained almost 
unchanged for malignancies of the female breast or the prostate, and regrettably 
worsened for female lung cancer (Fig. 3C). The latter can probably be explained by 
changes in female smoking habits (more and more women are smokers). 
Considering all these numbers and the suffering of people that they represent, it is 
one of the most urgent objectives of biomedical research to gain a detailed 
understanding of the causes and the processes involved in carcinogenesis and to use 
these insights to develop new concepts for an effective therapy. 
 
 
 
Figure 3. German cancer mortality statistics for the year 2000. (A) Age-specific mortality rates for men and 
women, averaged over “all cancers” excluding non-melanoma skin cancer. (B) Trends of age-standardized 
mortality rates for “all cancers” excluding non-melanoma skin cancer (C) Trends of age-standardized mortality 
rates for various common types of cancer. Source: CancerMondial / IARC (http://www-dep.iarc.fr/). 
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1.2 The Human Genome 
 
Many human diseases have a causal connection to changes in the genetic 
constitution and may therefore be seen as diseases of the genome. But whereas 
classical hereditary diseases trace back to mutational events in germ line cells of the 
parental generation (or earlier), thereby affecting all somatic cells of their offspring, 
cancer is caused by the accumulation of genetic changes in a single somatic cell, 
which collectively promote its clonal expansion. 
The human genome (entirety of genetic information) consists of nuclear as well as 
mitochondrial DNA. The nuclear genome contains more than 99.99% of the total 
genetic information, most of which specifies protein synthesis on cytoplasmic 
ribosomes. Nuclear DNA is arranged in 46 chromosomes representing 23 pairs of 
chromosomes. This condition is called a diploid set of chromosomes and consists of 
a haploid set from each parent, each comprising 22 autosomes as well as one 
gonosome. The haploid human genome spans approximately 3.08 x 109 bp, the 
euchromatic portion being 2.88 x 109 bp in length 8.  
It is currently estimated that approximately 20,000 - 25,000 genes exist in the human 
genome 8,9, but this number has been a source of continued controversy with other 
estimates reaching as high as 120,000 genes 10, which is almost certainly much too 
high 11-16. Of the estimated genes, 42% have an unknown function. The average size 
of a human gene is around 27,000 bp, with typical ranges between 20,000 and 
50,000 bp. However, only about 1,300 bp are required to encode an average-sized 
human protein of approx. 430 amino acids 17. The vast majority of protein-coding 
genes from higher eukaryotes consist of both protein-coding sequences (exons) and 
sequences that do not code for protein (introns). The transcripts of these genes are 
called pre-mRNA (precursor-mRNA), from which the intervening intron sequences 
are removed in a process termed splicing. After some further processing (capping 
and tailing), mature mRNA exits the nucleus and is translated in the cytoplasm. The 
average number of exons in human genes ranges between 8 - 9. The average size of 
an exon is around 150 nucleotides, whereas introns average approx. 3,500 
nucleotides and can be as much as 100 times larger 17,18. 
Coding regions in the human genome are estimated to account for only around 3% of 
the total DNA sequence, intronic sequences together with pseudogenes 
(nonfunctional homologues of functional genes) and gene fragments contribute 
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~22%, and intergenic regions account for the remaining ~75% 19. The proportion of 
non-coding DNA in humans is particularly striking when compared to other metazoan 
eukaryotes. For example, the human genome is 30 x larger than the genomes of 
Caenorhabditis elegans (nematode, roundworm) 20 and Drosophila melanogaster 
(fruit fly) 21, but has only ~2 - 3x as many genes. Sequence repeats (interspersed 
repetitive DNA, i.e., SINEs, LINEs; tandemly repeated DNA, i.e., megasatellite DNA, 
satellite DNA, ministatellite DNA, microsatellite DNA) are another very prominent 
feature of the human genome 19. 35% of the entire human genome (including coding 
regions) is classified as repetitive, compared to only 10% in Arabidopsis thaliana 
(wall cress) 22. If exclusively non-coding regions are considered, the proportion of 
repetitive DNA climbs to 46% 19. 
Another important feature of the human (and other mammalian) genomes are CpG 
islands. The cytosines of most CpG dinucleotides in the human genome are 
methylated. However, methyl-cytosine frequently mutates to thymine via 
deamination 23 (whereas deamination of cytosine gives rise to uracil, which is easily 
recognized as foreign within the DNA strand and replaced), and so CpG 
dinucleotides tend to decay to TpG / CpA. This is why CpG dinucleotides are vastly 
underrepresented genome-wide compared to what would be expected by chance 
(five times less frequently). A CpG island is a region of DNA that has a higher relative 
proportion of CpG dinucleotides when compared to the entire genome, in which the 
predominant absence of methylation slows CpG decay. About 56% of human genes 
are associated with CpG islands 24. CpG island methylation correlates with gene 
inactivation during gene imprinting 25, X-chromosome inactivation 26 and tissue 
specific gene expression 27. The methyl group displaces transcription factors that 
normally bind to the DNA; and it attracts methyl-binding proteins, which in turn are 
associated with gene silencing and chromatin compaction, probably through 
interactions with complexes that modify the tails of histone proteins 28. Histone 
proteins form octamers around which the DNA helix loops to form the nucleosome, 
the individual packaging unit of genomic DNA. The histone tails that extrude from the 
nucleosomes can be modified by methylation 29, acetylation 30, phosphorylation 31 or 
ubiquitylation 32 at different sites, creating potential combinations that have been 
referred to as the ‘histone code’ 33 in which gene regulatory information is encrypted. 
Cell-type-specific cytosine methylation and histone-tail modifications could contribute 
to the differences in gene expression patterns between cell types. 
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1.3 Genetic Aberrations of Cancer Cells 
 
The formation of cancer is a consequence of genetic changes in somatic cells with a 
capability for cell division. However, not every mutation results in carcinogenesis, as 
very special kinds of genes have to be affected. Their gene products are generally 
involved in the cellular maintenance or repair machinery, or they fulfill key functions in 
control and/or regulatory mechanisms, which in normal cells modulate the rate of 
growth, proliferation and apoptosis according to the needs of the organism. The 
German Biologist Theodor Boveri was among first to realize the connection between 
cancer and genetic aberrations. Working on the fertilization of sea-urchin eggs by two 
sperms instead of one, he discovered that distribution of unequal numbers of 
chromosomes to the daughter cells results in specific characteristics that depend on 
the random combinations of inherited chromosomes. Whereas some daughter cells 
survive but develop abnormally, others have a genetic imbalance that is too severe 
for survival. Boveri concluded that individual chromosomes carry different 
information 34-36, and he suggested that tumors might likewise arise as a 
consequence of particular, incorrect chromosome combinations 37. Boveri even 
postulated the existence of ‘growth stimulatory’ as well as ‘growth inhibitory 
chromosomes’, and he attributed the unlimited proliferation of tumor cells to an 
increase in the number of growth-promoting and/or to a physical removal of the 
growth-inhibiting chromosomes. The concept that cancer originates from defects in 
particular genes was originally proposed by Fritz Anders in 1967 and deduced from 
his work with breed hybrids of the fish Platypoecilus maculatus (southern platyfish) 
and Xiphophorus helleri (swordtail) from the genus Xiphophorus 38. He showed that 
the occurrence and the degree of the so-called Gordon-Kosswig melanoma is 
cooperatively controlled by a set of two genes, one with a tumor-promoting and the 
other with a tumor-suppressing effect.  
 
1.3.1 Oncogenes 
In 1976, Harold Varmus and Mike Bishop discovered that normal cells contain genes 
that are related to the transforming genes of RNA tumor viruses (retroviruses) 39. 
They showed that some of these retroviruses had captured and modified cellular 
genes that, when expressed at high level or in mutant form in normal cells, confer a 
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tumor phenotype of rapid, uncontrolled growth 40. The group of Robert Weinberg 
could demonstrate that these cellular proto-oncogenes are activated in the DNA of 
chemically transformed cells. They transfected mouse fibroblasts with genomic DNA 
of these cells and, through this, were able to transfer the altered phenotype 41. 
Therefore, oncogenes are defined as genes with products capable of transforming 
cells in culture 42-44 or inducing cancer in an organism 45. Most oncogenes actually 
trace back to genes which, in normal cells, fulfill key functions in the regulatory 
networks controlling and promoting proliferation. They may also be involved in the 
repression of apoptosis. In normal cells, proto-oncogenes can become deregulated, 
amplified or overexpressed and contribute to malignancy. This activation of a proto-
oncogene, which is the conversion to its corresponding oncogene, is usually caused 
by a gain of function mutation triggered by one of several possible events. Point 
mutations within the proto-oncogene may generate a constitutively active protein 
product, which is insensitive to cellular control and promotes proliferation even 
without prior induction. Alternatively, the amplification of a DNA segment harboring a 
proto-oncogene may result in an over-expression of the corresponding protein and 
thereby cause an unwanted stimulation of proliferation. Another mechanism of 
activation is chromosomal translocation that, e.g., puts the proto-oncogene under 
control of a strong promoter or enhancer, once more resulting in an inadequate level 
of gene expression. Independent of its underlying mechanism, a gain of function 
mutation is always dominant, meaning that a mutation in one allele is sufficient to 
promote carcinogenesis.  
Prominent examples for oncogenes are MYC, RAS and ABL 46. ABL, for instance, is 
a non-receptor tyrosine kinase that transduces signals from cell-surface growth 
factors and adhesion receptors. ABL can shuttle between the nucleus and the 
cytoplasm of cells and interacts with a large variety of proteins, including signaling 
adaptors, kinases, phosphatases, cell-cycle regulators, transcription factors and even 
components of the cytoskeleton, affecting cellular processes including the regulation 
of cell growth and survival, the response to oxidative stress and DNA damage as well 
as cell migration 47. In chronic myelogenous leukemia (CML), the hallmark genetic 
abnormality is the reciprocal translocation t(9;22)(q34;q11) 48, which results in an 
abnormal, small chromosome, called the ‘Philadelphia chromosome’ 49, and 
generates the BCR-ABL fusion gene. BCR is also a signaling protein, which contains 
multiple modular domains. The fusion of BCR sequences to ABL 50 during the CML-
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specific translocation increases the tyrosine-kinase activity of ABL and even appends 
additional regulatory domains, contributing to the neoplastic transformation of cells in 
the pathogenesis of CML 49,51. 
 
1.3.2 Tumor Suppressor Genes 
Tumor suppressor genes encode proteins which, in contrast to oncogenes, play 
important roles in the inhibition of cellular proliferation, e.g., as regulators of the cell 
cycle, receptors for anti-proliferatory hormones etc. They may also be involved in 
apoptosis induction or cellular adhesion. A single copy of the gene is usually 
sufficient to maintain its proper function. To promote the formation of a tumor, both 
alleles have to get lost by mutations or become inactivated, e.g., via the methylation 
of promoter-associated CpG islands 52, eliminating the generation of functional tumor 
suppressor (loss of function mutation). This principle was originally formulated in 
Alfred Knudson’s ‘two hit’ hypothesis 53, which implies that cancer predisposition can 
result from an inherited mutation in a tumor suppressor gene, but that the 
development of a tumor requires additional somatic alterations that result in the loss 
of the wild-type allele. Still, only a small fraction of all cancers , 0.1-10%, depending 
on the cancer type, are estimated to occur in patients with an inherited mutation 54. 
The prototype tumor suppressor gene is RB, the retinoblastoma-susceptibility gene 
discovered by Robert Weinberg and co-workers 55. Germline mutation in the RB gene 
causes the highly penetrant hereditary retinoblastoma, which results from the bi-
allelic loss of RB in embryonic retinoblasts 56. Consistent with its tumor-suppressor 
function, RB inhibits cell growth and proliferation by blocking cell-cycle progression at 
the G1/S boundary. This is mediated through the interaction of RB with the E2F 
family of transcription factors 57 as well as the recruitment of chromatin-modifying 
enzymes 57-59, resulting in the repression of genes that are required for DNA 
synthesis 57. Subsequent to the identification of RB as the retinoblastoma gene, 
FAP 60 and BRCA1 61were discovered as the primary factors conferring susceptibility 
to hereditary colon cancer (familial adenomatous polyposis) or ovarian and breast 
cancer, respectively. 
A very special example for a tumor suppressor gene is TP53, which is one of the 
most commonly mutated genes in human cancer. The protein p53 was first identified 
in a complex with SV40 T antigen, an oncogenic protein produced by a DNA tumor 
virus (adenovirus SV40) 62. This is why TP53 was initially assumed to act as an 
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oncogene. It was then shown that adenoviral oncoproteins act through the binding 
and concomitant inactivation of cellular tumor suppressor proteins 63, and that TP53 
maps to a chromosomal region that was consistently deleted or inactivated in 
colorectal carcinomas 64-66. This clearly demonstrated the role of p53 as a tumor 
suppressor. p53 acts primarily as a transcription factor and can mediate different 
downstream functions by activating or repressing a large number of target genes 67,68, 
and mutations generally affect amino acids within the DNA-binding domain 69,70. In 
addition to its role in transcriptional regulation, p53 is even involved in the 
(transcriptionally independent) regulation of apoptosis, genome integrity, DNA repair 
and DNA recombination 71.  
 
1.3.3 ‘Mutator Genes’ 
The majority of human cancers show signs of a dramatically enhanced mutation rate. 
The cells are said to be genetically unstable 72. In 1976, Lawrence Loeb and 
colleagues postulated the existence of ‘mutator genes’, which increase the rate of 
mutation within tumor cells when they themselves are mutated 73. This concept 
proved to be true when the mismatch repair gene MSH2 was identified as a 
susceptibility gene for hereditary non-polyposis colon cancer (HNPCC) 74. Loss of 
function of MSH2 leads to microsatellite instability, notable as frequent point 
mutations, insertions and deletions affecting mono- and dinucleotides repeats. More 
recently, genome-wide hypomethylation was discovered as a reason for 
chromosomal instability 75. Generally speaking, ‘mutator genes’ are involved in the 
repair of local DNA damage, the correction of replication errors or the maintenance of 
chromosomal and genome integrity. Analogous to tumor suppressor genes, a single 
copy of a ‘mutator gene’ is usually sufficient to maintain its proper function. If both 
alleles are lost, the affected cells adopt a ‘mutator phenotype’ 72,76 that drives further 
mutations in oncogenes and tumor suppressor genes and, thereby, provides a 
selective growth advantage 77. 
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1.4 Multistage Carcinogenesis 
Tumors can be defined as diseases in which a single cell acquires the ability for 
abnormal proliferation. Cancers are those tumors that have additionally gained the 
ability to invade through surrounding normal tissues. If the cancer cells can finally 
break away from their original location, penetrate into lymphatic and blood vessels, 
circulate through the bloodstream, and grow in a distant focus, the state of 
metastasis has been reached. 
Despite the existence of many forms of cancer and global changes in gene 
expression observed in many of them, a relatively small number of essential 
alterations, affecting few essential pathways, seems to be shared by most, if not all 
tumors 78. Tumorigenesis is generally thought to be a multi-step process, in which 
genetic events that activate oncogenes or inactivate tumor suppressor genes are 
sequentially acquired, and whereby each genetic change confers a proliferative 
advantage 79. Each event is thought to contribute specific malignant features, such as 
cell-autonomous proliferation, cellular immortalization, induction of angiogenesis, 
blocked differentiation, genomic destabilization or metastasis, and the accumulation 
of these genetic events is thought to be responsible for the neoplastic phenotype of a 
tumor. In human solid tumors, at least four to six mutations are required to reach this 
state 80. Liquid tumors, i.e., leukemias and lymphomas, can even evolve from a 
smaller number of mutations 54. It is statistically most unlikely, though, that a cell 
acquires even this relatively small number of mutations merely by random 
(stochastic) genotoxic events (e.g., chemicals, radiation, viruses, DNA replication 
errors, oxidative DNA damage, deamination). Therefore, it is believed that a ‘mutator 
phenotype’ (see 1.3.3) has to be induced at an early stage or even the first stage of 
carcinogenesis (initiation step), which subsequently induces genetic changes at 
much higher frequencies 72,77.  
Today, human colorectal cancer is the most intensively studied example of this 
principle 80. Taking “snap-shots” of the genetic aberrations coinciding with its 
successive pathological stages of tumor progression, researchers found convincing 
evidence for what is also referred to as ‘multistage carcinogenesis’, whereby 
malignant neoplasias are a consequence of multiple genetic defects which 
successively accumulate over time in a self-accelerating process 81. 
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1.5 Microarray Technology in Cancer Research 
 
In order to further extend our knowledge on the molecular principles of cancer, we 
have to identify the genes that are frequently affected by mutations (oncogenes, 
tumor suppressor genes) as well as those that become deregulated as a 
consequence. This helps to reveal underlying regulatory pathways and, ultimately, 
provides an informative basis regarding the search for new drug targets. Ideally, this 
search should be performed using multiplexed assays on the level of proteins, as 
proteins are both the endpoint of gene expression and the usual target of drugs. 
However, it is challenging to define conditions that are equally suitable for a large 
number of different proteins, both in terms of solubility, stability as well as capture 
molecule (e.g., antibody) cross-reactivity and availability. Consequently, multiplexed 
proteome analysis is still in its infancy 82. Nucleic acid molecules, on the other hand, 
bind tightly and specifically to complementary sequences, they are much more 
uniform in terms of biophysical properties and can easily be produced in bulk 
amounts using standard methods. Transcriptome analysis (gene expression analysis 
on the level of RNA) is therefore much less of a challenge. 
Within the past years, many powerful methods for the detection and quantification of 
gene expression were developed, including Northern Blotting 83, analysis of S1 
endonuclease-digested hybrids 84, Differential Display 85, large scale cDNA 
sequencing 86,87 and Serial Analysis of Gene Expression (SAGE)  88. Additionally, 
there are two array-based approaches, namely, cDNA 89-91 and oligonucleotide 
microarrays 92-94. 
The latter methods provide the valuable potential for multiplexing, which means that 
many thousand genes can be expression-monitored in parallel within a single 
experiment. This allows for the generation of both static (which tissues express a 
certain gene, which genes are expressed in a certain tissue; spatial expression 
patterns) and dynamic (what is the chronological expression pattern of a certain gene 
compared to other genes) expression profiles. In this thesis, the nucleic acid 
molecules to be detected and quantified are referred to as ‘targets’, whereas those 
molecules that contain target-complementary sequences to allow for the identification 
of specific targets in a large pool via the formation of detectable hybrids are denoted 
as ‘probes’. 
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Like many other biomolecular techniques, microarrays use the principle of 
hybridization, which is based on the mutual affinity of complementary nucleic acid 
strands. But whereas most of the established hybridization-based techniques make 
use of a single or few labeled oligonucleotide or polynucleotide probes in solution, in 
combination with complex mixture of polynucleotide targets immobilized on a solid 
support, microarrays employ a different strategy to allow for multiplexed target 
detection. In Northern Blotting, an RNA pool is separated by electrophoresis and 
transferred to a nitrocellulose membrane. Selected gene transcripts (targets) are 
subsequently detected by hybridization of radioactively labeled complementary 
probes. Parallel analysis of different transcripts within the same experiment is 
difficult, unless the transcript lengths are both known and differ sufficiently to allow for 
electrophoretic separation. Even so, only small numbers of targets can be analyzed 
in parallel.  
Microarrays, on the other hand, bypass this limitation by using large numbers of 
gene- or transcript-specific oligonucleotide or polynucleotide probes attached in close 
proximity and marginal amounts but at defined positions on a solid support (small 
arrays of probes, hence microarrays), which is either a membrane, coated glass or 
silicon. Labeled cDNA or cRNA targets corresponding to complete transcriptomes are 
hybridized to the arrays, allowing for a localized, fluorescence-based detection of 
gene-specific signals. The ratios of fluorescence intensities from different 
transcriptomes (extracted from, e.g., cancer tissue and corresponding healthy tissue), 
which can either be obtained by competitive hybridization using two distinguishable 
labels or by comparing the results from two individual array hybridizations, represent 
the relative expression of the assayed genes relating to the analyzed cells or tissues.  
Different methods were established for the production of gene- or transcript-specific 
array probes. PCR-amplification of cDNA libraries can be used to generate gene-
specific amplicons usually ranging from several hundred to a few thousand basepairs 
in size 89. As an alternative, several commercial suppliers offer large collections of 50-
80-mer oligonucleotides synthesized by phosphoramidite chemistry 94. In both cases, 
the DNA probes are dissolved in an appropriate buffer, and high precision robotic 
devices are employed for the localized deposition of the probe solutions on a 
chemically modified glass surface (Fig. 4). In a different approach, using in situ 
synthesis of oligonucleotides 95,96 via a combination of custom phosphoramidite 
chemistry and either photolithography 92,97,98 (Fig. 5) or ink-jet technology 93, 
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subsequent deposition of the DNA probes is circumvented. Light-directed synthesis 
of oligonucleotides using photolithography is a complex procedure commercialized by 
the company Affymetrix. Their microarrays are available under the trade name 
‘GeneChip’ and contain sets of 11-16 perfect-match and single-base mismatch 25-
mer probes, as single 25-mers are too short to specifically detect unique transcripts 
(Fig. 5C). 
With regard to these explicit technical differences, it is necessary to determine 
whether the results from different array-based expression profiling platforms actually 
are comparable. 
 
 
 
Figure 4. Principle of spotted DNA microarrays. The workflow includes (1) the preparation and (2) robotic 
deposition of DNA probes onto chemically modified glass slides, (3) hybridization of fluorescent DNA targets, 
usually generated in reverse transcription reactions with Cy3- or Cy5-dUTP, respectively, as well as (4) data 
acquisition and evaluation. Parts of the figure reproduced with kind permission of Aventis Pharma Deutschland 
GmbH. 
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Figure 5. Principle of commercial Affymetrix GeneChip microarrays. (A) Light-directed synthesis of 
oligonucleotides. The surface of a solid support modified with photolabile protecting groups is illuminated 
through a photolithographic mask, yielding reactive hydroxyl groups in the illuminated regions. A 3'-O-
phosphoramidite-activated deoxynucleoside protected at the 5'-hydroxyl with a photolabile group is then 
presented to the surface and coupling occurs at sites that were exposed to light. Following capping and oxidation, 
the substrate is rinsed and the surface is illuminated through a second mask, to expose additional hydroxyl 
groups for coupling. A second 5'-photoprotected, 3'-0-phosphoramidite-activated deoxynucleoside is presented to 
the surface. The selective photodeprotection and coupling cycles are sequentially repeated until the desired set of 
products is completed. Most commonly, all synthesis steps are repeated until 25-mer oligonucleotides have been 
obtained. (B) Site-specific photodeprotection occurs via illumination at 365 nm through custom-built sets of 
photolithographic masks. (C) As 25-mer sequences are too short to specifically detect unique transcripts, genes 
are analyzed by sets of oligonucleotides consisting of 11–16 perfect-match and the same number of single-base 
mismatch probes, which span representative regions of the selected transcripts. (D) For target preparation, total 
RNA is used in a T7-based linear amplification procedure to produce biotin-labeled cRNA targets. Subsequent to 
RNA fragmentation, hybridization and washing, target detection occurs via sequential staining with streptavidin-
phycoerythrin, biotinylated antistreptavidin and once more streptavidin-phycoerythrin, which allows for 
fluorescence detection using standard hardware. (E) Section of a fluorescence image obtained from a stained 
GeneChip array. Figure modified from Lipshutz et al. 98 and from http://www.affymetrix.com. 
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1.6 RNA Amplification 
 
Expression profiling by DNA microarrays is based on hybridization methods 
developed by Ed Southern about 30 years ago 99,100. Early microarray studies used 
large amounts of cells (> 106), which were obtained either from large tumors or cell 
lines 101. 
Although cancers emerge from single malignant cells, the analysis of tumor sections 
detected a strong heterogeneity of the cell populations 102. Metastasizing cells often 
acquire numerous genotypic and phenotypic alterations, which may also influence 
their response to anti-tumor therapy 103. The expression analysis of large and hence 
potentially heterogeneous tumors may therefore yield inconclusive results. 
The large amount of RNA material needed for array-based expression profiling 
thereby represents a serious obstacle for cancer-related research intending to benefit 
from the potential of this promising new technology. Using fine-needle aspiration, a 
method for the collection of small tumor samples (< 100,000 cells) for histological 
characterization, the amount of RNA which can be obtained (about 2 µg) is hardly 
sufficient for most of the standard protocols, and the results may still be impaired by a 
high proportion (20 - 60%) of non-tumor cells 104,105. To generate a representative 
expression profile of a cancer, one should ideally use microdissection approaches to 
obtain single or at least very small numbers of individually selected tumor cells 106,107, 
but this will yield even smaller amounts of RNA material. 
Proper amplification procedures are therefore indispensable if limited source material 
is to be analyzed by microarray technology (Fig. 6). In principle, this amplification can 
either be performed on the limited source material itself (target amplification) or on 
the signal generated by this material (signal amplification). Target amplification can 
be conducted exponentially using PCR-based approaches 108-110 or linearly via the 
generation of cDNA and subsequent in vitro transcription using T7 RNA 
polymerase 111,112. The kinetics of PCR 113,114 implies that sequence dependent and 
concentration dependent bias accumulates in an exponential fashion as well, and at 
very low amounts of starting material sampling errors become increasingly 
problematic 115,116. Due to these reasons, amplification by PCR is generally 
considered less appropriate for the parallel, microarray-based analysis of multiple 
targets. 
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Figure 6. Conceptual differences of target amplification and signal amplification procedures. Methods for target 
amplification duplicate the source material prior to the hybridization step. The amplified target material is 
labeled with, e.g., fluorescent dyes and subsequently hybridized to the array, where it can be detected. Signal 
amplification procedures, on the other hand, employ the limited source material for hybridization and amplify the 
signal generated on the array. Although different approaches exist for the latter step, they all require some sort of 
tagging (e.g., via haptens or capture sequences) of the source material that allows for a localized amplification. 
Modified from a figure kindly provided by Prof. Peter Lichter. 
 
 
 
Most of the current target amplification procedures therefore perform a linear 
amplification by in vitro transcription, as initially proposed by van Gelder et al. for the 
cloning and expression analysis of low-abundance transcripts from small populations 
of neuronal cells 112. For this purpose, total RNA is reversely transcribed to cDNA, 
using a modified oligo(dT) primer that contains the promoter sequence of phage T7 
RNA polymerase, and an RNase H- MMLV RNA dependent DNA polymerase (e.g., 
SuperScript II). This reaction yields an RNA/DNA hybrid. In a subsequent step, partial 
digestion of the RNA portion of the heteroduplex with RNase H generates small RNA 
primers that initiate second strand synthesis by E. coli DNA polymerase I. Fragments 
that originated from different RNA primers are joined by enzymatic ligation, similar to 
the joining of Okazaki fragments in the discontinuous lagging strand synthesis of 
eukaryotic DNA replication 117-119. This yields uninterrupted double-stranded cDNA 
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containing the T7 promoter sequence downstream of the transcript sequences. 
Subsequent in vitro transcription with T7 RNA polymerase yields multiple antisense-
oriented copies of the initial transcripts, as transcription from each promoter is 
initiated repeatedly (Fig. 7). Commercial T7-based amplification kits are available 
,e.g., from Arcturus (Mountain View, USA; RiboAmp) and Ambion (Austin, USA; 
MessageAmp) and have been reported to perform well 120,121. 
Unfortunately, the original T7-based protocols cannot be used with commercially 
available oligonucleotide probe libraries when combined with conventional reverse 
transcription labeling methods. Their sequences are sense-oriented to be compatible 
with cDNA targets obtained by reverse transcription. T7 amplification yields RNA with 
antisense orientation, and RT labeling would transform these sequences into sense-
oriented cDNA targets, incompatible with sense-oriented oligonucleotide probes.  
A T7-based study by t’ Hoen et al. 122 used aminoallyl-UTP nucleotides in the in vitro 
transcription reaction, which allowed them to label the aRNA in a subsequent 
coupling reaction with Cy-NHS-esters. Labeled aRNA would be suitable for 
hybridization to sense-oriented oligonucleotide arrays (Fig. 8).  
 
 
 
 
Figure 7. T7 RNA amplification. An RNA polymerase promoter is incorporated into each cDNA molecule by 
priming cDNA synthesis with a synthetic oligonucleotide containing the phage T7 RNA polymerase promoter. After 
synthesis of double-stranded cDNA, T7 RNA polymerase is added and antisense RNA is transcribed from the cDNA 
template. The processive synthesis of multiple RNA molecules from a single cDNA template results in amplified 
antisense RNA (aRNA).  
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A recent publication by Smith et al. 123 claimed that their amplification procedure, 
termed “Single Primer Amplification” (SPA), could also be used for microarrays 
containing oligonucleotide probes in sense orientation. The first steps in this protocol 
generate double-stranded cDNA, initially primed by a modified oligo(dT) primer. A 
primer equivalent to the heel of the modified oligo(dT) primer is then used to direct 
semi-linear Taq DNA polymerase amplification of the first strand cDNA. Hence, the 
protocol is essentially a modified cycle sequencing reaction so far. Then, Klenow 
fragment is used to perform a randomly primed labeling reaction, initially producing 
fluorescent cDNA in sense orientation. However, it can be expected that at least a 
portion of this primary product will be used to template another round of 
polymerization (“strand switch”) that generates antisense-oriented cDNA. This would 
allow hybridization to both sense and antisense strands and consequently render the 
method compatible with oligonucleotide microarrays containing probes in sense 
orientation (Fig. 9).  
 
 
 
Figure 8. Preparation of fluorescent cRNA targets by in vitro transcription. Following the generation of double 
stranded cDNA containing the T7 promoter downstream of the coding sequence, repeatedly initiated in vitro 
transcription yields multiple copies of fluorescent aRNA. These molecules are antisense-oriented and can 
therefore be hybridized to sense-oriented oligonucleotides. 
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Figure 9. Single Primer Amplification (SPA). In theory, the SPA method can yield both sense- and antisense-
oriented fluorescent cDNA targets. The generation of antisense cDNA depends on a “strand switch” of the 
polymerase, in which the primary, sense-oriented product serves as a template for another, randomly primed 
round of polymerization.  
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1.7 Signal Amplification 
 
Target amplification is just one approach to permit DNA microarray experiments with 
limited amounts of source material. A further possible procedure is to amplify the 
signal generated on the array subsequent to the hybridization step (Fig. 9). Several 
methods have been proposed to achieve this amplification. 
Tyramide signal amplification (TSA) 124,125 uses fluorescein (as hapten for subsequent 
labeling with the fluorescent dye Cy3) or biotin (as hapten for subsequent labeling 
with the fluorescent dye Cy5) modified nucleotides, which are incorporated during 
first-strand cDNA synthesis. After array hybridization and stringent washing, two 
antibody-enzyme conjugates recognize the fluorescein or biotin haptens. The 
enzyme portion of these conjugates is horseradish peroxidase (HRP), which, in 
subsequent step, catalyzes the local deposition of Cy3/5-labeled tyramide 
immediately adjacent to the immobilized HRP. In this enzymatic process, HRP-
activated highly reactive and short-lived tyramide radicals undergo covalent coupling 
to nucleophilic residues in the vicinity of the HRP-target interaction site, whereby the 
amount of tyramide relative to cDNA hapten label is greatly amplified. However, 
previously published evaluations concerning the TSA method report inconsistent 
labeling 126, increased background fluorescence and insufficient reproducibility, i.e., 
poor signal correlations from co-hybridizations of identical cDNA targets 127. 
The 3DNA system offered by Genisphere uses fluorescently labeled DNA 
dendrimers 128. DNA dendrimers are complex, branched molecules built from 
interconnected monomeric subunits 129. The 3DNA dendrimers contain an average of 
about 850 fluorescent labels and recognize a capture sequence introduced by a 
modified RT primer during first-strand cDNA synthesis. The results from present 
studies on the 3DNA system for microarray analysis are inconclusive. Yu et al. 126 
report strong signal correlations in self-self hybridization experiments and reasonable 
consistency of 3DNA expression profiles with those from direct labeling experiments, 
whereas Richter et al. 127 obtained high signal intensities but no meaningful 
expression patterns. 
Rolling-circle DNA replication is the basic principle for a further signal amplification 
procedure, termed Rolling Circle Amplification (RCA). In RCA, a circular, single-
stranded DNA molecule is duplicated repeatedly by a DNA polymerase, creating long 
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concatameric copies of the circular template (for more details, see 1.7.2). For this 
purpose, the polymerase has to offer an extremely strong strand displacement 
activity as well as superior processivity. The monomeric 66.52 kDa DNA polymerase 
of the lytic bacteriophage Φ29 possesses both of these properties and is therefore of 
fundamental importance for any RCA protocol. Since RCA for microarray expression 
analysis is one of the subjects of this thesis, I will provide more detailed information 
on the Φ29 phage, its DNA polymerase and the rolling-cirlce mechanism of DNA 
replication. 
 
 
1.7.1 Phage Φ29 
The Φ29-like genus of phages includes, in addition to Φ29, phages PZA, Φ15, BS32, 
B103, M2Y, Nf, and GA-1 130. They are all lytic phages belonging to the Podoviridae 
family. They infect bacteria of the genus Bacillus, which incorporates many species of 
gram-positive, aerobic, endospore-forming bacteria that normally inhabit the soil of 
decaying plant material. Φ29-like phages are commonly found in Bacillus subtilis, but 
often they may also infect related species such as Bacillus pumilus, Bacillus 
amyloliquefaciens, and Bacillus licheniformis.  
Phage Φ29 has been subject to intensive studies, and the results have contributed to 
the understanding of several molecular mechanisms of biological processes, such as 
DNA replication, regulation of transcription, phage morphogenesis, and phage DNA 
packaging. Electron microscopy analysis revealed that Φ29 comprises a head of 41.5 
by 31.5 nm with sixfold radial symmetry and a short noncontractile tail of 32.5 by 
6.0 nm 131. Being the smallest Bacillus phages isolated so far, the Φ29-like phages 
are also among the smallest phages containing dsDNA. The genomes of the Φ29-like 
phages consist of a linear dsDNA molecule of about 20 kb (19,285 kb for Φ29 132), 
which has a phage-encoded terminal protein (TP) covalently attached at each 5’-end. 
Genomes consisting of a TP covalently linked to their 5’-ends have also been found 
for animal viruses (e.g., adenoviruses) and bacteria (e.g., Streptomyces), and in all of 
these cases, initiation of DNA replication occurs via a so-called protein-priming 
mechanism 133,134. DNA polymerases are unable to initiate de novo DNA synthesis on 
a DNA template but require the existence of a primer containing a free hydroxyl 
group. Generally, RNA primers provide the 3’-hydroxyl group needed by the DNA 
polymerase to elongate the DNA chain. However, in most linear genomes containing 
CHAPTER 1.7 SIGNAL AMPLIFICATION  23 
 
 
a 5’-TP, the 3’-OH of a specific serine, threonine or tyrosine residue of the TP is used 
for DNA elongation.  
Bacteriophage Φ29 DNA polymerase, the product of the viral gene 2, was originally 
characterized as a protein involved in the initiation of Φ29 DNA replication based on 
both in vivo 135 and in vitro 133,136,137 studies. The cloning 138of gene 2, the 
overproduction and purification of its product 139, and the development of an in vitro 
system for complete Φ29 DNA replication 134 allowed the characterization of protein 
p2 as the viral DNA replicase 140. It belongs to the B-type superfamily of DNA-
dependent DNA polymerases, which are also referred to as eukaryotic or α-like 
polymerases and contain many prokaryotic and eukaryotic enzymes that are 
sensitive to certain drugs (aphidicolin, phosphonoacetic acid) and nucleotide analogs 
(butylanilino-dATP, butylphenyl-dGTP). The monomeric Φ29 DNA polymerase has a 
size of 66.52 kDa and catalyzes both the initiation and elongation stages of Φ29 DNA 
replication. To accomplish this, it is able to carry out two distinct synthetic reactions: 
TP deoxynucleotidylation, which consists of the formation of a covalent phosphoester 
bond between the hydroxyl group of a specific serine residue (Ser232) in Φ29 TP and 
dAMP, and DNA polymerization 139. In addition to the synthetic activities, Φ29 DNA 
polymerase has two degradative activities: pyrophosphorolysis and ssDNA 3’-5’-
exonuclease (proofreading), which processively degrades DNA substrates longer 
than six nucleotides. Moreover, it has the intrinsic properties of high processivity 
(> 70 kb) and strand displacement activity, even during the polymerization 
process 141. Due to these characteristics, Φ29 DNA polymerase is the only enzyme 
required for efficient in vitro replication of the Φ29 genome, with the Φ29 TP, the 
initiation primer, as the only additional protein requirement 134. DNA synthesis starts 
non-simultaneously from either end of the DNA molecule with the covalent linkage of 
dAMP (from dATP) to a free molecule of the TP. The subsequent elongation of the 
DNA chain occurs by a strand-displacement mechanism, which allows for efficient in 
vitro synthesis of full length Φ29 DNA. 
 
1.7.2 Rolling Circle Replication 
The rolling-circle mechanism of DNA replication (RCR) is used by small prokaryotic 
genomes, such as single-stranded phages and plasmids. Filamentous single-
stranded phages are intermediates between lytic phages (e.g., fX174) and plasmids 
(e.g., pT181): they do not cause cell lysis but exist intracellularly as stable plasmids 
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and generate infective particles more or less indefinitely. Several groups have 
demonstrated that even in vitro-generated circular ssDNA can support a rolling circle 
replication 142 to produce concatemeric repeats of monomers as short as 
34 nucleotides, using either E. coli DNA polymerase I, E. coli DNA polymerase large 
fragment (Klenow fragment) or modified T7 DNA polymerase (Sequenase) 142, and 
the method has been applied for amplified detection (rolling circle amplification; RCA) 
of viral RNA from tissue samples 143 and for preparative in vitro synthesis of catalytic 
antisense RNA 144. It was then realized that Φ29 DNA polymerase, due to its superior 
processivity and strand displacement activity, is a better choice for this 
purpose 145,146. For the same reasons, Φ29 polymerase is also used for the 
generation of sequencing templates 147,148, for whole genome DNA amplification prior 
to genotyping 149,150 or array-CGH 151-154 and even for the amplification of CGH array 
clones 155,156. 
In RCA, a circle of DNA, a short DNA primer (complementary to a portion of the 
circle) and an enzyme catalyst convert dNTPs into a single-stranded concatemeric 
DNA molecule that is composed of thousands of tandemly repeated copies of the 
circle. Unlike other amplification procedures, RCA produces a single amplified 
product that remains linked to the DNA primer. Consequently, RCA is well suited to 
solid phase formats such as microarrays for generating localized signals at specific 
microarray locations. PCR or other solution phase amplification procedures, on the 
other hand, cannot be configured for on-chip amplification due to the lack of 
accumulation of amplified signal at the site of amplification, i.e., diffusion of products 
into the solution, and/or deleterious effects of temperature cycling on reaction 
components, such as analytes, samples or microarray substrates. Applications of 
RCA signal amplification for the detection of DNA targets immobilized on solid 
surfaces 157 as well as for ultrasensitive detection of proteins on microarrays 158,159 
have been previously demonstrated. RCA signal amplification on microarrays 
involves a universal amplification circle, regardless of the nature and number of 
targets being assayed. This approach minimizes bias during amplification. Therefore, 
and in contrast to target amplification methods, such as PCR or T7-based in vitro 
transcription, universal RCA signal amplification can be expected to introduce 
significantly less sequence-dependent bias. In addition, the RCA procedure is less 
costly and time-consuming. The circular oligonucleotides needed for the amplification 
can be generated from padlock probes, which are linear oligonucleotides with 5’  and 
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3’ end regions designed to base pair next to each other on a target strand. If properly 
hybridized, the ends can be joined by enzymatic ligation, converting the probes to 
circularly closed molecules that are catenated to their target sequence  160. So far, 
RCA on microarrays has not been applied for the amplified detection of expression 
profiles. In this thesis, I evaluate the applicability of a protocol I conceived to adapt 
on-chip RCA for expression profiling approaches (Fig. 10). 
 
 
 
  
 
Figure 10. Signal amplification by rolling circle amplification (RCA) on DNA microarrays. Total RNA is 
reversely transcribed to cDNA, using a special oligo(dT) primer that additionally contains a sequence 
complementary to a portion of the circular DNA to be amplified. This part of the primer is synthesized in reverse 
(5’ to 3’), providing an additional 3’-end to prime the downstream RCA reaction. Subsequenty, the cDNA is 
hybridized to standard spotted DNA microarrays, followed by hybridization of the circular oligonucleotides 
generated in a separate enzymatic ligation reaction. The circle-complementary part of the cDNA contains a free 
3’-end to which the circles hybridize, serving as templates for the RCA reaction. The linear concatameric RCA 
product, comprising repeating units of a sequence complementary to the circle, can be detected by hybridization 
of molecular beacons or conventional short oligonucleotides containing fluorescent labels. 
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1.8 Objective 
 
All truths are easy to understand once they are discovered; the point is to discover 
them. 
GALILEO 
 
 
Initially, there were just two alternatives for microarray-based analysis of gene 
expression, which were self-spotted cDNA arrays and commercial 25-mer arrays 
from Affymetrix. More recently, spotted microarrays of long sense-oriented 
oligonucleotides were introduced as an attractive alternative to the two former 
methods. Their probes are designed to have similar biophysical properties and avoid 
secondary structures as well as repetitive sequences, which is a considerable 
advantage compared to cDNA arrays. Additionally, they are long enough (50 - 80 nt) 
to allow for a specific detection of target molecules with just one probe, compared to 
11 - 16 probes for the Affymetrix platform.  
To use spotted oligonucleotide arrays for the analysis of minimal amounts of RNA 
material, either a target or a signal amplification method must be applied in order to 
yield adequate results. T7-based target amplification protocols had been reported to 
perform well with cDNA microarrays. However, reverse transcription labeling 
transforms the antisense-oriented amplification products to fluorescent cDNA targets 
with sense orientation, which are obviously inapplicable for hybridization to sense-
oriented oligonucleotides. Available methods for signal amplification, on the other 
hand, which used, e.g., three-dimensional multi-labeled structures (DNA dendrimers), 
or the enzymatically activated deposition of dye molecules via tyramide (TSA), had 
been evaluated with rather heterogeneous results. Signal amplification based on 
rolling circle mechanism of DNA replication (RCA), had very successfully been used 
for the detection of antigens on protein microarrays, but the method had not yet been 
implemented for microarray expression analysis. The objective of this thesis was 
therefore to develop and optimize a target amplification protocol specific to the 
problems and characteristics of spotted oligonucleotide microarrays. The desired 
protocol had to generate fluorescent target molecules with antisense orientation, 
compatible for hybridization to sense-oriented oligonucleotide probes. 
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Additionally, an RCA-based signal amplification protocol should be developed, as an 
alternative to the target amplification procedure. Pre-ligated circular oligonucleotides 
should be used to detect a common sequence introduced to the cDNA targets and 
serve as templates for a subsequent rolling circle replication reaction. This would 
yield long concatameric amplification products continuous with the hybridized cDNAs, 
which could finally be detected by complementary molecular beacons or short 
labeled oligonucleotides. 
Both protocols should finally be used to evaluate the performance of the novel 
oligonucleotide arrays in comparison to the commercial, well-established Affymetrix 
GeneChip system. Both platforms should be applied to generate expression profiles 
from a set of head and neck squamous cell carcinoma patients. These data should 
be used as a basis to estimate the degree of concordance between the two systems 
and, thereby, answer the question whether or not spotted oligonucleotide arrays can 
deliver on their promise.  
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2 Materials and Methods 
 
Give me a lever long enough and a fulcrum on which to place it, and I shall move 
the world. 
ARCHIMEDES 
 
 
2.1 Materials 
 
2.1.1 Chemicals and Biochemicals 
 
Table 1. Chemicals and Biochemicals.  
Chemical Supplier (Cat #) 
2-Mercaptoethanol (thioethylene glycol) Sigma-Aldrich, Munich (M3148) 
2-Propanol (isopropanol) Merck, Darmstadt (109634) 
Aminoallyl-dUTP Fermentas, St. Leon-Rot (R0091) 
Ammonium acetate solution, 7.5 M Sigma-Aldrich, Munich (A2706-100ML) 
Betaine (trimethylglycine), inner salt, unhydrous  Sigma-Aldrich, Munich (B2629) 
Bovine serum albumin (BSA) New England Biolabs, Frankfurt am Main (B9001S)
C0t human DNA Roche Diagnostics, Mannheim (11 581 074 001) 
Chloroform, pro analysis Merck, Darmstadt (102445) 
Cyanin 3-dUTP Amersham Biosciences, Freiburg (PA53022) 
Cyanin 5-dUTP Amersham Biosciences, Freiburg (PA55022) 
Deoxynucleotide (dNTP) set, 100 mM solutions Amersham Biosciences, Freiburg (27-2035-02) 
DEPC-treated water Ambion, Austin, USA (9922) 
EDTA, 0.5 M, pH 8.0 Ambion, Austin, USA (9260G) 
Formamide, pro analysis Merck, Darmstadt (109684) 
Hydrochloric acid, 1 M  JT Baker, Pillipsburg, USA (7088) 
Linear polyacrylamide (LPA), 5 µg/µl Ambion, Austin, USA (9520) 
NHS-psoralen (SPB) Pierce Biotechnology, Rockford, USA (23013) 
Nitrocellulose (cellulose nitrate) Sigma-Aldrich, Munich (N7892) 
Nuclease-free water (not DEPC-treated)  Ambion, Austin, USA (9937) 
Nucleotide (NTP) set, 100 mM solutions Amersham Biosciences, Freiburg (27-2025-01) 
PCR nucleotide mix, 10 mM each dNTP Amersham Biosciences, Freiburg (US77212-500µl) 
Phenol-chloroform-isoamyl alcohol 25:24:1, pH 8.0 Sigma-Aldrich, Munich (P2069-100ML) 
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Polyadenylic acid (Poly(A)), potassium salt  Sigma-Aldrich, Munich (P9403-500MG) 
Primer random (random hexamers) Roche Diagnostics, Mannheim (1034731) 
RNA 6000 ladder Ambion, Austin, USA (7152) 
RNasin ribonuclease inhibitor Promega, Mannheim (N2111) 
SDS solution, 10% Ambion, Austin, USA (9823) 
Second-strand buffer for SSII cDNA synthesis, 5x Invitrogen, Karlsruhe (10812-014) 
Sodium chloride (NaCl) solution, 5 M Ambion, Austin, USA (9760G) 
Sodium hydroxide (NaOH) solution, 10 M Sigma-Aldrich, Munich (72068-100ML) 
SSC, 20X Ambion, Austin, USA (9763) 
T4 gene 32 protein, high concentration USB, Cleveland, USA (74029Y) 
TE, pH 8.0 Ambion, Austin, USA (9858) 
Total RNA, human breast, female, Lot #0330574 Stratagene, La Jolla, USA (735044) 
Trizol reagent Invitrogen, Karlsruhe (15596-018) 
ULTRAhyb hybridization buffer Ambion, Austin, USA (8670) 
Universal human reference RNA, Lot # 0810006 Stratagene, La Jolla, USA (740000) 
Yeast tRNA (lyophilized) Invitrogen, Karlsruhe (15401-011) 
   
 
 
 
2.1.2 Enzymes 
 
Table 2. Enzymes.  
Enzyme Supplier (Cat #) 
Advantage cDNA polymerase mix BD Biosciences Clontech, Heidelberg (8417-1) 
AmpliTaq DNA polymerase Applied Biosystems, Weiterstadt (N808-0155) 
DNA ligase (E.coli) Amersham Biosciences, Freiburg (E70020Z) 
DNA polymerase I (E. coli) Promega, Karlsruhe (M2055) 
Phi29 DNA polymerase Fermentas, St. Leon-Rot (EP0092) 
PowerScript reverse transcriptase BD Biosciences Clontech, Heidelberg (8460-1) 
Ribonuclease H (E. coli) Epicentre, Madison, USA (R0601K) 
SuperScript II reverse transcriptase Invitrogen, Karlsruhe (18064-071) 
T4 DNA ligase Amersham Biosciences, Freiburg (E70042X) 
T4 DNA polymerase New England Biolabs, Frankfurt am Main (M0203L)
Terminal deoxynucleotidyl transferase Amersham Biosciences, Freiburg (E2230Y) 
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2.1.3 Kits 
 
Table 3. Kits.  
Kit Supplier (Cat #) 
Buffer kit Ambion, Austin, USA (9010) 
Cooled RNA 6000 nano reagents Agilent Technologies, Waldbronn (5065-4475) 
MEGAscript T7 kit  Ambion, Austin, USA (1334) 
MessageAmp aRNA kit Ambion, Austin, USA (1750) 
RiboMAX large scale RNA production system-T7 Promega, Karlsruhe (P1300) 
RNA 6000 nano LabChip kit Agilent Technologies, Waldbronn (5065-4476) 
RNeasy mini kit Qiagen, Hilden (74104) 
RNeasy midi kit Qiagen, Hilden (75144) 
   
 
 
2.1.4 Other Materials 
 
Table 4. Other Materials.  
Material Supplier 
ART 1000E nuclease free 1000 µl tips Molecular BioProducts, San Diego, USA (2079E) 
ART 100E nuclease free 100 µl tips Molecular BioProducts, San Diego, USA (2065E) 
ART 200 nuclease free 200 µl tips Molecular BioProducts, San Diego, USA (2169) 
ART 20P nuclease free 20 µl tips Molecular BioProducts, San Diego, USA (2149P) 
ART REACH nuclease free 10 µl tips Molecular BioProducts, San Diego, USA (2140) 
AutoSeq G-50 columns Amersham Biosciences, Freiburg (27-5340-01) 
Dynabeads M-280 streptavidin Dynal Biotech, Hamburg (112.06) 
Micro Bio-Spin 6 columns in Tris buffer Bio-Rad Laboratories, Munich (732-6222) 
Microcentrifuge tubes, PCR clean, 0.5 ml Eppendorf, Hamburg (0030 123.301) 
Microcentrifuge tubes, PCR clean, 1.5 ml Eppendorf, Hamburg (0030 123.328) 
Microcentrifuge tubes, PCR clean, 2.0 ml Eppendorf, Hamburg (0030 123.344) 
Microcon YM-100 centrifugal filter devices Millipore, Schwalbach (42412) 
Microcon YM-30 centrifugal filter devices Millipore, Schwalbach (42411) 
mSeries LifterSlips 22 x 60 mm Erie Scientific, Portsmouth, USA (22x60I-M-5522) 
Nexterion slide E Schott Jenaer Glas, Jena (1066643) 
Nexterion slide E with barcode Schott Jenaer Glas, Jena (1064016) 
PCR Tubes, 0.2 ml Molecular BioProducts, San Diego, USA (3412) 
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Phase lock gel heavy, 0.5 ml Eppendorf, Hamburg (0032 005.055) 
RNase away Molecular BioProducts, San Diego, USA (7003) 
RNaseZap Ambion, Austin, USA (9780) 
Stealth SMP3 microarray spotting pins TeleChem / ArrayIt, Sunnyvale, USA (SMP3) 
Stealth SPH48 printhead matrix TeleChem / ArrayIt, Sunnyvale, USA (SPH48) 
   
 
 
 
2.1.5 Instruments 
 
Table 5. Instruments.  
Instrument Manufacturer 
Agilent 2100 Bioanalyzer Agilent Technologies, Waldbronn 
Biofuge Fresco refrigerated tabletop centrifuge Heraeus / Kendro, Hanau 
Cary 50 Bio UV-photometer Varian, Darmstadt 
DNA Engine Dyad PCR-cycler MJ Research 
GenePix 4000B array scanner Molecular Devices / Axon Instruments, Union City, USA 
GeneTAC hybridization station Genomic Solutions (GeneMachines), Ann Arbor, USA 
Heating block QBT2 Grant Instruments 
Heating cabinet series 6000 Heraeus / Kendro, Hanau 
HMT 702 C microwave oven Bosch, Stuttgart 
Microcentrifuge neoLab Laborbedarf, Heidelberg 
MiniTrak liquid handling system PerkinElmer, Rodgau-Jügesheim 
MultiPROBE IIex liquid handling system PerkinElmer, Rodgau-Jügesheim 
OmniGrid microarrayer Genomic Solutions (GeneMachines), Ann Arbor, USA 
Stratalinker 2400 UV-crosslinker Stratagene, La Jolla, USA 
Ultra Turrax T25 tissue homogenizer Janke & Kunkel, Staufen 
Varifuge 3.0/3.0R floor model centrifuge Heraeus / Kendro, Hanau 
VersArray ChipWriter Pro system Bio-Rad Laboratories, Munich 
Water bath SW22 Julabo Labortechnik, Seelbach 
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2.1.6 Software 
 
Table 6. Software.  
Software Manufacturer 
Adobe Creative Suite CS Adobe Systems, Unterschleissheim 
ChemDraw Ultra 9.0 CambridgeSoft, Cambridge, USA 
EditPlus 2.11 text editor ES-Computing, Chinju, South Korea 
EndNote 8.0 Thomson ResearchSoft, Carlsbad, USA 
Expression Analysis Systematic Explorer 2.0 National Institutes of Health, Rockville, USA 
FlashFXP 3.0 FTP client IniCom Networks, Socorro, USA 
GenePix Pro 4.0, 5.0 & 5.1 Molecular Devices / Axon Instruments, Union City, USA 
Microsoft Office professional edition 2003 Microsoft, Unterschleissheim 
Microsoft Windows 2000 & service pack 4 Microsoft, Unterschleissheim 
R 1.9.1 & 2.0.0 R Foundation for Statistical Computing, Vienna, Austria 
   
 
 
 
2.1.7 Standard Solutions 
 
Table 7. Standard Solutions.  
Solution Composition 
5 x TBE, pH 8.0 0.445 M Tris-Borat, pH 8.0 
10 mM EDTA, pH 8.0 
 
1 x TE, pH 8.0 10 mM Tris-HCl, pH 8.0 
1 mM EDTA, pH 8.0 
 
SDS, 20% 20% SDS (w/v) 
 
20 x SSC, pH 7.0 0.3 M NaCl 
0.03 M Sodium citrate 
 
DEPC-H2O 0.1% DEPC (v/v), autoclaved 
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2.1.8 Human Total RNA 
To assess the performance of RNA amplification protocols, high quality total RNA 
was purchased from Stratagene (La Jolla, USA). Universal Human Reference RNA 
precipitate in ethanol was pelleted, washed in 70% (v/v) ethanol, air dried and 
dissolved in RNase-free water at 5 µg/µl, 500 ng/µl, 50 ng/µl, 5 ng/µl and 0.5 ng/µl. 
Human Adult Breast (female) RNA was precipitated at -80 °C for 30 min with 5 µg 
linear polyacrylamide (LPA), 2.5 vol 100% (v/v) ethanol and 0.5 vol 7.5 M NH4OAc 
and subsequently processed as described for the Reference RNA. Integrity and 
purity of total RNA were assessed on a Bioanalyzer 2100 using an RNA 6000 Nano 
LabChip Kit according to the manufacturer’s instructions (see 2.3.3). 
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2.2 Tumor Samples 
 
2.2.1 Human HNSCC Tumor Samples 
Tissue samples from six patients were obtained in the years 1998 - 2002 from 
patients undergoing surgical resection at the department of otolaryngology, J.-W.-
Goethe-Universität Frankfurt. All cases were diagnosed histopathologically as 
HNSCC and staged according to the TNM classification of malignant tumors 161, 
based on criteria recommended by the ‘Union International contre le Cancer (UICC)’ 
(Table 1). The study protocol was approved by the local ethics committee after 
obtaining the patients’ informed consent to participate in the study, and was 
processed anonymously. Grade 2 HNSCC specimens, corresponding healthy control 
mucosa surrounding the tumor and lymph node metastases were surgically resected, 
immediately frozen in liquid nitrogen and stored at -80 °C. The neoplastic specimens 
contained > 80% tumor tissue and < 10% necrotic debris.  
The samples, collected and processed as described above, were kindly provided by 
Dr. med. Markus Hambek and Prof. Dr. med. Rainald Knecht 
 
Table 8. Patient and disease characteristics.  
 
Patient Primary Site Age Sex pT pN pM Grading Samples Analyzeda 
   160 hypopharynx  48  M  3  1  0       2           PT / N 
   171 hypopharynx  58  M  3  2a  0       2           PT / M 
   173 oropharynx  56  M  3  2  0       2           PT / N 
   180 hypopharynx  57  M  2  3  0       2           PT / N 
   186 hypopharynx  47  F  2  2  0       2           PT / N 
   205 oropharynx  49  M  3  1  0       2           PT / M 
       
aAll cases were diagnosed histopathologically as HNSCC and staged according to the TNM classification of malignant tumors. The indicated 
tissues were used for gene expression profiling. N: normal mucosa, PT: primary HNSCC, M: lymph node metastasis. 
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2.3 RNA Extraction 
 
2.3.1 RNA Extraction from Tissue Samples 
Frozen tissue samples (30-50 mg) were combined with 1 ml Trizol and dispersed 
using an Ultra-Turrax T25 tissue homogenizer. Total RNA was extracted according to 
the recommendations given by the Trizol protocol and further purified on RNeasy 
Mini spin columns. Extracted RNA material was kindly provided by Dr. Negusse 
Habtemichael (Chemotherapeutisches Forschungszentrum Georg-Speyer-Haus, 
Frankfurt am Main). Integrity and purity of total RNA were assessed on a Bioanalyzer 
2100 using an RNA 6000 Nano LabChip Kit according to the manufacturer’s 
instructions (see 2.3.3).  
 
 
2.3.2 RNA Quantification by Spectrophotometry 
 
The concentration of RNA and DNA solutions is usually determined by spectro-
photometry. This procedure is based on the absorption maximum of nucleic acids at 
260 nm, which is caused by the aromatic ring structures of the nucleotide bases. The 
absorption is measured in quartz cuvettes with a gage of 1 cm, which facilitates the 
estimation of concentrations via the law of Lambert-Beer: 
 
 A = ε ּ c ּ d  
A: absorption (optical density; OD) 
ε: molar absorption coefficient [l ּ mol-1 ּ cm-1] 
c: concentration [mol/l]  
d: gage of the measured solution [cm] 
 
Following calibration with the appropriate solvent, the sample readings should range 
between 0.05 and 1 OD, which is the linear range of common photometric devices. 
The concentrations can then be determined using one of these formulas: 
 
    [DNAds] = OD260 x 50 μg/ml x dilution factor 
    [DNAss] = OD260 x 37 μg/ml x dilution factor 
    [RNAss] = OD260 x 40 μg/ml x dilution factor 
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The absorption maximum of proteins is at 280 nm, due to the absorbance of aromatic 
amino acids. The ratio OD260/OD280 can be used as an indication for the purity of 
nucleic acid solutions. Pure DNA solutions have a ratio of about 1.8, whereas the 
ratio of pure RNA solutions is about 2.0. Contamination by phenol or proteins causes 
a significant decrease of this value, and solutions with ratios smaller than 1.5 have to 
be considered inappropriate for further analyses. 
 
 
2.3.3 Assessment of RNA Integrity and Purity 
Slab gel electrophoresis in cross-linked sieving matrices is one of the most powerful 
tools for nucleic acid analysis, but a major limitation is the low speed of analysis as 
well as the difficulty of automating the entire process, including sample loading, gel 
imaging and data analysis. The dimensions of a slab gel limit the electrical field 
strength that can be applied before severe band broadening occurs due to Joule 
heating and diffusion. This problem was addressed by introducing capillary 
electrophoresis (CE) in polymer matrices 162, which allowed nucleic acid separation 
under much higher electrical field strengths. CE allows for very fast nucleic acid 
separations when high electrical field strengths are applied. A more recent 
development involves the separation of DNA or RNA fragments on microfabricated 
devices (microfluidic chips; lab-on-a-chip technology) 163. These chips allow the same 
speed of analysis as do separations on CE equipment and, moreover, due to their 
planar structure, make it easier to achieve parallel analysis. In addition, 
microfabricated chips allow the integration of several sequential steps in an 
automated manner. 
The Agilent 2100 Bioanalyzer is the first commercially available system to utilize 
chip-based nucleic acid separation technology. Chips are fabricated from glass and 
comprise an interconnected network of fluid reservoirs and microchannels made by 
semiconductor-like microfabrication techniques, which must be filled with a polymer-
dye mixture. Each chip contains a total of 16 wells. Three are used for loading the 
gel-dye mixture consisting of a linear polymer and a fluorescent, intercalating dye of 
a proprietary nature. One well is used for a molecular size ladder, and the 12 
remaining ones for experimental samples. Both, the ladder and the samples have to 
be blended with a marker mixture consisting of a buffer along with lower and upper 
molecular size markers, which the Bioanalyzer uses as references when sizing 
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nucleic acid fragments. The upper marker is also used as a reference for calculating 
the concentration of DNA or RNA fragments in each sample. The movement of 
nucleic acids through the microchannels is controlled by a series of electrodes, which 
create electrokinetic forces capable of driving fluids and DNA molecules. As the 
electrical voltage is applied, DNA fragments of different sizes intercalating with the 
fluorescent dye are separated according to their mass and can be quantified by 
laser-induced fluorescence detection. The Bioanalyzer displays data as both 
migration-time plots and as computer-generated virtual gels (Fig. 11).  
 
Briefly, RNA 6000 nano chips were filled by pipetting 9 µl of polymer-dye mix into the 
appropriate well and then forcing the mix into the microchannels by applying 
pressure to the well via a 1 ml syringe. 5 µl of marker mix were loaded into each 
sample well, followed by 1 µl of molecular weight ladder into the ladder well and 1 µl 
aliquots of samples into the sample wells. The contents of each well on the chip were 
mixed by vortexing for 1 min at setting 4 using a Fisherbrand Vortex Genie-2. 
Subsequently, chips were immediately inserted into the Bioanalyzer and processed 
using the Bioanalyzer software settings “Eucaryotic total RNA nano” or “Eucaryotic 
mRNA nano”. 
 
 
Figure 11. Assessment of total RNA (Stratagene Universal Human Reference RNA) integrity and purity with 
the Agilent 2100 Bioanalyzer. The Agilent 2100 Bioanalyzer allows for a fast and accurate estimation of the 
quality of RNA samples, both in an automated fashion and by visual inspection. Migration-time plots are shown 
for (A) high quality total RNA, (B) slightly degraded total RNA and (C) heavily degraded total RNA 
(inappropriate for further analyses). Computer-generated virtual gels (D) are useful for direct comparison of 
various samples. 
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2.4 Oligonucleotides 
 
2.4.1 Probe Sequences for High-Density Oligonucleotide Microarrays 
The Human Genome Oligo Set 2.1 and Human Genome Oligo Set 2.1 Upgrade, 
containing 21,329 and 5,462 70-mer probes, respectively, were purchased from 
Operon Technologies (Cologne). For enhanced coupling to the microarray surface, 
an amino linker is attached to the 5’ end of each oligo. The design of the original 
oligo set 2.1 is based on representative sequences from NCBI Homo sapiens 
UniGene build #147 (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene) and 
the NCBI RefSeq database, whereas the upgrade uses sequence and mapping 
information provided by the human Ensembl database build #13.31 
(http://www.ensembl.org). All oligos are within a TM range of 78 °C ± 5 °C and within 
1,000 (original) or 2,000 nucleotides (upgrade) from the 3’ end of the available gene 
sequence. Single nucleotide repeats and stem-loop structures are avoided. Each 
oligo has ≤ 70% sequence identity and ≤ 20 contiguous bases common to all other 
genes represented in the collection. 
 
 
2.4.2 Primer Sequences for RQ-PCR Analysis 
The following primer sequences were used to verify gene expression ratios in the 
context of comparing results between the Operon long oligonucleotide and the 
Affymetrix GeneChip microarray platform. The primers were designed by Dr. 
Negusse Habtemichael (Chemotherapeutisches Forschungszentrum Georg-Speyer-
Haus, Frankfurt am Main) an purchased from Biospring (Frankfurt am Main). 
 
 
Table 9. Primer sequences used for RQ-PCR. 
 
Gene Symbol        Forward Primer (5'→3')         Reverse Primer (5'→3') 
     OSF2      ATTAGGCTTGGCATCTGCTC      CTCGCGGAATATGTGAATCG 
     GMDS      GCGCTCATCACCGGTATCAC      CTCTGGGCTCCAAGGTTGTAG 
     TMPRSS2      TCCTGACGCAGGCTTCCAAC      CGAACACACCGATTCTCGTCC 
     BGN      TGGTTCAGTGCTCCGACCTG      GGATCTCCACCAGGTGGTTC 
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2.4.3 Padlock probes and associated sequences for RCA on microarrays 
The following oligonucleotides (Biospring) were used for on-chip signal amplification 
via RCA. 
 
 
Table 10. Padlock probes and associated sequences.  
Oligo Name Function Modification         Sequence (5'→3') 
  PL-1216g Padlock oligo, green system 5’-phosphate GGGATTATAAAGAACTGTTGCCTCGACCGTTAGCAGCATGATTCCGAGATGTACCGCT
ATCGTGTTGATGTCATGTGTCGCACTTCT
TCTGGGCTAATTACAGC 
  PL-6121g Padlock oligo, red system 5’-phosphate CCCTAATATTTCTTGACAACGGAGCTGGCAATCGTCGTACTAAGGCTCTACATGGCGA
TAGCACAACTACAGTACACAGCGTGAAGA
AGACCCGATTAATGTCG 
  T-1216g Ligation template, green system 5’-biotin GCAACAGTTCTTTATAATCCCGCTGTAAT
TAGCCCAGAAGAA 
  T-6121g Ligation template, red system 5’-biotin CGTTGTCAAGAAATATTAGGGCGACATTA
ATCGGGTCTTCTT 
  1216g-double-3’ RT primer, green system Inverse synthesis; 
3’-thioat 
3’-dAsdCTACAGTACACAGCGTG-5’-
TTTTTTTTTTTTTTTTTTTTTVN-3’ 
  6121g-double-3’ RT primer, red system Inverse synthesis; 
3’-thioat 
3’-dTsdGATGTCATGTGTCGCAC -5’-
TTTTTTTTTTTTTTTTTTTTTVN-3’ 
  Detect1-1216g Detection probe 1, green system 5’-Cy3; 3’-thioat GGGATTATAAAGAACTGTdTsdG 
  Detect2-1216g Detection probe 2, green system 5’-Cy3; 3’-thioat CTCGACCGTTAGCAGCATGsdA 
  Detect3-1216g Detection probe 3, green system 5’-Cy3; 3’-thioat TCCGAGATGTACCGCTATCsdG 
  Detect4-1216g Detection probe 4, green system 5’-Cy3; 3’-thioat TCTTCTGGGCTAATTACAGsdC 
  Detect1-6121g Detection probe 1, red system 5’-Cy5; 3’-thioat CCCTAATATTTCTTGACAAsdC 
  Detect2-6121g Detection probe 2, red system 5’-Cy5; 3’-thioat GAGCTGGCAATCGTCGTACsdT 
  Detect3-6121g Detection probe 3, red system 5’-Cy5; 3’-thioat AGGCTCTACATGGCGATAGsdC 
  Detect4-6121g Detection probe 4, red system 5’-Cy5; 3’-thioat AGAAGACCCGATTAATGTCsdG 
  Inv1216Arl RCA primer for spotting, green 
system 
5’-Amino-C6 TCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCGTGCGACACA
TGACATCAAC 
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2.5 Oligonucleotide Microarrays 
 
 
2.5.1 Preparation of Fluorescent Targets 
 
2.5.1.1 Reverse Transcriptase (RT) Labeling 
For preparation of unamplified cDNA target, 40 µg of total RNA were heated for 4 min 
at 70° C in the presence of 2 µg oligo(dT21)VN in a total volume of 13.9 µl and chilled 
on ice. Labeling-mix was added, yielding final concentrations of 1x First-Strand 
Buffer, 10 mM dithiothreitol, 500 µM each of dATP, dGTP and dCTP, 200 µM dTTP, 
100 µM Cy3- or Cy5-dUTP, 2 U/µl RNasin ribonuclease inhibitor as well as 
13.33 U/µl Superscript II reverse transcriptase in a total volume of 30 µl. Samples 
were incubated first at 25° C for 3 min and, thereafter, at 42°C for 2 h, with further 
200 U Superscript II (200 U/µl) added after one hour. 15 µl 0.1 M NaOH, containing 
2 mM EDTA, were added to stop the reaction. RNA was hydrolyzed at 70 °C for 
20 min. Finally, the pH was neutralized by addition of 15 µl 0.1 M HCl. 
 
2.5.1.2 TAcKLE 
For amplification and labeling using the TAcKLE protocol, 2000, 200, 20 or 2 ng total 
RNA were employed in first- and second-strand cDNA synthesis as previously 
described 164, with minor modifications. Briefly, RNA was mixed with 100 ng (dT)-T7 
primer (5’-GCATTAGCGGCCGCGAAATTAATACGACTCACTATAGGGAGA(T)21VN-
3’) to a final volume of 5 µl, denatured 4 min at 70 °C and chilled on ice. 5 µl ice-cold 
RT-mix were added to the samples, yielding final concentrations of 1x First-Strand 
Buffer, 10 mM DTT, 500 µM of each dNTP, 400 ng/µl T4gp32, 2 U/µl RNasin 
ribonuclease inhibitor as well as 10 U/µl Superscript II reverse transcriptase. Reverse 
transcription was performed for 1 h at 50 °C and reactions were stopped by heating 
to 65 °C for 15 min. Following the addition of 65 µl ice-cold reaction-mix, second-
strand synthesis was performed for 2 h at 15 °C in 1x Second-Strand buffer, 200 µM 
of each dNTP, 0.27 U/µl DNA polymerase I, 1 U RNase H and 5 U E. coli DNA 
ligase. Then, 10 U T4 DNA polymerase (3.33 U/µl) were added to the samples and 
cDNA ends were polished for 15 min at 15 °C. Enzymes were heat inactivated by 
10 min incubation at 70 °C. To extract double-stranded cDNA, samples were mixed 
with 75 µl phenol/chloroform/isoamylalcohol (pH 8.0) and transferred to prespun 
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0.5 ml PLG heavy tubes. After 5 min centrifugation at 13,000 rpm, the aqueous 
phase was further purified on a P-6 Micro BioSpin column according to the 
manufacturer’s instructions, followed by ethanol precipitation. The cDNA was 
dissolved in 10 µl nuclease-free water and employed in an in vitro transcription 
reaction using a RiboMAX Large Scale RNA Production System T7 according to the 
manufacturer’s recommendations, but in 40 µl reaction volume and regularly mixing 
the samples every 30 min for 6 h. Following purification on RNeasy Mini filters and 
ethanol precipitation, aRNA was dissolved in nuclease-free water, preferentially at 
0.25 µg/µl. 
Second round RT was performed on 1 µg aRNA (where available) as described 
above, but with the following modifications: 0.5 µg random hexamer primer was used 
instead of (dT)-T7 primer. Samples were incubated 5 min at room temperature before 
addition of RT-mix to allow for annealing of N6-primer. The following temperature 
profile was employed for reverse transcription: 20 min at 37 °C, 20 min at 42 °C, 
10 min at 50 °C, 10 min at 55 °C, 15 min at 65 °C. RNase H digestion (1 U per 
reaction) was carried out for 30 min at 37 °C, followed by 2 min at 95 °C to degrade 
enzymes. 
When starting with 20 ng total RNA or less, two rounds of amplification were 
performed. For this purpose, purified aRNA samples were precipitated, dissolved in 
4 µl nuclease-free water and subjected to second round reverse transcription as 
described above. First-strand cDNA was mixed with 100 ng (dT)-T7 primer in a final 
volume of 11 µl, incubated 10 min at 42 °C and chilled on ice. Thereafter, second-
strand synthesis, cDNA purification, in vitro transcription, aRNA clean-up and third 
round reverse transcription (primed with random hexamers) were performed as 
described above.  
cDNA labeling by Klenow fragment was performed using the Bioprime Kit, but with a 
modified protocol. Briefly, 10 µl cDNA sample were mixed with 90 µl Klenow-mix to 
yield a reaction mixture that contained 1x random primer solution, 200 µM each of 
dATP, dCTP and dGTP, 50 µM dTTP, 30 µM Cy3- or Cy5-dUTP and 0.8 - 1 U/µl 
Klenow fragment. DNA polymerization was carried out at 37 °C for 16 h. 
 
2.5.1.3 Sample Purification 
To remove unincorporated nucleotides and nucleotide-dye conjugates, cDNA 
samples were purified on Microcon YM-30 filter columns. This separation is based on 
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size exclusion centrifugation (ultrafiltration) through a custom cellulose membrane. 
The membrane pores are permeable for salts, nucleotides and small macro-
molecules of up to 30 kDa (50 bp, 60 b), whereas the cDNA product is retained on 
the membrane.  
Corresponding cDNA samples were combined and purified on Microcon YM-30 filter 
columns, as previously described 90. For blocking of repetitive sequence elements, 
25 µg C0t-1 DNA, 25 µg poly-A RNA and 75 µg yeast tRNA were added before the 
final washing step. 
 
 
 
2.5.2 Preparation and Post-Processing of Microarrays 
 
2.5.2.1 Microarray Spotting 
Synthetic 70mer oligonucleotides ("Human Genome Oligo Set Version 2.1"; 
consisting of 21,329 oligonucleotides representing human genes and transcripts plus 
24 controls, as well as “Human Genome Oligo Set Version 2.1 Upgrade”, consisting 
of 5,462 human 70mer probes) were purchased from Operon Technologies 
(Cologne) and dissolved in FBNC spotting buffer 165 (25% (v/v) formamide, 0.5 M 
betaine, 0.5 µg/µl = 0.05% (w/v) nitrocellulose, 2.5% (v/v) DMSO) at 40 µM, using a 
MiniTrak robotic liquid handling system. DNA spotting was performed in duplicates 
on QMT epoxysilane coated slides using an OmniGrid Microarrayer equipped with 
Stealth SMP3 Micro Spotting Pins. Spot centers were 129 µm apart.  
 
2.5.2.2 DNA Immobilization 
DNA adhesion to the glass surface was accomplished by 1 h incubation at 60 °C, 
followed by UV irradiation (2x 120 mJ/cm2 at 254 nm) in a Stratalinker Model 2400 
UV illuminator.  
 
2.5.3 Microarray Hybridization 
Just prior to hybridization, slides were washed for 2 min in 0.2% SDS (w/v), 2 min in 
ddH2O at room temperature and 2 min in boiling ddH2O (95 °C), followed by 3 min 
centrifugation at 2,000 rpm. 
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Purified, dye-labeled cDNA was mixed with 120 µl UltraHyb hybridization buffer 
(Ambion), agitated for 30-60 min at 60 °C, then for 10 min at 70 °C on a thermo mixer 
and subsequently applied to pre-heated (60 °C) microarrays mounted in a GeneTAC 
Hybridization Station. Hybridizations were performed for 16 h at 42 °C with gentle 
agitation. Thereafter, the arrays were automatically washed at 36 °C with (i) 
0.5x SSC, 0.1% (w/v) SDS for 5 min; (ii) 0.05x SSC, 0.1% (w/v) SDS for 3 min; (iii) 
0.05x SSC for 2 min. Flow time was set to 40 sec, respectively. Immediately after 
completion of the final washing step, the arrays were unmounted, immersed in 
0.05x SSC, 0.1% (w/v) Tween 20 and dried by centrifugation in 50 ml Falcon tubes 
(30 sec at 500, 1000 and 1500 rpm, respectively, followed by a final step of 90 sec at 
2000 rpm). 
 
 
2.5.4 Data Acquisition 
Hybridized microarrays were scanned at 5 µm resolution and variable PMT voltage to 
obtain maximal signal intensities with <0.1% probe saturation, a count ratio of 0.8-1.2 
(Cy5 / Cy3) and maximal congruence of histogram curves, using a GenePix 4000B 
microarray scanner. Subsequent image analysis was performed with the 
corresponding software GenePix Pro 5.0. Spots not recognized by the software were 
excluded from further considerations. 
 
2.5.5 Affymetrix GeneChip Arrays 
5 µg of total RNA were used to prepare fragmented, biotinylated cRNAs for 
hybridization, following the guidelines given in the Affymetrix GeneChip Expression 
Analysis Technical Manual 166. cRNA clean-up was performed on RNeasy Mini filters. 
10 µg of fragmented, labeled cRNA were hybridized to Affymetrix HG U133A arrays 
(Affymetrix, Santa Clara, CA) using standard conditions (16 h, 45 °C). Arrays were 
washed and stained in a Fluidics Station 400 (Affymetrix) and scanned on a Gene 
Array Scanner 2500 (Agilent), as recommended by Affymetrix. This work was 
performed by Dr. Negusse Habtemichael (Chemotherapeutisches Forschungs-
zentrum Georg-Speyer-Haus, Frankfurt am Main). 
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2.5.6 Data Processing and Analysis 
 
If debugging is the process of removing bugs, then programming must be the 
process of putting them in. 
EDSGER DIJKSTRA 
 
 
Most of the data processing and analysis was carried out in close collaboration with 
Dr. Carina Ittrich (Central Unit Biostatistics, German Cancer Research Center). Dipl.-
Biol. Grischa Toedt (Division of Molecular Genetics, German Cancer Research 
Center) provided valuable support, especially concerning data normalization, by 
means of the ‘ChipYard’ framework for microarray data analysis. 
 
2.5.6.1 Data Normalization 
Result files containing all relevant scan data were further processed using the open 
source statistical software environment R (http://www.r-project.org) 167 together with 
libraries (packages) of the Bioconductor project (http://www.bioconductor.org) 168. For 
each hybridization, raw fluorescence intensities were normalized applying variance 
stabilization 169. For GeneChip arrays, raw fluorescence intensities from all 
hybridizations were normalized applying variance stabilization 169 with additional 
scaling. Additionally, MAS5 170 as well as gcRMA 171 expression values were 
calculated. 
 
2.5.6.2 Data Filtering 
To eliminate low quality data from spotted microarrays, the data points were ranked 
according to spot homogeneity, as assayed by the ratio of median to mean 
fluorescence intensity, the ratio of spot to local background intensity and the standard 
deviation of the logarithmic ratios (log2 Cy5 / Cy3) between spot replicates. Those 
data points ranked among the lower 20% were removed from the data set. Genes 
that could not be quantified in more than 33% of all experiments after filtering were 
excluded as well. To combine the data of dye swap experiments, the log2-
transformed intensity ratios of one array were inverted and averaged with the 
corresponding values of the other array.  
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Concerning the comparison of the array platforms, an optional filtering procedure 
additionally excluded those data points considered unreliable 172,173 as they 
correspond to probes associated with signal intensities less than two standard 
deviations above local background for at least one channel of the pair of Operon 
chips or to probe sets with mean log2 expression values below the median for all 
probe sets of the pair of GeneChips 172,173. This strategy was chosen in order to 
extract high quality data from both array platforms as a sound foundation for 
quantitative comparisons. More sophisticated filtering based on variance rather than 
absolute expression levels was not applied due to the deliberate shortage of 
replicates. Expression ratios of genes with a signal close to the background (low 
abundance) in only one of the two investigated conditions are clearly significant in a 
biological context. They were, however, considered less appropriate to this 
comparative study, as their results were expected to carry an increased and 
mathematically inevitable degree of variation not caused by characteristics of the 
investigated platforms. 
 
2.5.6.3 Orthogonal Regression and Pearson Correlation 
To investigate the linear relationship between data points, regression lines were 
determined by minimizing the sum of squares of the Euclidean distance of points to 
the fitted line (“orthogonal regression”), as there is no clear assignment of dependent 
and independent variables. Correlations were estimated using the Pearson 
correlation coefficient together with its 95% confidence interval.  
 
2.5.6.4 Linear Modeling 
To compare log2 ratios obtained by TAcKLE amplifications of 2,000, 200, 20 and 2 ng 
starting material to those obtained by RT labeling, a linear model with RT labeling as 
reference was fitted separately for each gene. p-values were calculated using Wald 
statistics. This analysis was performed for all spots with quantified log2 ratios in at 
least 9 of the 10 arrays remaining after exclusion of self-self and dye swap 
hybridizations (see Table 11), hence the Wald statistics were checked for 
significance using a t-distribution with 4 or 5 degrees of freedom, respectively. The 
magnitude of the effects as well as the corresponding p-values are illustrated as 
volcano plots 174.  
 
46 MATERIALS AND METHODS 
 
 
2.5.6.5 Identification of Differentially Expressed Genes 
Identification of differentially expressed genes was performed by empirical Bayes 
inference for paired data 175. Moderated t-statistics, based on shrinkage of the 
estimated sample variance towards a pooled estimate and corresponding p-values, 
were calculated using the Bioconductor R package limma 176. P-values were adjusted 
according to the method proposed by Benjamini and Hochberg 177 to control the false 
discovery rate at a level of 10%. The magnitude of the effects as well as the 
corresponding p-values are illustrated as volcano plots 174.  
 
2.5.6.6 Distance Weighted Discrimination 
To remove systematic variation resulting from the different technical approaches of 
the investigated array platforms or differences in sample handling procedures 
between the two labs participating in this study, ‘Distance Weighted Discrimination 
(DWD)’ 178 was performed on normalized log2-ratios from both array platforms, using 
Matlab software freely available at https://genome.unc.edu/pubsup/dwd/. Further 
details about cross platform adjustment of microarray data can be obtained at 
http://genome.med.unc.edu:8080/caBIG/DWDNCI60.htm and http://genome.med. 
unc.edu:8080/caBIG/paper1.pdf. Identification of differentially expressed genes and 
DWD were only performed for spots with quantified log2 ratios in all four primary 
HNSCC versus normal mucosa experiments. 
 
2.5.6.7 GO Data Mining and EASE Overrepresentation Analysis 
GO (Gene Ontology) 179 data mining was performed using the GOCharts functionality 
of the ‘Database for Annotation, Visualization and Integrated Discovery (DAVID)’ 180, 
which is available at http://david.niaid.nih.gov/david/. Overrepresentation analysis 
was carried out with the software application ‘Expression Analysis Systematic 
Explorer (EASE)’ 181, downloaded from http://david.niaid.nih.gov/david/ease.htm.  
 
2.5.6.8 Matching of Oligonucleotide Probe Sequences 
The Bioconductor R package AnnBuilder 182 and GenBank accession numbers, 
provided by Affymetrix and Operon, were used to map probe sequences to 
corresponding UniGene clusters (build #175). Microarray data were only used if the 
Affymetrix probe set and the Operon probe corresponded to the same UniGene 
cluster from the intersection of both platforms (n = 4,425). For simplicity, if probe sets 
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(Affymetrix) mapped to multiple UniGene clusters or if several probes (Operon) or 
probe sets (Affymetrix) mapped to the same UniGene, they were excluded from 
further analyses. 
 
 
 
 
2.5.7 Accession Numbers 
 
Science is organized knowledge. Wisdom is organized life. 
IMMANUEL KANT 
 
 
All relevant data from the TAcKLE study are available from GEO 
(http://www.ncbi.nlm.nih.gov/geo) under the accession numbers GPL1384 (for the 
array platform), GSM27816-GSM27819, GSM27835, GSM27836 and GSM27915-
GSM27928 (for expression data from individual arrays) as well as GSE1645 (for the 
experimental series). 
Data from the cross-platform comparison are available under the accession numbers 
GPL96 and GPL1384 (for the array platforms), GSM29702-GSM29705, GSM29747-
GSM29758, GSM29808-GSM29813, GSM29818 and GSM29820 (for expression 
data from individual arrays) as well as GSE1722 (for the experimental series). 
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2.6 RQ-PCR Analysis 
 
For selected genes, changes in mRNA levels detected in microarray experiments 
were evaluated by reverse transcription (RT) and quantitative real-time PCR 
analysis, using the iCycler (BioRad, Munich, Germany). This work was carried out by 
Dr. Negusse Habtemichael (Chemotherapeutisches Forschungszentrum Georg-
Speyer-Haus, Frankfurt am Main). One microgram of total RNA was converted to 
cDNA using Superscript II reverse transcriptase (Invitrogen) and oligo(dT) primer, 
according to the manufacturer’s specifications. PCR reaction mixtures consisted of 
12.5 µl of 2x iQ™ SYBR® Green Supermix (Abgene, Hamburg, Germany), 0.5 µl of 
each 10 µM target primer and 1 µl diluted cDNA template (1:10) in a reaction volume 
of 25 µl. Thermal cycling conditions comprised an initial denaturation step of 15 min 
at 95 °C, 40 cycles of 30 s at 95 °C and 30 s variable annealing/elongation 
temperature, depending on the respective set of target primers. dsDNA-specific 
fluorescence was measured at the end of each extension phase. Product-specific 
amplification was confirmed by a melting curve analysis. The relative expression ratio 
(R) of a target gene was calculated using the equation: 
 
( )
( ) sample)(controlref
sample)(controltarget
ref
target
−
−
Δ
Δ
= CP
CP
E
E
R  
 
based on its real-time PCR efficiencies (E) and the crossing point (CP) differences of 
sample versus a control, and expressed in comparison to a reference gene 183. The 
target gene expression was normalized to glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). 
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2.7 Rolling Circle Amplification 
 
 
2.7.1 Padlock Probe Ligation 
To prepare the circular oligonucleotides used as templates for the rolling circle 
amplification, DNA ligation was performed for 1.5 h at 37 °C in a final volume of 1 ml 
containing 1 µM linear padlock oligo (Table 10), 3 µM biotinylated ligation template 
(Table 10), 1x T4 DNA ligase buffer, 0.5 µg/µl BSA, 1 mM ATP as well as 0.05 U/µl 
T4 DNA ligase. The reaction was stopped by addition of EDTA ad 5 mM. 
 
 
2.7.2 Purification of Circularized Padlock Probes 
To separate the ligated oligonucleotides from the biotinylated ligation templates and, 
thus, obtain pure circular probes, the ligation product was purified using streptavidin-
coated magnetic beads. Briefly, 1500 µl suspension of beads was washed with an 
equal amount of 1x B&W buffer (binding and washing buffer; 5 mM Tris-HCl, 0.5 mM 
EDTA, 1 M NaCl, pH 7.5) - as a magnetic particle concentrator was unavailable, the 
beads were separated from the supernatant by 1 min centrifugation at 2000 rpm -
 and resuspended in 1500 µl 2x B&W buffer. Subsequently, 1000 µl ligation product 
as well as 500 µl ddH2O was added and the suspension was incubated 30 min at RT, 
applying gentle rotation or frequent mixing to keep the beads in suspension and thus 
allow for efficient binding of the ligation templates bound to the circularized probes. 
Then, the beads were again washed with 1500 µl 1x B&W buffer, separated by 
centrifugation and resuspended in 500 µl ddH2O. Finally, the sample was denatured 
for 2 min at 95 °C and the beads were spun down. The supernatant containing the 
circularized probes was collected and transferred to a fresh tube. The DNA 
concentration was measured by spetrophotometry and, if applicable, adjusted in a 
vacuum concentrator to obtain an appropriate working concentration of 0.1 - 1 µM. 
 
 
2.7.3 Reverse Transcription with Aminoallyl-dUTP 
For preparation of aminoallyl-tagged cDNA suitable for subsequent rolling circle 
amplification, 50 µg total RNA were heated for 4 min at 70 °C in the presence of 2 µg 
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1216g-double-3’ or 6121g-double-3’ primer (Table 10) in a total volume of 13.9 µl and 
chilled on ice. Labeling-mix was added, yielding final concentrations of 1x First-
Strand Buffer, 10 mM DTT, 500 µM each of dATP, dGTP and dCTP, 320 µM dTTP, 
166.66 µM aminoallyl-dUTP, 2 U/µl RNasin ribonuclease inhibitor as well as 
13.33 U/µl Superscript II reverse transcriptase in a total volume of 30 µl. Samples 
were incubated first at 25 °C for 3 min and, thereafter, at 42 °C for 1 h. 15 µl 0.1 M 
NaOH, containing 2 mM EDTA, were added to stop the reaction. RNA was 
hydrolyzed at 70 °C for 20 min. Finally, the pH was neutralized by addition of 15 µl 
0.1 M HCl, and the samples were purified using Microcon YM-30 centrifugal filter 
devices and PBS. 
 
 
2.7.4 Psoralen Conjugation (Preparation of cDNA-psoralen conjugates) 
Psoralen (C11H6O3; CAS # 66-97-7) is the basic material of the furocoumarin family of 
drugs. The substance can be found in essential oils from plants of the Psoralea 
genus of Leguminosae. If activated by UV-A light, psoralen can introduce inter-strand 
cross-links between nucleotides in complementary DNA strands. For this reason, it is 
used together with UV light to treat skin diseases such as psoriasis, vitiligo and even 
skin nodules of cutaneous T-cell lymphoma. We intended to use the cross-linking 
potential of psoralen as a means of covalently coupling hybridized cDNA strands to 
their complementary oligonucleotides attached to the microarray surface. 
To derivatize the aminoallyl-tagged cDNA with psoralen, 20 µl purified cDNA sample 
were mixed with 15 µl conjugation buffer (1 M sodium bicarbonate NaHCO3, 150 mM 
NaCl) and 40 nmole SPB (succinimidyl-[4-(psoralen-8-yloxy)]butyrate; C19H15NO8; 
NHS-psoralen; Pierce Biotechnology, Rockford, USA) in 1.2 µl DMSO. SPB is an 
amine-reactive NHS ester coupled to the DNA-intercalating, photoreactive psoralen-
group. The NHS ester will cross-link to primary amines in target molecules 
(aminoallyl-tagged cDNA) at pH 7-9 to form stable amide bonds (Fig. 12). For this 
purpose, the sample was protected from light and incubated for 30 min at RT. 
Subsequently, it was purified by 2 PBS washes using a Microcon YM-30 centrifugal 
filter device. 
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Figure 12. Coupling of NHS-psoralen to aminoallyl residues. 
 
 
 
2.7.5 Photoreactive Coupling 
For photoreactive coupling of psoralen-derivatized cDNA molecules to their 
complementary array probes, human 27K oligonucleotide microarrays were prepared 
as described in 2.5.2.1 and hybridized with psoralen-cDNA as described in 2.5.3. 
Subsequently, the arrays were exposed for 15 min to 366 nm UV-A light (8 W) from a 
distance of 3 cm, yielding inter-strand cross-links to the 5,6 double bonds in thymine 
residues (Fig. 13). 
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Figure 13. Photoreactive inter-strand cross-linking of dsDNA via psoralen. The figure was modified from an 
illustration kindly provided by cand. biol. Daniel Haag. 
 
 
 
2.7.6 Rolling Circle Amplification on Oligonucleotide Microarrays 
The reaction mixture for on-chip RCA contained 1x Ф29 buffer, 0.5x SSC, 200 µM of 
each dNTP, 200 nM circularized PL-1216g and/or circularized PL-6121g, 20 nM of 
each Detect1-1216g - Detect4-1216g and/or 20 nM of each Detect1-6121g - Detect4-
6121g as well as 350 ng (35 U) Ф29 DNA polymerase in a total volume of 120 µl. To 
perform the reaction, human 27K oligonucleotide microarrays containing 
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complementary, psoralen-coupled cDNA were mounted in a GeneTAC Hybridization 
Station and overlaid with 120 µl reaction mixture. Subsequently, the following 
temperature profile was applied: 15 min at 25 °C to allow for hybridization of the 
circular oligonucleotide templates to their complementary sequences in the cDNA, 
30 - 90 min at 37 °C for rolling circle replication and another 15 min at 25 °C for 
efficient hybridization of the dye-labeled detection probes. Finally, the arrays were 
automatically washed at 25 °C with (i) 0.75x TNT buffer (0.1 M Tris-HCl, pH 7.5) for 
3 min, (ii) 0.1x SSC, 0.1% (w/v) SDS for 2 min and (iii) 0.05x SSC for 1 min, followed 
by 5 min of automatic draining. The arrays were scanned as decribed in 2.5.4. 
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3 Results 
 
 
3.1 Target Amplification for Oligonucleotide Microarrays 
 
3.1.1 Motivation 
The large amount of required RNA material is a restricting aspect of any array-based 
expression profiling approach. cDNA arrays usually require at least 15 µg total RNA, 
and the preferred amount for spotted oligonucleotide arrays is increased to about 
50 µg, due to the decrease in possible base pairings. Hence, reliable transcriptome 
amplification is essential for many quantitative analytical approaches, such as RNA 
expression analysis of tumor biopsies 107, sorted cell populations 184, laser capture 
microdissected cells and tissues 185 or any other study based on small tissue samples 
or minute numbers of cells. Methods were developed that amplify initial poly(A) RNA 
and, thereby, increase detection sensitivity by orders of magnitude.  
Amplification can, in principle, either be performed exponentially using PCR-based 
approaches 108-110, or in a linear fashion, mostly by generation of cDNA followed by in 
vitro transcription with T7 RNA polymerase 111,112,164,186. However, the kinetics of 
PCR-based methods implies that both sequence-dependent and copy-number 
dependent bias will be amplified exponentially as well and accumulate. Another 
important issue is the influence of sampling errors when handling very limited 
amounts of RNA 115,187. For these reasons, exponential amplification protocols are 
generally considered less applicative for quantitative transcriptome analyses.  
T7-based methods, on the other hand, are routinely used for expression profiling 
studies in combination with cDNA microarrays, and several studies have 
demonstrated their reliability 164,186. Recently, large collections of long 
oligonucleotides (50-80 bases) have become increasingly popular as probes for 
spotted DNA arrays. Technical advantages of oligonucleotide arrays include a 
constant DNA concentration across all spots and biophysically optimized sequences, 
reducing secondary structures, avoiding repetitive sequences and providing a fixed 
range for both Tm and length. This accounts for more uniform, stable and predictable 
hybridization conditions.  
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Figure 14. Compatibility of unamplified and T7-amplified target molecules with sense-oriented oligonucleotide 
arrays. Sense-oriened mRNA can be transformed to fluorescent antisense-oriented cDNA by means of a simple 
reverse transcription reaction. The resulting first-strand cDNA can be hybridized to oligonucleotide arrays with 
probes in sense orientation. Fluorescent cDNA targets obtained by reverse transcription labeling of antisense-
oriented amplified RNA, on the other hand, are incompatible for hybridization to sense-oriented oligonucleotide 
libraries. 
 
 
 
However, starting from cellular, sense-oriented mRNA, the orientation of T7-amplified 
RNA will be antisense (aRNA). Therefore, it cannot be used for reverse transcription 
labeling and hybridization to sense-oriented, gene specific oligonucleotide libraries. 
Oligonucleotides of commercial libraries are sense-oriented to complement antisense 
targets produced by reverse transcription of unamplified RNA. Sense cDNA derived 
from aRNA is incompatible for hybridization to these sequences (Fig. 14). 
 
3.1.2 Protocol Variants 
 
The best way to have a good idea is to have lots of ideas. 
LINUS PAULING 
 
 
Both the conception and the execution of the initial experiments presented in 3.1.2 
must be ascribed in part to Dipl.-Biol. Dirk Olaf Thürigen.  
Some approaches try to overcome the strand orientation problem by producing 
labeled aRNA during in vitro transcription 122 (Fig. 8), but in our hands the yield of this 
procedure was insufficient. Therefore, the method was not further investigated. 
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Another option for the generation of antisense-oriented target molecules would be in 
vitro transcription from a promoter positioned upstream of the cDNA sequence, e.g., 
by exploiting the template-switching effect 188 of Moloney murine leukemia virus 
(MMLV) reverse transcriptase (“inverse IVT”, Fig. 15).  
 
 
 
 
Figure 15. Inverse in vitro transcription. The inverse IVT method exploits the template-switching effect of 
MMLV reverse transcriptase to permit in vitro transcription from a promoter positioned upstream of the cDNA 
sequence. See text for details. 
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It had been observed that, upon reaching the 5’-end of the RNA template, MMLV 
reverse transcriptases add a few non-template nucleotides, primarily deoxycytidine, 
to the 3'-end of a newly synthesized cDNA strand. Oligonucleotides with an oligo(dG) 
sequence at the 3’-end (so-called template-switch or TS-oligos) can basepair with the 
deoxycytidine stretch at the 3’-end of the cDNA, creating an extended template that 
causes the enzyme to continue replicating to the end of the oligonucleotide 188. Thus, 
a sequence complementary to the TS-oligo is attached to the cDNA 3’-end. Following 
second strand cDNA synthesis, repeated transcription from the T7-promoter 
sequence incorporated by the TS-oligo yields multiple copies of sense-oriented RNA 
molecules. These can be labeled by reverse transcription and hybridized to 
microarrays containing oligonucleotide probes in sense orientation (Fig. 15).For 
unknown reasons, however, this method did not generate sufficient amounts of RNA 
material, and no analyzable results could be obtained. 
In a recent publication, Smith et al. 123 claimed that their amplification procedure, 
termed “Single Primer Amplification” (SPA), could also be used for microarrays 
containing oligonucleotide probes in sense orientation, enabled by a “strand switch” 
of the polymerase used for target labeling (Fig. 9). Unfortunately, these 
considerations could not be confirmed in practice. Arrays hybridized with cDNA 
targets prepared by the SPA method displayed hardly any perceivable signals, and 
no interpretable data were obtained. 
A protocol termed “Template Switch Single Primer Amplification” (ts-SPA) was 
devised as a combination of the basic concepts of the inverse IVT approach and 
SPA. Once again the template-switching effect 188 of Moloney murine leukemia virus 
(MMLV) reverse transcriptase is exploited, but this time the specific sequence 
attached upstream of the cDNA is used as a priming site for Taq DNA polymerase 
rather than being a promoter for an RNA polymerase. A primer complementary to the 
sequence introduced by the TS-oligo binds to the first-strand cDNA and drives 
amplification by Taq DNA polymerase cycling extensions. The resulting sense-
oriented second strand molecules can be used as templates for dye labeling by 
Klenow fragment (Fig. 16). 
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Figure 16. Template Switch Single Primer Amplification (TS-SPA). The protocol exploits the template-
switching effect of MMLV reverse transcriptase, thermal cycling with Taq DNA polymerase and dye labeling by 
Klenow fragment. Details are given in the text. 
 
 
 
Two-color co-hybridizations of fluorescent target molecules prepared from 2 µg total 
RNA of the cell line HL-60 yielded reasonable correlations of fluorescence intensities 
(Fig. 17A). However, hybridizing targets prepared from 2 µg HL-60 total RNA versus 
such made from 2 µg total RNA of DLHL cells (RNA from both cell lines was kindly 
provided by Dipl.-Biol. Olaf Thuerigen) did not significantly reduce the degree of 
correlation (Fig. 17B). Consequently, using the TS-SPA method would drastically 
decrease our ability to identify differentially expressed genes, and it was decided not 
to conduct further investigations concerning this protocol. 
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Figure 17. Scatter plots of fluorescence intensities from amplification and labeling reactions using the TS-SPA 
method. (A) Co-hybridizations of independently amplified HL-60 RNA were used to assess the reproducibility 
of amplification. Fluorescent targets prepared from HL-60 RNA were hybridized versus targets prepared from 
DLHL RNA to estimate the method’s potential to identify differentially expressed genes. 
 
 
 
3.1.3 T7 Amplification and cDNA Klenow Labeling for Expression Analysis  
One more protocol for the generation of labeled antisense cDNA was devised. The 
method utilizes mRNA amplification by in vitro transcription (IVT) of cDNA, as first 
described by van Gelder et al. 112, and fluorescent labeling by Klenow fragment. 
Initial mRNA is copied by an RNase H- MMLV reverse transcriptase, using a modified 
oligo(dT)-primer to incorporate the promoter sequence of phage T7 RNA 
polymerase. An RNase H- polymerase is used to ensure that an RNA/DNA hybrid is 
produced. RNase H treatment of this heteroduplex creates RNA fragments that prime 
second strand synthesis by E. coli DNA polymerase I. Repeated transcription from 
the T7 promoter on the cDNA template results in multiple copies of antisense RNA 
(aRNA), which may be reamplified as previously described 111. 
Briefly, random hexamers prime another round of reverse transcription, which 
generates sense-oriented cDNA with 5’-oligo(dA). An oligo(dT)-T7 primer recognizes 
this sequence and initiates second strand synthesis, once more generating double-
stranded cDNA with a T7-promoter downstream of the transcript sequence. Then, 
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another round of in vitro transcription yields additional antisense-oriented copies 
(aRNA) of the initial mRNA.  
Finally, and regardless of the number of transcription reactions, random hexamers 
are used to reversely transcribe the aRNA into sense cDNA. This serves as template 
for randomly primed Klenow labeling, yielding mainly fluorescent antisense cDNA as 
a suitable target for oligonucleotide libraries in sense orientation (Fig. 18).  
 
As initial experiments with this protocol were very promising (data not shown), it was 
decided to evaluate the method, termed Target Amplification and cDNA Klenow 
Labeling for Expression analysis (TAcKLE), in more detail.  
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Figure 18. Schematic overview of the TAcKLE protocol. mRNA is linearly amplified by in vitro transcription 
(“T7 amplification”). The resulting aRNA is subsequently converted to cDNA and labeled by dye-dUTP 
incorporation using Klenow fragment. The resulting antisense-oriented cDNA is suitable for hybridization to 
sense-oriented oligonucleotide microarrays. 
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3.1.4 Experimental Design 
 
Things should be made as simple as possible, but not any simpler. 
ALBERT EINSTEIN 
 
 
A single source of reference (pooled from ten human cell lines representing distinct 
tissues) and breast total RNA was used for all experiments to avoid variations in 
transcript abundance imposed by the RNA preparation. Each RNA pool was serially 
diluted to provide four distinct starting quantities equivalent to 2, 20, 200 and 
2,000 ng. In total, 20 two-color hybridizations were performed, comprising one co-
hybridization of reference RNA, two hybridizations of breast RNA versus reference 
RNA (Cy5 / Cy3) and one hybridization of reference RNA versus breast RNA (dye 
swap), both for TAcKLE amplifications of all four amounts of input material and for 
reverse transcription labeling (Table 11). All dye labeling reactions using Klenow 
fragment were made from separately amplified RNA aliquots. One round of linear 
RNA amplification resulted in approximately 103-fold amplification of starting mRNA 
and two rounds yielded up to 105-fold the starting amount, as determined by 
spetrophotometry and based on an estimated initial mRNA content of 2%. Labeled 
cDNAs were hybridized to microarrays containing 26,791 gene specific 70mer 
oligonucleotide probes, each spotted in duplicate. 
 
 
Table 11. Experimental design (n denotes the number of arrays). 
 
Group 
 
Labeling Method 
 
Input / Channel 
 
Breast vs. Ref. (n) 
 
Ref. vs. Breast (n) 
 
Ref. vs. Ref. (n)
 
    1 
 
        TAcKLE 
 
         2 ng 
 
                2 
 
                1 
 
            1 
    2         TAcKLE        20 ng                 2                 1             1 
    3         TAcKLE      200 ng                 2                 1             1 
    4         TAcKLE    2000 ng                 2                 1             1 
    5             RT        40 µg                 2                 1             1 
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3.1.5 Reproducibility of Amplification 
Hybridizations of differentially labeled targets, independently prepared from the same 
dilutions of reference RNA, were performed as a first assessment of random bias 
introduced by the amplification and labeling procedure. The Pearson correlation 
coefficient of fluorescence intensities (Fig. 19) was high for all tested amounts of 
input RNA (r = 0.9945, r = 0.9900, r = 0.9905 and r = 0.9657 for 2,000 ng, 200 ng, 
20 ng and 2 ng starting material, respectively) and in good agreement with previous 
reported values for T7-based amplification protocols 164,186. This reflects a reliable 
amplification and consistent labeling with both Cy5- and Cy3-dUTPs. There is an 
increased scattering of low intensity data points for 2 ng of starting material, which 
might be attributed to sampling errors 115,187 (i.e., errors resulting from the stochastic 
distribution of low-copy-number templates) and represents a restricting aspect when 
depending on very strong amplifications. Still, the reproducibility of the amplification 
is equivalent or even superior when compared to target preparation by reverse 
transcription (r = 0.987; Fig. 20A). 
Of note, the correlation drops considerably if targets prepared from different amounts 
of starting material are compared (Fig. 22A). 
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Figure 19. Scatter plots of fluorescence intensities from replicate amplification and labeling reactions. Co-
hybridizations of independently amplified reference RNA were used to assess the reproducibility of 
amplification under diverse conditions. (A) 2,000 ng, (B) 200 ng, (C) 20 ng, (D) 2 ng starting material. 
Orthogonal regression lines are shown in red; the corresponding linear equations are given together with Pearson 
correlation coefficients and their 95% confidence intervals. A defined section of the respective microarray image 
is displayed in the lower right corner of each plot. 
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3.1.6 Reproducibility of Expression Ratios with and without Dye Swap 
Hybridizations of targets derived from human reference RNA and RNA extracted 
from normal human breast tissue were compared to determine the effect of the 
amplification procedure on the reproducibility of expression ratios. The Pearson 
correlations of log2-transformed normalized expression ratios were r = 0.9948, 
r = 0.9889, r = 0.9780 and r = 0.9938 for identically repeated hybridizations as well as 
r = -0.9803, r = -0.9496, r = -0.9424 and r = -0.9017 for hybridizations repeated with 
inverse assignment of fluorophores (dye swap), starting from 2,000 ng, 200 ng, 20 ng 
and 2 ng RNA material, respectively (Fig. 21). Apparently, the concordance of 
expression ratios is stable and independent of the amount of input RNA for identically 
repeated experiments, but decreases considerably in case of dye swap repeats as 
the amount of starting material is reduced. This might reflect differences in dye 
incorporation between cyanine-3 and cyanine-5 labeled dUTP, a known bias 
previously reported for fluorescent cDNA prepared by reverse transcription 
labeling 189. The respective correlations for these unamplified targets were r = 0.986 
and r = -0.872 (Fig. 20B-C). 
Once again, using unequal amounts of starting material for the hybridization 
experiments to be compared resulted in considerably decreased correlations 
(Fig. 22B-D). 
 
 
 
 
Figure 20. Characteristics of reverse transcription labeling reactions. (A) Scatter plot of fluorescence intensities 
from duplicate reverse transcription labeling reactions using universal reference RNA. (B-C) Scatter plots of 
log2-transformed expression ratios (log2 Cy5 / Cy3) from duplicate hybridizations of RT-labeled breast and 
reference RNA, with and without reversed assignment of fluorophores (dye swap); replicate spots were averaged 
before plotting. Defined sections of the respective microarray images are displayed in (A) the lower right or (B-
C) the lower right (adscissa) and upper left (ordinate) corner of each plot. Orthogonal regression lines are shown 
in red. 
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Figure 21. Scatter plots of log2-transformed expression ratios (log2 Cy5 / Cy3) from duplicate hybridizations. 
Amplified breast and reference RNA, with and without reversed assignment of fluorophores (dye swap) was 
employed to evaluate the accuracy and reproducibility of the experiment. Replicate spots were averaged. (A) 
2,000 ng; (B) 2,000 ng, dye swap; (C) 200 ng; (D) 200 ng, dye swap; (E) 20 ng; (F) 20 ng, dye swap; (G) 2 ng; 
(H) 2 ng, dye swap. The data were subjected to orthogonal regression analysis (red lines), associated linear 
equations are listed along with Pearson correlation coefficients. The 95% confidence intervals of the correlation 
coefficients are (0.9946, 0.9950), (-0.9809, -0.9796), (0.9885, 0.9892), (-0.9513, -0.9478), (0.9772, 0.9788),  
(-0.9444, -0.9404), (0.9936, 0.9940) and (-0.9050, -0.8983) for panels (A) through (H). Underlying microarray 
images are shown as fixed sections in an upper (ordinate) and lower (abscissa) corner of each plot. 
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Figure 22. Adverse effect of using unequal amounts of starting material. (A) 200 ng and 2,000 ng universal 
reference RNA were used in discrete amplification and labeling reactions with the TAcKLE protocol. The 
resulting cDNA targets were co-hybridized to the same array, and their fluorescence intensities were used to 
calculate the Pearson correlation. A defined section of the array is shown in the lower right corner of the plot. 
(B-D) To assess the influence of variable amounts of starting material on the agreement of expression ratios from 
replicate chip experiments, 2,000 ng, 200 ng, 20 ng and 2 ng breast and reference RNA were independently 
amplified by the TAcKLE protocol and used for duplicate microarray hybridizations with reversed assignment of 
fluorophores (dye swap). The log2-transformed expression ratios were averaged and used to calculate Pearson 
correlations of (B) 200 ng vs. 2,000 ng, (C) 20 ng vs. 200 ng and (D) 2 ng vs. 2,000 ng starting material. 
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3.1.7 Comparison of Amplified and Unamplified Targets 
 
The main practical application of microarray analysis is the identification of transcripts 
whose abundance differs between samples. To test the fidelity of target amplification, 
we determined the ratios of amplified breast cDNA versus amplified universal 
reference cDNA hybridizations, and examined how these correlated with the 
corresponding ratios obtained with unamplified targets. This analysis was used to 
test whether amplified targets would identify the same set of differentially expressed 
transcripts recognizable with unamplified targets. Not unexpectedly, Pearson 
correlations of the corresponding log2 ratios (r = 0.8727, r = 0.8713, r = 0.8565 and 
r = 0.8441 for the comparison of RT labeling to amplifications of 2000 ng, 200 ng, 
20 ng and 2 ng starting material) were not as high as for the comparison of repeated 
experiments (Fig. 23). The scattering of corresponding values increases towards 
higher absolute log2 ratios. Additionally, we observed an increase in the slope of the 
regression lines (m = 1.325, m = 1.338, m = 1.355 and m = 1.379; same order as 
above), demonstrating a common deviance in the absolute log2 ratios. On average, 
absolute ratios obtained with amplified targets were higher than those corresponding 
to the unamplified samples, prepared by reverse transcription labeling. 
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Figure 23. Scatter plots comparing log2-transformed expression ratios of amplified targets to ratios obtained 
with unamplified targets. Breast and reference RNA was used as starting material. Dye swap experiments were 
combined before plotting. Target amplified (TAcKLE) from (A) 2,000 ng, (B) 200 ng, (C) 20 ng and (D) 2 ng 
starting material was compared to unamplified target prepared by reverse transcription labeling. Orthogonal 
regression analysis was performed to derive the regression lines shown in red and their respective linear 
equations. Dashed lines through origin with slope 1 are displayed to accentuate the elevated slope. Pearson 
correlation coefficients and their associated 95% confidence intervals are listed as well. 
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3.1.8 Linear Modelling and Statistical Analysis 
 
To determine whether target amplification affected our ability to reliably profile gene 
transcription in the breast tissue, the relationship of the observed differences of log2 
ratios between amplified versus unamplified targets and the degree of differential 
expression was analyzed. We found 1479, 1483, 1444 and 1667 genes to be up-
regulated as well as 1237, 1291, 1376 and 1598 genes to be down-regulated in 
samples TAcKLE-amplified from 2000 ng, 200 ng, 20 ng and 2 ng RNA of healthy 
human breast tissue when compared to universal human reference RNA. 1171 and 
993 genes were identified as up- or down-regulated by reverse transcription labeling, 
respectively. Apparently, and in agreement with previous reports, target amplification 
yielded a slightly larger number of differentially expressed genes 190,191. The 
distribution of log2 ratios for the genes detected as differentially expressed in 
amplified and/or unamplified targets is depicted in Figure 24, which shows that a 
substantial number of those genes found by merely one method were close to 
reaching the threshold for differential expression (2-fold difference) with the other 
method as well. This observation is strengthened in Figure 25, where of the genes 
common to the data sets under comparison, only very few displayed a deviation of 
log2 ratios greater than 1 or smaller than -1 (44 and 47, 72 and 57, 45 and 66 as well 
as 85 and 115 genes, respectively, for the comparison of dye labeling by reverse 
transcription to TAcKLE amplifications using 2000 ng, 200 ng, 20 ng and 2 ng 
starting material; Fig. 25). Additionally, we applied a linear model to assign p-values 
to these differences. The results are displayed as volcano plots 174,192 (see 2.5.6.4) of 
p-value against log2 ratio difference (Fig. 26). These show the statistical significance 
of the observed differences in relation to their magnitude. Supporting the findings of 
Figure 25, similarly small numbers of genes (26 and 33, 59 and 43, 34 and 52, 68 
and 100) showed a significant (p < 0.001) difference of log2-transformed ratios when 
comparing across the target preparation techniques. In Figure 25, the intersection of 
the “outliers” from all amounts of starting material contains 275 genes for the 
unfiltered data sets and is empty for the filtered data sets. For Figure 26, the 
respective numbers of genes are 246 for the unfiltered data sets and 18 for the 
filtered data sets. No more than 1-4% of the considered probes were affected by a 
≥ 2-fold difference. Accordingly, there is strong concordance between expression 
ratios obtained with amplified and unamplified targets. 
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Figure 24. Scatter plots showing log2 ratios of the genes detected as differentially expressed between breast and 
reference RNA by either one or both target preparation techniques (reverse transcription labeling and 
amplification via the TAcKLE protocol). Data are shown for the comparisons of RT labeling versus targets 
prepared from (A) 2,000 ng, (B) 200 ng, (C) 20 ng and (D) 2 ng starting material. Genes showing differential 
expression with both methods are shown as red dots, while blue and green dots denote genes only found by 
either amplification or RT labeling, respectively. The numbers of genes found up- or down-regulated with either 
one or both methods are given in the lower right corners of the plots. 
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Figure 25. Mean difference (MA) plots displaying the difference of log2 ratios against the mean of log2 ratios. M 
is a measure for the difference of log2 ratios observed between amplified and unamplified targets, prepared from 
breast and universal human reference RNA (log2 [breast / reference]TAcKLE - log2 [breast / reference]RT). A is a 
measure for the average differential expression (½ [log2 [breast / reference]TAcKLE + log2 [breast / reference]RT]). 
Ratios of targets amplified from (A) 2,000 ng, (B) 200 ng, (C) 20 ng and (D) 2 ng starting material were 
compared to ratios of unamplified targets. Replicated experiments were averaged before calculating the 
differences and means of log2 ratios. Black dots correspond to probes detected on at least one array of each 
considered target preparation approach, probes shown as red dots additionally reached fluorescence intensities at 
least two standard deviations above local background. The respective quantities are specified underneath the 
panel headings, values for red dots given in parentheses. Values in the upper and lower left corners of each plot 
indicate genes that show at least a twofold change of expression ratios to either direction, as illustrated by 
horizontal dashed lines. 
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Figure 26. Volcano plots of p-values against the difference of log2-transformed expression ratios. The difference 
of log2 ratios observed between amplified and unamplified targets (log2 [breast / reference]TAcKLE –
 log2 [breast / reference]RT) is shown on the x-axis. The corresponding p-value of significance, derived by linear 
modeling, is shown on the y-axis. Ratios of targets amplified from (A) 2,000 ng, (B) 200 ng, (C) 20 ng and (D) 
2 ng starting material were compared to ratios of unamplified targets. Black dots correspond to probes detected 
on all or all but one arrays of all target preparation approaches, red dots indicate probes which additionally 
reached fluorescence intensities at least two standard deviations above local background on the arrays under 
consideration. The associated numbers of genes are given underneath the panel headings, values for red dots 
printed in parentheses. The plots were segmented to illustrate the relation of statistical significance (p < 0.001) to 
significance based on a twofold change criterion. Only genes indicated by spots in the upper left and right 
segments of the plots satisfy both criteria, their numbers explicitly shown. Genes located in the lower left and 
right segments display a large fold-change difference between amplified and unamplified targets but fail to 
achieve statistical significance. Genes found in the middle segments show no relevant difference of expression 
ratios, with (upper segments) or without (lower segments) additional statistical significance associated with this 
observation.
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3.2 Signal Amplification by Rolling Circle Replication 
 
3.2.1 Motivation 
Proper amplification procedures are required to analyze limited source material by 
microarray technology. The amplification can either be performed on the material 
itself (target amplification) or on the signal it generates on the array (signal 
amplification). For target amplification, T7-based protocols had most commonly been 
used. However, spotted oligonucleotide microarrays contain sense-strand probes, so 
traditional T7 amplification schemes producing anti-sense RNA are not appropriate 
when combined with conventional reverse transcription labeling methods (see 1.6). 
As shown in 3.1, target amplification via the TAcKLE protocol is a good solution to 
this problem.  
In terms of signal amplification, both tyramide signal amplification (TSA) and three-
dimensional multi-labeled structures (DNA dendrimers, 3DNA) had previously been 
used 126,127, but the results of these studies showed little promise. Furthermore, it had 
been shown that rolling circle replication could be adapted to an array-based format 
(RCA), and the methodology had successfully been used to analyze minimal 
amounts of cytokines on protein microarrays 158. It had also been demonstrated that 
spotted oligonucleotides could serve as primers for on-chip RCA 157. What was 
missing, although it had been suggested 157, was the implementation of the method 
for microarray-based expression profiling. There were, however, several both 
practical and theoretical considerations in favor of adapting on-chip RCA for a use in 
expression profiling. As shown above for the TAcKLE protocol, target amplification by 
in vitro transcription can yield excellent results. It is, however, both time-consuming, 
error-prone (e.g., for RNA degradation) and expensive due to the numerous enzymes 
and reagents necessary to complete the protocol. In addition, off-chip target 
amplification strategies can lead to sequence-dependent quantitation bias, because 
different transcripts with different biophysical properties have to be processed. In 
RCA, identical circles of DNA hybridize to short DNA primers (complementary to a 
portion of the circle) attached to the target molecules, and Ф29 polymerase 
synthesizes single-stranded concatameric DNA molecules composed of thousands of 
tandemly repeated copies of the circle. A more detailed explanation has already been 
given in the introduction. Since RCA, unlike other amplification procedures, produces 
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single amplified products that remain linked to the DNA primers, it is well suited to 
solid phase formats such as microarrays for generating localized signals at specific 
array locations. 
For these reasons, it was decided to evaluate the applicability of on-chip RCA for 
microarray expression analysis as a possible alternative to the TAcKLE protocol. 
 
3.2.2 Preparatory Experiments 
To choose a substrate with properties favorable for on-chip RCA, several 
commercially available microarray slides with different surface coatings (A: Slide E, 
epoxysilane-coated, Schott Nexterion, Jena; B: Slide AL, coated with aldehyde-
derivatized aminosilane, Schott Nexterion; C: GAPSII, aminosilane-coated, Corning 
Life Sciences, Acton, USA; D: CodeLink, coated with a three-dimensional amine-
reactive polymer, Amersham Biosciences) were selected and used for spotting of the 
RCA primer Inv1216Arl (Table 10). This oligonucleotide allows for a simplified 
experimental setup, in which circularized PL-1216g can directly be hybridized to DNA 
immobilized on the array surface without the need for prior generation and 
hybridization of compatible cDNA. Both RCA and detection were performed as 
described in 2.7.4, but without any oligonucleotides from the 6121g collection. These 
experiments were performed in the Research Group on Molecular Medicine 
(Department for Genetics and Pathology, Rudbeck Laboratory, University Uppsala, 
Sweden) in collaboration with Jonas Jarvius, MD, MSc. 
 
 
 
Figure 27. Evaluation of RCA performance with regard to the microarray surface coating. The oligonucleotide 
Inv1216Arl (Table 11), containing 20 nucleotides complementary to a portion of PL-1216g (Table 11) as well as 
an oligo(dTdC) sequence as spacer, was spotted on substrates coated with either (A) epoxysilane, (B) aldehyde-
derivatized aminosilane, (C) aminosilane or (D) a three-dimensional long-chain, hydrophilic polymer containing 
amine-reactive groups. RCA and detection were performed as described in 2.7.4. All arrays were scanned with 
the same PMT voltage (700 V) and are displayed with identical settings for brightness and contrast. 
76 RESULTS 
 
 
The strongest signals were clearly obtained with epoxysilane-coated slides 
(Fig. 27A). Both the aldehyde coating (Fig. 27B) and the three-dimensional polymer 
(Fig. 27D) yielded approximately comparable and second strongest signal intensities, 
but with increased background fluorescence detected on the 3D-coated substrates. 
The lowest intensities were obtained on aminosilane-coated substrates (Fig. 27C). 
Accordingly, Slide E epoxysilane-coated substrates were chosen for all consecutive 
experiments. 
 
3.2.3 The Challenge Caused by Long Amplification Products 
All of the subsequent experiments were conceptuated and carried out in collaboration 
with cand. biol. Daniel Haag. 
Depending on the assay conditions 141,145,146, Ф29 polymerase possesses an 
exponentially decaying polymerization rate of initially 1000 - 3180 nt/min and a half 
life of 11 h. This means that Ф29-catalyzed RCA yields approximately 600 - 2000-fold 
amplification of a circular 104-mer within 60 min, corresponding to 60 - 190 kb or 30 -
 95 µm of concatameric ssDNA.  
However, only 70 nucleotides of each cDNA carrying an attached amplification 
product are available for base-pairing to complementary array probes. Furthermore, 
these probes are contained in spots with an average diameter of 60 µm, which is in 
the range of the length of the amplification product.  
It is therefore of fundamental importance to keep the forces that act on the hybridized 
cDNA as week as possible. Otherwise, the amplification products might become 
stretched and dispersed or even displaced from the spots. Drying the microarrays by 
centrifugation is obviously not compatible with this situation (Fig. 28A).  
To approach this problem, the centrifugation step was omitted and replaced by the 
automatic draining functionality of the GeneTAC hybridization station (Fig. 28B). This 
procedure yielded clearly improved results, but a tendency towards stretching and 
possibly even dislocation remained. 
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We therefore devised a procedure that covalently links the hybridized cDNA 
molecules to their complementary array probes. To accomplish this, the cDNA is 
initially tagged with a primary amine by addition of aminoallyl-dUTP to the reverse 
transcription reaction. Then, amine reactive NHS-psoralen (Succinimidyl-[4-
(psoralen-8-yloxy)]-butyrate; SPB) is coupled to the aminoallyl residues of the cDNA 
(Fig. 12), forming stable amide bonds. 
Upon hybridization, the psoralen tricyclic planar ring system intercalates into the DNA 
duplex formed by the cDNA molecules and their complementary oligonucleotide 
probes on the array. Photoreactive coupling of psoralen to thymine residues is 
achieved by brief exposure to long UV light (366 nm), creating covalent inter-strand 
cross-links (Fig. 13) that firmly attach the cDNA to the array via their complementary 
oligonucleotides that are covalently linked to the array’s surface coating. 
This approach yielded a vast improvement in array performance with virtually no 
dispersion of the amplification products (Fig. 28C). As the basic protocols now 
seemed to function properly, the next goal was to implement a second 
oligonucleotide system to allow for competitive hybridization of two differently tagged 
cDNA populations, system-specific RCA and subsequent detection by distinguishable 
fluorophores. 
 
 
 
Figure 28. Successive improvements of the RCA protocol. (A) Section of a microarray after hybridization with 
tagged HL-60 cDNA and subsequent RCA using the system 1216g. The array was dried by centrifugation, as 
described in 2.5.3. A large portion of the concatemeric RCA product, visible as green threads, was stretched out 
by centripetal forces and detached from the site of amplification. (B) Section of a microarray hybridized with 
tagged HL-60 cDNA, RCA-amplified using the system 1216g and dried by automated draining. Compared to 
slides dried by centrifugation, considerably less RCA product was dispersed from the array spots. (C) Section of 
a microarray containing cDNA cross-linked to its oligonucleotide probes. HL-60 cDNA containing the 1216g-
tag as well as aminoallyl residues was reacted with NHS-psoralen as described in 2.7.4 and hybridized to the 
array. Inter-strand DNA cross-linking was achieved by 15 min irradiation with UV-A light (366 nm), as 
described in 2.7.5. Finally, RCA was performed using the system 1216g, and the array was dried by automated 
draining. 
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3.2.4 Two-Color Hybridizations 
To obtain a second set of oligonucleotides for the various steps of the RCA protocol 
(reverse transcription, oligonucleotide circularization, replication and detection), all 
sequences from the set 1216g were modified by exchanging every base for its 
complementary base, creating the set 6121g (Table 10). In this way, both sets were 
as different as possible regarding the respective sequences but still had similar 
biophysical properties, i.e., same length, same GC content etc. The oligonucleotides 
used for the detection of 6121g RCA product were labeled with Cy5 instead of Cy3. 
Now, both 1216g- and 6121g-tagged cDNA was prepared independently and applied 
on the same array for on-chip RCA (Fig. 29). 
Unfortunately, not only yellow spots of variable intensities were detected, as one 
would expect for a two-color co-hybridization of cDNAs prepared from the same 
RNA. There was also a considerable number of spots that were primarily if not 
exclusively green or red. Possible reasons for this are discussed in 4.2. Further 
improvements can be expected from a stepwise refinement of the protocols, and 
some conceivable points are mentioned in the discussion part of this thesis. The 
current procedure for on-chip RCA is summarized in Figure 30. 
 
 
 
Figure 29. Section of a microarray containing both 1216g-tagged and 6121g-tagged cDNA. Following 
hybridization and cross-linking, on-chip RCA products were detected by dye-labeled detection probes, using 
Cy3 for 1216g and Cy5 for 6121g. 
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Figure 30. On-chip RCA for microarray expression analysis. To allow for a larger illustration and, thus, achieve 
better readability, the figure was rotated 90° counterclockwise. Details of the successive protocol steps are given 
in the text. Modified from a figure kindly provided by cand. biol. Daniel Haag. 
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3.3 Cross-Platform Reproducibility of Oligonucleotide 
 Microarray Expression Profiles 
 
One who asks a question is a fool for five minutes; one who does not ask a 
question remains a fool forever. 
CHINESE PROVERB 
 
 
3.3.1 Motivation 
In the scope of this thesis, the protocol for on-chip RCA for microarray expression 
analysis could unfortunately not be sufficiently advanced to allow for a reasonable 
analysis of biological samples. Target amplification via the TAcKLE protocol, 
however, yielded excellent results, at least in terms of reproducibility and 
comparability of expression profiles to those generated on the same array platform 
with unamplified targets (see 3.1). Since it was planned to use this new method for a 
large-scale expression profiling study of primary breast cancer samples, it was of 
outstanding interest to find out about the comparability of expression profiles 
generated using the TAcKLE protocol and our platform of spotted 70-mer 
oligonucleotide arrays to profiles from other platforms. 
Today, researchers can choose from a broad variety of methods for global 
transcriptional profiling. Among the different technical approaches, microarray 
technology has gained a premier position. In principle, microarrays can be produced 
either by robotic printing (“spotting”) of DNA on a chemically modified glass 
surface 89, or by in situ synthesis of oligonucleotides via custom phosporamidite 
chemistry using either photolithography on a silane-reacted quartz substrate 92 or ink-
jet technology on a hydrophobic glass support 93.  
Spotted arrays usually contain cDNA-specific PCR amplicons (cDNA arrays), ranging 
from several hundred to a few thousand basepairs in size. Generally, no more than 
one amplicon is used to probe a given gene. Although they are technically 
challenging and require both optimized protocols 165 and workflow 193, cDNA arrays 
are typically produced by individual research groups or core facilities. Alternatively, 
they can be purchased from several commercial suppliers. But after the discovery of 
frequent discrepancies in the annotation of cDNA clones 194, investigators began to 
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realize potential drawbacks of this highly advocated technology. In situ synthesis of 
oligonucleotide probes requires sophisticated equipment for photolithography and 
solid phase chemistry, which is usually too complex and elaborate for an academic 
environment. A widespread commercial implementation of this technology is the 
Affymetrix GeneChip platform 92, which currently uses 11-16 pairs (11 for the arrays 
used in this study) of perfect-match and single-base-mismatch 25-mer 
oligonucleotides for each gene. Recently, large collections of longer oligonucleotides 
(50-80 bases), produced by established suppliers using conventional 
phosphoramidite chemistry, have become increasingly popular as probes for spotted 
DNA arrays. Technical advantages of oligonucleotide arrays include a constant DNA 
concentration across all spots and biophysically optimized sequences, reducing 
secondary structures, avoiding repetitive sequence motives and providing a fixed 
range for both Tm and length. All this accounts for more uniform, stable and 
predictable hybridization conditions. The overall costs for long oligonucleotide arrays 
will often be lower when labor and other costs associated with cDNA libraries, such 
as replication, amplification or sequence verification, are regarded.  
Considering this diversity of approaches and the resulting technical differences, 
researchers are highly interested in the general accuracy and reliability of microarray 
data and the cross-platform comparability. Several independent methods like 
Northern blotting or real-time quantitative reverse transcription PCR (RQ-PCR) have 
been used to validate microarray results for a small number of transcripts. Generally, 
there was good agreement between the corresponding values, affirming the ability to 
accurately profile gene expression with array-based approaches. 
Former studies also compared global expression measurements between cDNA 
arrays and short oligonucleotide arrays 195,196 or SSH 197. Recently, Barczak et al. 173 
compared results between spotted arrays of 70-mer oligonucleotides and in situ 
synthesized Affymetrix GeneChip arrays. Using RNA of a cell line and a commercial 
reference RNA, they found strong correlations of the corresponding data sets. 
Despite these studies clarifying some fundamental questions, there still remains 
considerable uncertainty regarding the comparability of data from clinical specimens.  
This lack of understanding constitutes a barrier, which keeps researchers from an 
immense amount of potentially valuable information (via efficient integration of 
microarray data generated on different array platforms). In this thesis, a comparison 
with a small set of HNSCC tumor samples from clinical practice evaluates the cross-
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platform reproducibility between spotted 70-mer oligonucleotide arrays and the well-
established commercial Affymetrix GeneChip platform in a practical setting. 
 
3.3.2 Experimental Design 
To assess the degree of concordance between expression profiles obtained with 
either spotted oligonucleotide microarrays made from a large collection of 70-mer 
probes or commercial arrays produced by in situ synthesis of sets of multiple 25-mer 
oligonucleotides per gene, we analyzed relative gene expression in a set of six 
human head and neck squamous cell carcinoma (HNSCC) samples versus either 
healthy control mucosa (n = 4) or lymph node metastases (n = 2) of the respective 
patients as the reference (Table 12). For the spotted 70-mer arrays, relative 
expression levels were calculated by averaging the normalized log2-ratios of two 
replicate two-color hybridizations per patient, one performed with inverse assignment 
of fluorophores (dye swap). This procedure was used to eliminate dye-related signal 
correlation bias 198,199. For the commercial 25-mer arrays, relative expression levels 
were derived by subtracting normalized log2-transformed probe-level data 
(fluorescence intensities) of two single-color hybridizations per patient, corresponding 
to the respective tumor and reference tissue. 
 
 
 
Table 12. Patient and disease characteristics.  
 
Patient Primary Site Age Sex pT pN pM Grading Samples Analyzeda 
   160 hypopharynx  48  M  3  1  0       2           PT / N 
   171 hypopharynx  58  M  3  2a  0       2           PT / M 
   173 oropharynx  56  M  3  2  0       2           PT / N 
   180 hypopharynx  57  M  2  3  0       2           PT / N 
   186 hypopharynx  47  F  2  2  0       2           PT / N 
   205 oropharynx  49  M  3  1  0       2           PT / M 
       
aAll cases were diagnosed histopathologically as HNSCC and staged according to the TNM classification of malignant tumors. The indicated 
tissues were used for gene expression profiling. N: normal mucosa, PT: primary HNSCC, M: lymph node metastasis. 
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3.3.3 Probe Matching 
In this study, the gene expression profiles of 12 specimens obtained from six head 
and neck cancer patients were analyzed (Table 12). Four primary HNSCC were 
assayed versus corresponding healthy mucosa and another two primary HNSCC 
versus corresponding lymph node metastases of the respective patients. 
This analysis was performed both on in situ-synthesized Affymetrix HG-U133A 
arrays, containing 22,283 sets of 25-mer probes, and on spotted long oligonucleotide 
arrays containing 26,791 70-mer probes of the Operon Human Genome Oligo Set 
Version 2.1 and Version 2.1 Upgrade. A total of 9,867 UniGene clusters were found 
for the probe sets of the HG-U133A arrays, while 13,604 were retrieved for the 
Operon arrays, using GenBank accession numbers provided by the manufacturers. 
4,425 genes were represented on both platforms, as identified by consistent 
assignment of UniGene clusters to the corresponding probes or probe sets (Fig. 31). 
This large set of genes was used as a basis for comparing expression data from the 
two array systems. 
 
 
 
 
Figure 31. Intersection of probes or probe sets from the different array platforms. Probe sequences were mapped 
to UniGene clusters (build #175), based on GenBank accession numbers provided by the manufacturers. 9,867 
UniGene clusters were found for the probe sets of the HG-U133A arrays, while 13,604 were retrieved for the 
Operon arrays. A total of 4,425 genes were represented on both array types. 
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3.3.4 Intra-Platform Reproducibility of Expression Ratios 
For the platform of spotted long oligonucleotide arrays, correlations of expression 
ratios measured on individual arrays were r = 0.99 for identically repeated 
hybridizations and r = -0.98 for dye swap hybridizations repeated with inverse 
assignment of fluorophores (Fig. 21). Similar correlations had been reported for the 
Affymetrix system 164. Hence, both array platforms provide highly reproducible 
measurements of gene expression profiles, which is an essential pre-requisite for the 
success of a cross-platform comparison. 
 
3.3.5 Cross-Platform Reproducibility of Expression Ratios 
Normalized log2-transformed absolute signal intensities were calculated for the arrays 
from both platforms using variance stabilization by vsn 169. For GeneChip arrays, log2 
expression ratios were obtained by subtracting log2-transformed absolute signal 
intensities of the two respective arrays from each patient. For the spotted long 
oligonucleotide array, log2-ratios from two-color dye swap hybridizations were 
inverted and averaged. To ensure that the observed effects were not due to 
characteristics of the data processing algorithm, the analyses of GeneChip arrays 
were repeated using background correction and normalization by gcRMA 171 as well 
as the MAS5 algorithm 170. For all patients, there was a clear correlation between 
differential expression measurements made with either array type (r = 0.56 - 0.76), 
and the correlation improved substantially (r = 0.61 - 0.85) when measurements from 
probes with low intensity signals were excluded (Fig. 32). Except for patients 160 and 
186, the respective regression lines all showed a slope clearly smaller than 1, 
indicating that, on average, absolute log ratios obtained on the Operon long 
oligonucleotide platform were lower than the corresponding values measured with 
Affymetrix arrays. The changes in correlation were marginal when gcRMA was used 
to normalize the GeneChip results. MAS5 yielded lower correlations with unfiltered 
data, but the results were similar to those of vsn or gcRMA when filtered data were 
used (Table 13). 
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Figure 32. Scatter plots comparing normalized, log2-transformed expression ratios of spotted long 
oligonucleotide arrays to ratios obtained with Affymetrix GeneChip short oligonucleotide arrays. For the spotted 
arrays, normalized ratio data from dye swap experiments were combined. For Affymetrix arrays, the ratios of 
normalized intensity values from corresponding arrays were used. Hybridized targets were derived from (a) 
patient 160 (b) patient 171 (c) patient 173 (d) patient 180 (e) patient 186 and (f) patient 205. Orthogonal 
regression analysis was performed to derive the regression lines shown in black (unfiltered data) and red (filtered 
data) as well as their respective linear equations (shown in the lower part of the plots for unfiltered data and in 
the upper part for filtered data). Pearson correlation coefficients and their associated 95% confidence intervals 
are listed as well. Dashed lines through origin with slope 1 are displayed to accentuate the reduced slope. For 
panels (a) - (f), calculations were based on 3,472, 3,595, 3,600, 3,569, 3,522 and 3,474 data points for the 
unfiltered data sets as well as 1,796, 2,011, 1,889, 1,954, 1,816 and 1,866 data points for the filtered data sets. 
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Table 13. Correlation of gene expression ratios obtained with either Affymetrix GeneChip arrays or Operon long 
oligonucleotide arrays.  
 
 
Patient Affy vsn vs.  
Operon vsna 
Affy MAS5 vs.  
Operon vsnb 
Affy gcRMA vs.  
Operon vsnc 
   160 0.564  (0.606) 0.456  (0.571) 0.544  (0.585) 
   171 0.684  (0.759) 0.453  (0.707) 0.671  (0.749) 
   173 0.696  (0.786) 0.553  (0.783) 0.710  (0.795) 
   180 0.678  (0.772) 0.577  (0.763) 0.681  (0.777) 
   186 0.656  (0.722) 0.561  (0.712) 0.664  (0.734) 
   205 0.759  (0.848) 0.636  (0.837) 0.762  (0.841) 
    
aGeneChip results were normalized by variance stabilization (vsn), bMAS5 and cgcRMA. Values obtained upon removal of low-intensity-
signals are given in parentheses. 
 
 
 
3.3.6 Systematic Bias Correction by ‘Distance Weighted Discrimination 
 (DWD)’ 
As the samples were processed at different institutions (the 70-mer arrays were 
processed at the DKFZ, whereas all Affymetrix experiments were performed at the 
Georg-Speyer-Haus in Frankfurt a.M.) and assayed using different array platforms 
and protocols, considerable systematic biases were expected to be manifested in the 
data sets as differences in gene expression patterns. In order to identify and adjust 
systematic biases imposed by characteristics of the different array platforms, we 
used the method of ‘Distance Weighted Discrimination (DWD)’ 178. Following this 
procedure, there was a clear improvement in the correlations of relative expression 
measurements (Table 14). As before, correlations obtained after normalization by 
MAS5 were lower than the respective values generated with vsn or gcRMA, unless 
low-intensity signals were excluded from the analyses. The respective orthogonal 
regression lines showed little if any change in slope when the data from both 
platforms had been normalized by the vsn algorithm. Moderate changes were 
detected upon DWD in case gcRMA had been used to normalize Affymetrix data, 
whereas normalization by MAS5 tended to cause more severe variation. On average, 
the slopes were closest to 1 when vsn was used to normalize the Affymetrix data and 
deviated the most from 1 upon normalization by MAS5. As expected, systematic bias 
correction by DWD shifted the slopes towards one in almost all cases (Table 14). 
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Table 14. Correlation of gene expression ratios before and after systematic bias correction by DWD.  
 
Patient        Affy vsn vs.  
       Operon vsna 
       Affy MAS5 vs.  
       Operon vsnb 
       Affy gcRMA vs.  
       Operon vsnc 
   160 r: 0.550  (0.704)  [0.735] 
s: 1.343  (1.289)  [1.126] 
r: 0.431  (0.577)  [0.693] 
s: 0.755  (0.899)  [1.280] 
r: 0.525  (0.678)  [0.703] 
s: 1.137  (1.237)  [1.083] 
   173 r: 0.686  (0.848)  [0.893] 
s: 0.865  (0.906)  [0.867] 
r: 0.544  (0.701)  [0.886] 
s: 0.539  (0.677)  [0.911] 
r: 0.707  (0.850)  [0.896] 
s: 0.745  (0.853)  [0.811] 
   180 r: 0.697  (0.785)  [0.816] 
s: 0.852  (0.878)  [0.828] 
r: 0.577  (0.680)  [0.806] 
s: 0.644  (0.747)  [0.940] 
r: 0.696  (0.778)  [0.821] 
s: 0.767  (0.838)  [0.805] 
   186 r: 0.667  (0.771)  [0.830] 
s: 0.937  (0.956)  [0.874] 
r: 0.568  (0.680)  [0.819] 
s: 0.647  (0.744)  [0.895] 
r: 0.674  (0.767)  [0.824] 
s: 0.739  (0.809)  [0.726] 
    
aGeneChip results were normalized by variance stabilization (vsn), bMAS5 and cgcRMA. Values obtained upon bias correction by DWD are 
given in parentheses. Values in brackets were derived after additionally removing low-intensity-signals. r: Pearson correlation. s: slope of the 
respective orthogonal regression lines. 
 
 
 
3.3.7 Significant Differences and Similarities 
The comparison of the sets of genes identified as differentially expressed was used 
as a further approach to detect differences between the two array systems. In 
Figure 34, volcano plots 174 show the log2-ratios of those 2,861 genes consistently 
detected in the 4 primary HNSCC versus normal mucosa experiments and their 
respective p-values. The two platforms identified similar numbers of differentially 
expressed genes (≥ 2-fold difference), both regarding raw p-values (p ≤ 0.001) or 
FDR-adjusted p-values (adj. p ≤ 0.1) 177. There were 45 genes identified as 
differentially expressed in all tumor samples on the Affymetrix platform, 53 were 
scored on Operon arrays, and the intersection contained 21 genes discovered on 
both systems (Table 15, Fig. 33a). Plotting of the corresponding mean log ratios 
(Fig. 33b) revealed that even genes scored by only one of the systems generally 
showed the same direction, but not the same degree of differential expression on the 
other. GO data mining 180 for ‘biological process’ (at level 3) assigned the majority of 
annotated genes from each platform to cell growth and/or maintenance as well as 
various metabolic pathways (Fig. 35). However, using the software EASE 181, which 
performs a statistical analysis of the GO categories assigned to the differentially 
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expressed genes, accounting for the distribution of GO categories in the list of all 
analyzed genes to find those categories that are the most overrepresented (and can 
therefore be described as ‘themes’), revealed a trend towards components of the 
extracellular matrix for both of the platforms. Furthermore, genes involved in lipid 
metabolism were significantly overrepresented only among the differentially 
expressed genes identified on the Affymetrix system, whereas the Operon platform 
additionally detected genes engaged in ion binding (Table 16). 
 
 
 
 
Figure 33. Summary of genes scored as differentially expressed with either one or both evaluated platforms. (a) 
Venn diagram showing subsets of genes that exhibit a significant differential expression with either technology, 
taken from a pool that contained only those genes which could repeatedly be quantified in all Operon 
hybridizations. (b) log-log-plot illustrating the relationship of the log-ratios for the 77 genes shown in (a). 
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Table 15. Genes scored as differentially expressed with either one or both evaluated platforms. 
UniGene Gene Name Gene 
Symbol 
OMIM log2 
Affya 
p-value 
Affyb 
log2 
Operona 
p-value 
Operonb 
Δ exp 
Affyc 
Δ exp 
Operonc 
Hs.136348 osteoblast specific factor 2 (fasciclin I-like) OSF-2  6.01 0.07 4.67 0.01 + + 
Hs.443625 collagen, type III, alpha 1 COL3A1 120180 1.05 0.19 3.87 0.01  - + 
Hs.75823 ALL1-fused gene from chromosome 1q AF1Q 604684 3.78 0.10 2.99 0.04 + + 
Hs.28792 inhibin, beta A (activin A, activin AB alpha polypeptide) INHBA 147290 3.72 0.05 -0.11 0.85 +  - 
Hs.232115 collagen, type I, alpha 2 COL1A2 120160 3.60 0.06 0.58 0.39 +  - 
Hs.528321 collagen, type V, alpha 1 COL5A1 120215 2.44 0.09 3.38 0.01 + + 
Hs.437173 collagen, type IV, alpha 1 COL4A1 120130 3.28 0.06 3.05 0.04 + + 
Hs.409602 sulfatase 1 SULF1  2.88 0.10 2.59 0.03 + + 
Hs.372679 Fc fragment of IgG, low affinity IIIa, receptor for (CD16) FCGR3A 146740 1.10 0.40 2.67 0.07  - + 
Hs.434488 chondroitin sulfate proteoglycan 2 (versican) CSPG2 118661 2.66 0.08 2.43 0.04 + + 
Hs.821 biglycan BGN 301870 2.15 0.09 2.65 0.07 + + 
Hs.83354 lysyl oxidase-like 2 LOXL2 606663 0.10 0.86 2.39 0.05  - + 
Hs.435795 insulin-like growth factor binding protein 7 IGFBP7 602867 0.87 0.23 2.20 0.07  - + 
Hs.118893 Melanoma associated gene D2S448 600134 2.11 0.23 2.15 0.07  - + 
Hs.408096 fragile X mental retardation, autosomal homolog 1 FXR1 600819 2.06 0.07 1.21 0.14 +  - 
Hs.102308 potassium inwardly-rectifying channel, subfamily J, member 8 KCNJ8 600935 1.33 0.13 2.04 0.08  - + 
Hs.15099 Rho-related BTB domain containing 1 RHOBTB1 607351 2.03 0.06 0.88 0.17 +  - 
Hs.122645 laminin, beta 1 LAMB1 150240 1.89 0.07 1.96 0.02 + + 
Hs.81988 disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) DAB2 601236 1.48 0.26 1.93 0.07  - + 
Hs.235935 nephroblastoma overexpressed gene NOV 164958 1.82 0.10 1.40 0.13 +  - 
Hs.85195 myeloid leukemia factor 1 MLF1 601402 1.64 0.10 1.20 0.16 +  - 
Hs.246875 DRE1 protein DRE1  1.31 0.23 1.61 0.07  - + 
Hs.436708 Kruppel-like factor 7 (ubiquitous) KLF7 604865 1.55 0.10 0.35 0.49 +  - 
Hs.278469 taste receptor, type 2, member 14 TAS2R14  1.52 0.10 0.01 1.00 +  - 
Hs.7753 calumenin CALU 603420 1.48 0.15 1.27 0.07  - + 
Hs.528298 Sec23 homolog A (S. cerevisiae) SEC23A  1.43 0.10 -0.16 0.78 +  - 
Hs.433452 HEG homolog HEG  1.42 0.07 0.77 0.23 +  - 
Hs.179657 plasminogen activator, urokinase receptor PLAUR 173391 1.15 0.23 1.41 0.08  - + 
Hs.16530 chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) CCL18 603757 1.20 0.28 1.40 0.08  - + 
Hs.370774 ankyrin repeat and BTB (POZ) domain containing 2 ABTB2  0.65 0.36 1.38 0.07  - + 
Hs.312419 origin recognition complex, subunit 3-like (yeast) ORC3L 604972 1.36 0.11 1.37 0.08  - + 
Hs.462693 zinc finger protein 22 (KOX 15) ZNF22 194529 0.90 0.35 1.27 0.09  - + 
Hs.130958 ribonuclease/angiogenin inhibitor RNH  0.18 0.78 -1.06 0.10  - + 
Hs.1321 coagulation factor XII (Hageman factor) F12 234000 -0.02 0.98 -1.28 0.07  - + 
Hs.434933 regulator of G-protein signalling 12 RGS12 602512 0.26 0.67 -1.37 0.08  - + 
Hs.112028 misshapen/NIK-related kinase MINK  -0.46 0.51 -1.39 0.08  - + 
Hs.5215 integrin beta 4 binding protein ITGB4BP 602912 -1.41 0.10 -1.11 0.18 +  - 
Hs.211556 ELOVL family member 6, elongation of long chain fatty acids ELOVL6  -1.48 0.08 -0.60 0.32 +  - 
Hs.40968 heparan sulfate (glucosamine) 3-O-sulfotransferase 1 HS3ST1 603244 -0.11 0.85 -1.53 0.08  - + 
Hs.132853 enthoprotin ENTH 607265 -1.56 0.10 -0.70 0.55 +  - 
Hs.528666 RAR-related orphan receptor A RORA 600825 -1.56 0.10 -1.45 0.14 +  - 
Hs.15519 oxysterol binding protein-like 2 OSBPL2 606731 -1.66 0.06 -1.03 0.17 +  - 
Hs.91139 solute carrier family 1, member 1 SLC1A1 133550 -1.68 0.08 -1.34 0.14 +  - 
Hs.378738 AHNAK nucleoprotein (desmoyokin) AHNAK  -1.71 0.20 -1.51 0.09  - + 
Hs.393239 sterol-C4-methyl oxidase-like SC4MOL 607545 -1.81 0.10 -0.52 0.61 +  - 
Hs.77870 hypothetical protein FLJ12750 FLJ12750  -1.66 0.17 -1.83 0.08  - + 
Hs.212787 Microtubule associated serine/threonine kinase family member 4 MAST4  -1.80 0.12 -1.89 0.07  - + 
Hs.105435 GDP-mannose 4,6-dehydratase GMDS 602884 -1.91 0.13 -1.68 0.09  - + 
Hs.82237 tripartite motif-containing 29 TRIM29  0.13 0.83 -1.93 0.05  - + 
Hs.166311 SAM and SH3 domain containing 1 SASH1 607955 -1.42 0.11 -1.96 0.07  - + 
Hs.1588 4-aminobutyrate aminotransferase ABAT  -1.97 0.08 -0.94 0.18 +  - 
Hs.424551 integral type I protein P24B  -2.02 0.08 -1.56 0.08 + + 
Hs.434243 KIBRA protein KIBRA  -1.21 0.10 -2.04 0.06 + + 
Hs.90797 O-acyltransferase (membrane bound) domain containing 2 OACT2  -1.61 0.16 -2.06 0.08  - + 
Hs.437043 KIAA0540 protein KIAA0540  -1.43 0.10 -2.13 0.06 + + 
Hs.446429 prostaglandin D2 synthase 21kDa (brain) PTGDS 176803 -1.93 0.10 -2.15 0.05 + + 
Hs.5541 ATPase, Ca++ transporting, ubiquitous ATP2A3 601929 -1.89 0.09 -2.23 0.02 + + 
Hs.356726 scinderin SCIN  -0.76 0.32 -2.26 0.02  - + 
Hs.118747 solute carrier family 15 (H+/peptide transporter), member 2 SLC15A2 602339 -2.30 0.07 -2.13 0.11 +  - 
Hs.430324 annexin A9 ANXA9 603319 -1.80 0.34 -2.30 0.07  - + 
Hs.206501 hypothetical protein from clone 643 LOC57228  -2.35 0.07 -2.36 0.02 + + 
Hs.169238 fucosyltransferase 3 (galactoside 3(4)-L-fucosyltransferase) FUT3 111100 -2.43 0.08 -1.59 0.10 +  - 
Hs.348350 dehydrogenase/reductase (SDR family) member 1 DHRS1  -2.43 0.10 -2.20 0.03 + + 
Hs.257697 programmed cell death 4 (neoplastic transformation inhibitor) PDCD4  -2.45 0.06 -1.21 0.27 +  - 
Hs.282975 carboxylesterase 2 (intestine, liver) CES2 605278 -1.92 0.10 -2.49 0.02 + + 
Hs.31130 transmembrane 7 superfamily member 2 TM7SF2 603414 -2.08 0.07 -3.05 0.01 + + 
Hs.436657 clusterin (complement lysis inhibitor, apolipoprotein J) CLU 185430 -2.10 0.28 -3.11 0.04  - + 
Hs.167218 BarH-like homeobox 2 BARX2 604823 -1.23 0.09 -3.28 0.01 + + 
Hs.134478 RecQ protein-like 5 RECQL5 603781 0.26 0.65 -3.31 0.04  - + 
Hs.439309 transmembrane protease, serine 2 TMPRSS2 602060 -3.44 0.06 -3.19 0.02 + + 
Hs.298023 aquaporin 5 AQP5 600442 -1.44 0.36 -3.58 0.06  - + 
Hs.272813 dual oxidase 1 DUOX1 606758 -1.28 0.28 -3.72 0.08  - + 
Hs.103944 mucin 7, salivary MUC7 158375 -3.77 0.10 -0.62 0.32 +  - 
Hs.116651 epithelial V-like antigen 1 EVA1 604873 -3.96 0.07 -1.97 0.22 +  - 
Hs.438862 EPS8-like 1 EPS8L1  -3.63 0.07 -5.11 0.02 + + 
Hs.226391 anterior gradient 2 homolog (Xenopus laevis) AGR2 606358 -5.75 0.05 -1.33 0.14 +  - 
Hs.13775 homeodomain-only protein HOP 607275 -6.35 0.06 -2.42 0.07 + + 
          
 
 
 
Differentially expressed genes were selected from a subset (n = 2 861) consistently detected in the 4 primary HNSCC versus normal mucosa 
experiments. alog2-transformed expression ratios were averaged within each platform, bcorresponding p-values of significance derived by 
empirical Bayes inference and subsequent adjustment to control the FDR. cTo be scored as differentially expressed (Δ exp), genes had to 
satisfy both statistical significance (p ≤ 0.1) and significance based on a twofold change criterion. 
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Figure 34. Volcano plots of p-values against log2-transformed expression ratios. Mean log2 ratios of tumor 
versus reference samples are shown on the x-axis. The corresponding p-values of significance, derived by 
empirical Bayes inference (a-b) or empirical Bayes inference and subsequent adjustment to control the FDR (c-
d), are displayed on the y-axis. Results are shown for those 2,861 genes consistently detected in the 4 primary 
HNSCC versus normal mucosa experiments. The plots were segmented to illustrate the relation of statistical 
significance (p ≤ 0.005, adj. p ≤ 0.1) to significance based on a twofold change criterion. Only genes indicated 
by spots in the upper left and right segments of the plots satisfy both criteria, their numbers explicitly shown. 
Genes located in the lower left and right segments display a large fold-change but fail to achieve statistical 
significance. Genes found in the middle segments show no relevant difference of expression, with (upper 
segments) or without (lower segments) additional statistical significance associated with this observation. 
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Figure 35. GO data mining. The 45 regulated genes detected with the Affymetrix system as well as the 52 
regulated genes found with Operon arrays were characterized according to their biological process classification 
in the GO database (at level 3). Roughly half of the genes did not have a GO classification at this level. The 
majority of the remaining genes were involved with cell growth and/or maintenance as well as various metabolic 
pathways. 
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Table 16. EASE overrepresentation analysis of the genes listed in Table 15. 
Systema Gene Categoryb List 
Hitsc 
List 
Totald 
Population 
Hitse 
Population 
Totalf 
EASE 
Scoreg 
LH in    
PH (%)h 
LH in 
Δ exp (%)i 
Affymetrixj   
GO Cellular Component extracellular matrix 6 34 55 2348 0.00084 10.91 14.63 
GO Molecular Function extracellular matrix structural constituent 4 37 14 2410 0.0010 28.57 9.76 
GO Biological Process cell adhesion 6 37 99 2386 0.015 6.06 14.63 
GO Biological Process lipid metabolism 6 37 112 2386 0.025 5.36 14.63 
GO Biological Process lipid biosynthesis 4 37 44 2386 0.027 9.09 9.76 
GO Biological Process cellular lipid metabolism 5 37 78 2386 0.028 6.41 12.20 
GO Cellular Component endoplasmic reticulum 5 34 99 2348 0.048 5.05 12.20 
GO Cellular Component extracellular matrix (sensu Metazoa) 3 34 26 2348 0.050 11.54 7.32 
GO Biological Process fatty acid metabolism 3 37 26 2386 0.057 11.54 7.32 
GO Biological Process steroid metabolism 3 37 27 2386 0.061 11.11 7.32 
GO Molecular Function extracellular matrix structural constituent c. t. s.k 2 37 5 2410 0.073 40.00 4.88 
GO Cellular Component extracellular region 4 34 75 2348 0.086 5.33 9.76 
GO Cellular Component collagen 2 34 7 2348 0.094 28.57 4.88 
Operonj  
GO Cellular Component extracellular matrix 7 45 55 2348 0.00045 12.73 13.46 
GO Molecular Function extracellular matrix structural constituent 4 48 14 2410 0.0022 28.57 7.69 
GO Molecular Function cation binding 10 48 192 2410 0.010 5.21 19.23 
GO Molecular Function metal ion binding 10 48 225 2410 0.027 4.44 19.23 
GO Molecular Function ion binding 10 48 225 2410 0.027 4.44 19.23 
GO Biological Process cell adhesion 6 44 99 2386 0.031 6.06 11.54 
GO Molecular Function calcium ion binding 6 48 104 2410 0.049 5.77 11.54 
GO Cellular Component extracellular region 5 45 75 2348 0.050 6.67 9.62 
GO Molecular Function scavenger receptor activity 2 48 3 2410 0.057 66.67 3.85 
GO Cellular Component extracellular 5 45 79 2348 0.058 6.33 9.62 
GO Cellular Component extracellular matrix (sensu Metazoa) 3 45 26 2348 0.084 11.54 5.77 
GO Biological Process organismal physiological process 8 44 214 2386 0.085 3.74 15.38 
GO Cellular Component Golgi apparatus 5 45 93 2348 0.094 5.38 9.62 
GO Molecular Function extracellular matrix structural constituent c. t. s.k 2 48 5 2410 0.094 40.00 3.85 
         
 
 
 
aSystem: the system of categorizing genes, in this case the GO classification type. bGene Category: the specific category of genes within the 
classification system, in this case the GO category of the superordinate GO classification type (different levels are possible). cList Hits (LH): 
number of genes in the list of differentially expressed genes that belong to the respective GO category. dList Total: number of differentially 
expressed genes that could be annotated within the respective GO classification system. ePopulation Hits (PH): number of genes in the list of 
all analyzed genes (n = 2,861) belonging to the respective GO category. fPopulation Total: number of analyzed genes with annotation data in 
the respective GO classification system. gEASE Score: The upper bound of the distribution of Jackknife Fisher exact probabilities given the 
List Hits, List Total, Population Hits and Population Total. Categories with the lowest EASE score are significantly overrepresented in the 
list of differentially expressed genes. hLH in PH: percentage of differentially expressed genes belonging to the respective category in the 
group of all analyzed genes in this category. iLH in Δ exp: percentage of differentially expressed genes belonging to the respective category 
in the group of all differentially expressed genes. jDifferentially expressed genes from each platform were analyzed separately. kc.t.s.: 
conferring tensile strength. 
 
 
 
CHAPTER 3.3 CROSS-PLATFORM REPRODUCIBILITY OF EXPRESSION PROFILES  93 
 
 
3.3.8 RQ-PCR Analysis 
For a small subset of genes, the differential expression measurements were verified 
by RQ-PCR analysis (Fig. 36). There was good qualitative agreement between the 
values determined by either GeneChip arrays, Operon arrays or RQ-PCR. All 
platforms showed the same direction of regulated gene expression. However, the 
magnitude of differential expression differed considerably depending on both the 
experimental approach and the algorithm applied for normalization. Firstly, GeneChip 
intensity measurements were transformed by variance stabilization (vsn), which was 
also used for the long oligonucleotide arrays and derives an approximately constant 
variance along the complete intensity range 169. Normalization was additionally 
accomplished employing the MAS5 algorithm from the current version of the 
Affymetrix Microarray Suite software package 170. At least for the small number of 
genes and patients shown here, there is a tendency for higher ratios with vsn 
normalization. 
 
 
 
 
Figure 36. Comparison of relative gene expression for the genes OSF2, GMDS, TMPRSS2 and BGN. Expression 
ratios were determined for tumor versus control tissue of the indicated patients, using either Affymetrix 
GeneChip arrays (a-b), Operon long oligonucleotide arrays (c) or real-time quantitative PCR analysis (d). 
Affymetrix ratios were either normalized by variance stabilization (a) or the MAS5 algorithm (b). 
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4 Discussion 
 
There is no statement so absurd that no philosopher will make it. 
CICERO 
 
 
The objective of this thesis was to develop protocols that allow for the analysis of 
gene expression in minimal samples by means of spotted long oligonucleotide 
microarrays. Two different approaches were taken, one that amplifies the target 
material before hybridization (TAcKLE protocol) and another that amplifies the signal 
generated on the array (on-chip RCA). As the TAcKLE protocol performed 
particularly well, it was subsequently applied to evaluate the utility of spotted 
oligonucleotide microarrays compared to an accepted commercial reference 
platform. 
 
 
4.1 The TAcKLE Protocol 
 
RNA amplification by in vitro transcription yields up to 105-fold linear amplification of 
high quality aRNA starting from nanogram quantities of total RNA 164 and has been 
applied for microarray studies of differential gene expression for several years. In this 
thesis, a newly developed protocol broadens the utility of this approach to the 
application with spotted oligonucleotide microarrays and, thus, expands the utilization 
of these microarrays to the analysis of rare cell populations (Fig. 37). These could be 
derived by fine-needle aspiration or microdissection of clinical specimens, by cell 
sorting or micromanipulation of single cells. Utilizing elements of the approved 
Eberwine procedure 111,112, the TAcKLE protocol can easily be implemented, and 
even aRNA, produced for other applications, can be made accessible for 
oligonucleotide arrays by adding another reverse transcription and labeling step.  
The amplification itself does not increase the overall variability above that 
encountered during cDNA synthesis. This is clearly demonstrated by co-hybridization 
of material independently amplified from the same source. The reproducibility of a 
single round and even two rounds of amplification, estimated by the correlation 
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coefficient, is comparable or even superior to that obtained with unamplified targets 
and possibly more biased by the variability of the chip hybridization and readout 
procedure than by the enzymatic manipulations. 
A further level of amplification is added by the strong strand displacement activity of 
Klenow fragment, combined with random priming of DNA polymerisation 200,201, which 
adds a further level of amplification and, thereby, decreases the amount of RNA 
necessary for labeling. The amplification was estimated to be about 5-fold by 
spectrophotometrically measuring the amount of cDNA subsequent to the labeling 
reaction. This effect facilitates the conduction of additional experiments even with 
marginal amounts of starting material. This value seems reasonable since as little as 
1 µg Klenow-labeled material (500 ng still work fine) can be used for hybridization, 
whereas protocols using labeled aRNA or RT-labeled cDNA require as much as 3-
6 µg. Additionally, Klenow fragment is known to have a superior efficiency with 
modified nucleotides compared to any known reverse transcriptase. 
The generated data demonstrate that the ability to reproducibly identify differentially 
expressed genes after amplification is retained compared to conventional labeling by 
reverse transcription. This is true even when using as little starting material as 2 ng 
total RNA. 
 
 
 
 
Figure 37. Special demand on target amplification protocols for oligonucleotide microarrays containing sense-
oriented probe molecules. Fluorescent cDNA targets prepared by reverse transcription labeling of mRNA or 
rather the mRNA content of total RNA are antisense-oriented and thus compatible for hybridization to sense-
oriented arrays. However, antisense RNA (aRNA) generated by T7 amplification procedures cannot be used in 
this way, as the resulting cDNA targets would have sense orientation and hence could not basepair with the 
sense-oriented array probes. Instead, a modification of the original procedure must be used, in which aRNA 
labeling is achieved by reverse transcription and subsequent dye incorporation using Klenow fragment. 
96 DISCUSSION 
 
 
Some minor differences between transcription profiles generated from 2000 ng and 
2 ng of total RNA can still be detected, probably due to additional bias introduced by 
a second round of amplification, which includes a randomly primed RT reaction. But 
even after two rounds of amplification, reproducibility is sufficiently high for reliable 
quantification of differences between samples. Furthermore, and equally important, 
there is no compression of differences between RNA samples with either one or two 
rounds of amplification. In contrast, there is a systematic and reproducible expansion 
of expression ratios in amplified targets. A possible explanation can be differences in 
RT efficiency, depending on the template concentration. 
The presented analyses also indicate that reverse transcription labeling represents a 
significant source of variation between identical RNA samples and reaffirm the need 
for dye swap replicates. A part of the deviating ratios detected when comparing 
amplified and unamplified targets can probably be attributed rather to the inaccuracy 
of reverse transcription labeling than to systematic bias or random errors of the 
amplification procedure.  
A different approach to overcome the problem of strand orientation is the addition of 
fluorescent nucleotide derivatives to the in vitro transcription reaction. Barczak et 
al. 173 reported decreased signal intensities of fluorescent aRNA targets, compared to 
cDNA prepared by reverse transcription labeling. This could be confirmed in initial 
experiments that were performed with this method (data not shown). Apparently, 
RNA polymerase is not a favorable enzyme for the incorporation of dye-labeled 
nucleotides. As it clearly discriminates bulky nucleotide modifications, ratios of 
labeled to unlabeled nucleotides have to be optimized. It has been reported that the 
addition of DMSO during in vitro transcription can improve incorporation rates 122, and 
that utilization of aminoallyl-dUTP, followed by chemical coupling of reactive dye 
derivatives, may overcome some of the problems connected to the bulky nature of 
dye-labeled nucleotides. Still, there is no additional amplification by the labeling 
procedure. Smith et al. 123 claimed that their method termed ‘Single Primer 
Amplification’ would generate both sense-oriented and antisense-oriented fluorescent 
cDNA targets, the latter via a ‘strand switch’ during the Klenow labeling reaction. This 
effect, however, did not generate sufficient amounts of the antisense-oriented cDNA 
required for the spotted oligonucleotide arrays used in this thesis. A recent study by 
Rajeevan et al. 202 exploits the template-switching effect 188 of Moloney murine 
leukemia virus (MMLV) reverse transcriptase to incorporate an RNA polymerase 
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promoter sequence upstream of the generated cDNA, producing sense-oriented RNA 
(sRNA) by subsequent in vitro transcription. In a similar approach, the method of 
terminal continuation has been used to generate amplified transcripts with either 
sense or antisense orientation 203. However these reports had not yet been published 
at the time when the experiments described in 3.1.2 were conceived and performed. 
Similar to the report by Rajeevan et al. 202, it was tried to use the template switching 
effect of MMLV to incorporate a T7-promoter upstream of the cDNA sequence 
(inverse IVT, Fig. 15). However, the amount of sense-oriented RNA that could be 
generated was insufficient. One can only speculate about the reasons, which may be 
handling errors or, more likely, unfavourable conditions during second-strand cDNA 
synthesis that did not allow for the generation of a functional, double-stranded T7-
promoter. The template switching itself was probably successful, since the TS-SPA 
method (Fig. 16), which is identical to inverse IVT in terms of first-strand cDNA 
synthesis, produced large amounts of sense-oriented second-strand cDNA via 
thermal cycling with Taq DNA polymerase and T7-ts primer. This requires a 
functional priming site in the first-strand cDNA, which can only be generated by 
template switching. It was impossible, however, to use TS-SPA for the generation of 
reasonable expression profiles, since differentially expressed genes could hardly be 
detected (Fig. 17B). So far, it has been impossible to explain this observation.  
Commercial solutions utilize novel signal amplification and/or detection procedures, 
as in the QIAGEN HiLight Platform (http://www1.qiagen.com/Products/Micro 
ArrayAnalysis/MicroArrayAnalysisSystems.aspx), which uses resonance light 
scattering (RLS), a technology based on the optical light scattering properties of 
nano-sized metal colloidal particles 204. The system requires 1-2 µg total RNA and 
generates biotinylated and/or fluorescein-labeled target cDNA, which can be 
hybridized to commercial or custom made arrays. Gold particles, coated with anti-
biotin antibodies, and/or silver particles, coated with anti-fluorescein antibodies, are 
used to stain the targets after hybridization. Detection is performed on a specialized 
reader. The SensiChip System developed by QIAGEN and Zeptosens AG 
(http://www.zeptosens.com) uses planar waveguide (PWG) technology 205,206 and 
requires a minimum of 1 µg total RNA. Hybridizations are carried out on 70mer 
oligonucleotide arrays of a special format using the SensiChip HybStation.  
The SenseAmp RNA amplification kit offered by Genisphere, which was introduced 
after the completion of this study, generates amplified RNA in sense orientation 
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(senseRNA). This is achieved by poly(dT)-tailing of first strand cDNA and subsequent 
hybridization of a modified oligo(dA), which carries the T7 promoter sequence 
attached to its 5’-end and a 3’-ddA to block second strand synthesis. In this way, 
nucleotides can only be attached to the 3’-end of the first strand cDNA, which creates 
a double-stranded T7 promoter sequence upstream of the coding sequence. 
Although no double-stranded cDNA is created, the double-stranded promoter 
sequence is sufficient to initiate in vitro transcription, which yields multiple copies of 
sense-oriented RNA molecules, which can optionally be tailed with poly(A). A RQ-
PCR-based comparison of 192 transcripts before and after amplification yielded 
strong correlations 121. For a microarray-based analysis, however, the amplified RNA 
would have to be labeled by reverse transcription, primed either by oligo(dT) (in case 
of poly(A)-tailing) or by random hexamers, accepting dye-related incorporation bias 
that the TAcKLE protocol avoids by means of Klenow labeling. 
The Ovation RNA amplification system from NuGEN uses a combination of a 
proprietary primer, RNase H and a DNA polymerase. First strand cDNA is produced 
using a DNA/RNA chimeric primer. The DNA portion of the primer contains an 
oligo(dT)-sequence, whereas the RNA portion, attached at the 5’-end, contains a 
unique sequence that is used to incorporate a priming site for the subsequent linear 
amplification step. Second strand cDNA is produced by a combination of RNase H, a 
DNA polymerase and a DNA ligase, similar to the original T7 protocol. The 
amplification is initiated by the action of RNase H, which also degrades the RNA 
portion of the chimeric primer. A new primer molecule hybridizes to its released 
complementary sequence in the second strand cDNA. DNA polymerase binds to the 
annealed 3'-end of the primer and initiates primer extension. Due to its strand 
displacement activity, the forward anti-sense strand of the cDNA duplex is displaced 
from the template strand as cDNA elongation takes place. Simultaneously, RNase H 
degrades the RNA of the primer that is being elongated, exposing the binding site for 
another primer molecule and starting another round of primer extension. This cyclic 
process continues in a linear fashion until sufficient amounts of antisense cDNA have 
been obtained. For microarray applications, the cDNA can be labeled by addition of 
aminoally-dUTP to the amplification reaction, which allows for subsequent labeling 
with fluorescent dyes. Technical reports published on NuGEN’s website 
(http://www.nugentechnologies.com) look promising, but independent validations of 
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the method have to be awaited before reliable predictions on its performance can be 
made. 
In conclusion, it was shown that TAcKLE can faithfully amplify and label as little as 
2 ng of total RNA, an amount which can be obtained from a few hundred cells. It 
represents a robust method for the sensitive detection of expression profiles, which is 
particularly suited for the use with microarrays consisting of long sense-oriented 
oligonucleotides, which are currently gaining popularity. Meanwhile, the TAcKLE 
protocol has been used for a large-scale expression profiling study of more than 100 
primary mammary carcinoma samples, supported by a large pharmaceutical 
company. The project’s objective was to identify a gene expression signature that 
predicts the patient benefit from a novel neoadjuvant chemotherapy combining the 
drugs Gemcitabine, Epirubicin and Docetaxel 207. This goal has been achieved, and 
the results are currently being prepared for publication. 
 
 
4.2 RCA for Microarray Expression Analysis 
 
Rolling circle amplification holds some compelling theoretical advantages compared 
to PCR-based or T7 RNA polymerase-based target amplification procedures. A 
distinctive property of RCA is that the amplified product remains linked to the DNA 
primer attached to the target molecule. As another unique feature, RCA uses 
identical circular oligonucleotides for the amplified detection of all target molecules, 
circumventing sequence-dependent amplification bias. In addition, on-chip RCA can 
be expected to be less time-consuming, laborious and expensive. Schweitzer et 
al. 158 used RCA for the amplified detection of cytokines on protein microarrays. For 
this application, specific monoclonal antibodies targeting various cytokines were 
attached to a solid support and hybridized with supernatant samples from cultured 
Langerhans cells. Biotinylated, polyclonal secondary antibodies were added to detect 
the cytokines bound to the arrayed primary antibodies. Subsequently, a universal 
anti-biotin antibody attached to the 5’-end of a DNA primer could bind to the 
biotinylated secondary antibodies and initiate rolling circle amplification of a circular 
oligonucleotide. The amplified product was finally detected by hybridization of 
multiple fluorescent, complementary oligonucleotide probes. In terms of DNA 
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microarrays, Nallur et al. 157 used spotted oligonucleotides as primers for on-chip 
RCA. In a more advanced genotyping application, Lizardi et al. 145 performed allele 
discrimination by on-chip ligation and subsequent RCA. Briefly, a gene-specific 
oligonucleotide probe was covalently attached to a solid support via a reactive 3’-
amino group, ensuring that the 5’-phosphate was available for ligation. This 
orientation was preferred because it eliminates the possibility of non-specific priming 
by the 3’-end, which could otherwise interact with the circular oligonucleotide 
templates used for RCA. Two additional oligonucleotides were added in solution, 
capable of discriminating the allelic variants of the target gene. For this purpose, an 
allele-specific base was located at the 3’-end of a 20-mer target-complementary 
portion of these probes. The opposite end of these probes comprised a specific RCA 
primer sequence with an additional free 3’-OH terminus, obtained by reversal of 
backbone polarity during chemical synthesis. Guided by the target sequence 
hybridized to the immobilized oligonucleotide, allele-specific ligation of the cognate 
probe generated a surface-bound oligonucleotide with a free 3´ terminus capable of 
priming rolling circle amplification of the circular template complementary to the 
associated primer sequence. Finally, specific detection of the amplified DNA was 
achieved by hybridization of differentially labeled oligonucleotides complementary to 
either the mutant or the wild type RCA product.  
Several problems had to be addressed in order to adapt RCA for microarray 
expression analysis. One challenge was the inevitable requirement to generate 
cDNA that contained a primer sequence with a free 3’-OH terminus to initiate the 
RCA reaction. This was impossible by means of ordinarily coupling the sequence to 
an oligo(dT) primer for reverse transcription. In this case, the RCA primer sequence 
had either been located at the 5’-end, since the 3’-end of the molecule was 
necessary to prime the reverse transcription, and it had therefore been unavailable to 
prime the RCA reaction. Vice versa, locating the RCA primer at the 3’-end had 
created another completely useless molecule, as it had been unable to prime the RT. 
To solve this problem, oligonucleotides were used that were similar to the ones 
Lizardi et al. applied for genotyping by on-chip ligation and subsequent RCA 145. One 
part of the molecules was synthesized with reversed backbone polarity, assuring that 
both the oligo(dT) portion and the RCA primer portion had an opposite orientation, 
thereby creating two distinct free 3’-ends. 
CHAPTER 4.2 RCA FOR MICROARRAY EXPRESSION ANALYSIS  101 
 
 
Another issue was the single-strand specific 3’ to 5’ exonuclease activity of Ф29 DNA 
polymerase. The problem was actually twofold, since this activity would degrade any 
single-stranded molecule with an unprotected 3’-terminus and simultaneously occupy 
a substantial amount of polymerase molecules, thereby keeping them from 
synthesizing DNA. To minimize these implications, the 3’-ends of the detection 
probes and the RCA primers were protected by the  introduction of single 
phosphorothioate bonds 208. The phosphorothioate bond was described to be a much 
less favoured substrate to nuclease activity than the naturally occuring 
phosphodiester bond 209. It might also be beneficial to protect the cDNA analytes from 
nucleolytic degradation, which could be achieved by addition of either 2’-O-methyl-3’-
deoxy-NTP or 2’,3’-dideoxynucleoside-5’-O-(1-thiotriphosphate) (Fig. 38) to the 
reverse transcription reaction. The lack of a 3’-hydroxyl would terminate the 
polymerization and leave a nuclease-resistant 3’-end protected either by a 2’-O-
methyl residue 210 or a thiophosphate (phosphorothioate) bond 208,209. These reagents 
are commercially available, and respective experiments will be part of the diploma 
thesis of cand. biol. Daniel Haag. 
An additional complication resulted from the considerable length of the RCA-
amplified DNA product. Being several kb in length, corresponding to scores of 
nanometers, there was a risk that it would be dispersed or even flushed away from 
the site of amplification. Initial results showed that drying RCA-amplified slides by 
centrifugation was completely inapplicable. Using the automated draining
 
 
Figure 38. Nucleoside triphosphates with modifications conferring nuclease protection and causing chain 
termination. (A) 2’-O-methyl-3’-deoxy-CTP incorporation during reverse transcription causes chain termination 
due to the lack of a 3’-hydroxyl and renders the cDNA resistant to 3’-exonucleolytic attacks by means of the 2’-
O-methyl residue. (B) 2’,3’-dideoxycytidine-5’-O-(1-thiotriphosphate) features the same properties, but here 
nuclease resistance is obtained via a non-hydrolyzable thiophosphate. 
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functionality of the GeneTAC hybridization station improved the results to a certain 
extent, but the basic problem remained and interfered with any reasonable 
quantitative analysis. For that reason, a method was conceived that covalently links 
the hybridized cDNA molecules, to which the RCA reaction will append the amplified 
concatemeric copies of the circular DNA template, to their complementary array 
probes. Initially, the cDNA was tagged with aminoallyl residues, derivatized with the 
amine-reactive, DNA intercalating reagent NHS-psoralen and hybridized to the array. 
Irradiation with long UV light (366 nm) created inter-strand cross-links between 
thymine residues in the cDNA and the arrayed oligonucleotides. This procedure was 
able to efficiently prevent the spreading and release of hybridized cDNA. For 
substantially longer RCA incubations, yielding considerably longer amplification 
products, it might become necessary to condense the DNA via cross-linking with 
multivalent anti-hapten IgM, using hapten-tags in the detection probes, as suggested 
by Lizardi et al. 145. 
To move towards a comparative analysis of different transcriptomes on the same 
array, a second set of oligonucleotides for RCA was devised, and both systems were 
used in parallel for the RCA-amplified detection of HL-60 cDNA. 
Unfortunately, not only yellow spots of variable intensities were detected, as one 
would expect for a two-color co-hybridization of cDNAs prepared from the same 
RNA, but also a considerable number of spots that were primarily if not exclusively 
green or red. The most likely explanation is an overlap of specific RCA signals and 
unspecific background due to insufficient washing, and more stringent protocols are 
currently being tested by cand. biol. Daniel Haag. 
As anticipated, it turned out that efficient purification of the circularized padlock 
probes was essential for successful rolling circle amplification. Remaining ligation 
template (connector oligonucleotide) could prime an unlocalized, target-independent 
amplification, whereas unligated probes would arrest the reaction once it reaches the 
end of the linear template. As described in the “Materials and Methods” section, 
streptavidin-coated magnetic beads were used to obtain circularized probes for 
subsequent amplification. Although this procedure was fast and straightforward, it did 
not always efficiently remove the ligation template (data not shown). Furthermore, 
this approach is incapable of removing unligated probes. Separation by 
electrophoresis and subsequent gel extraction yielded extremely pure products (data 
not shown), but the procedure was both time consuming and difficult to scale up. 
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HPLC certainly holds the highest potential for a large-scale preparation of 
circularized probes, even circumventing the need for subsequent exonucleolytic 
treatment, but this method has not yet been implemented. We currently favor a 
combination of streptavidin-sepharose columns and subsequent exonuclease 
treatment to remove unligated probes, but this remains to be evaluated in more 
detail, despite of promising preliminary results (data not shown). 
 
 
4.3 Comparison of Oligonucleotide Microarray Platforms 
 
The comparison of relative gene expression measurements obtained with different 
technical approaches or different implementations of a proven technology is of 
considerable interest to researchers from all fields of the biological and biomedical 
sciences. Several studies have addressed this topic, with rather heterogeneous 
results. 
Mah et al. 196 compared absolute expression levels quantified on Affymetrix short 
oligonucleotide and radioactively labeled cDNA-based filter-arrays. The expression 
values from the two technologies showed merely poor correlations. Tan et al. 211 
evaluated the performance of three commercial microarray platforms and found 
merely modest correlations when comparing both absolute and relative gene 
expression measurements. Strikingly, log2-ratios from the two platforms using short 
oligonucleotide probes and biotinylated cRNA targets (Affymetrix and Amersham; 
r = 0.52) did not correlate better with each other than with those of cDNA arrays 
(Agilent; r = 0.53 or r = 0.59). In a comparison of Affymetrix GeneChip arrays and two 
different collections of 70-mer oligonucleotides, Barczak et al. 173 found moderate 
correlations of corresponding signal intensities (r = 0.56 - 0.60), but strong 
correlations of respective relative expression values (r = 0.80 without filtering, 
r = 0.83 - 0.89 after exclusion of probes or probe sets with low signal intensities). 
Similarly, Shippy et al. 212 described improved correlations between expression 
measurements from Affymetrix GeneChip and Amersham CodeLink arrays upon 
removal of genes within platform noise (r = 0.62 versus r = 0.79). Measuring relative 
gene expression values on Affymetrix short oligonucleotide arrays, commercial 
(Agilent) and custom-made, sequence-validated cDNA arrays, Järvinen et al. 213 
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observed reasonable correlations of log2-ratios. Interestingly, the correlation between 
the two different cDNA platforms (r =0.73) was weaker than the correlations between 
the commercial or custom-made cDNA arrays and the Affymetrix system (r = 0.84 
and r = 0.76, respectively). A recent study by Tan et al. 211, showing very little 
correlation between Affymetrix, Amersham and Agilent arrays, came to broad public 
attention 214 and raised general concerns regarding the comparability of expression 
data across labs and platforms. Shortly after the completion of this project, the 
prestigious journal ‘Nature Methods’ dedicated its May 2005 issue to the comparison 
of array platforms and published several new reports on this topic, emphasizing its 
relevance and the enduring interest of the scientific community. Larkin et al. 215 
compared gene expression between Affymetrix GeneChips and spotted cDNA arrays 
in a mouse model of angiotensin II-induced hypertension and found that biological 
treatment had a greater impact on the measured expression than the platform for 
more than 90% of the analyzed genes. In a multiple-laboratory comparison of 
Affymetrix GeneChips, spotted cDNA arrays and spotted oligonucleotide arrays, 
Irizarry et al. 216 showed that the results were more affected by the labs than by the 
different platforms, i.e., it was more important where an experiment was done than 
on which platform it was done. Bammler et al. 217 compared expression profiles 
between seven labs and across twelve array platforms. Initially, they found poor 
reproducibility both between labs and across platforms. Not unexpectedly, the 
reproducibility between labs could clearly be improved by the implementation of 
standardized protocols for target labeling, hybridization, microarray processing, data 
acquisition and data normalization. 
A different approach to review the possibility for meaningful translation of microarray 
data is meta-analysis of extensive datasets of similar type (generated from the same 
type of samples, but not from identical samples), produced in different labs and on 
different platforms 218-220. Since many additional parameters such as classification of 
the samples or individual laboratory practices (see Irizarry et al. 216 and Bammler et 
al. 217) influence the outcome of these studies, the results are rather inconclusive 
concerning comparability on the technological level. Generally, at least common 
patterns and/or groups of genes could be confirmed. 
The above mentioned studies were, except for meta-analyses, usually based on data 
generated with homogeneous cell lines and by averaging over several technical 
replicates. In this study, it was intended to increase the practical significance by the 
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use of clinical samples in combination with modest technical replication (two single 
arrays per patient for the Affymetrix platform and two dye swap replicates per patient 
for the spotted oligonucleotide arrays). Additionally, the protocols for target 
preparation were kept as comparable as possible. Since the Affymetrix platform 
utilizes biotinylated cRNA generated by in vitro transcription (IVT), the linear, IVT-
based TAcKLE protocol, which was used for the spotted oligonucleotide arrays, was 
much more similar compared to conventional dye-labeling by reverse transcription. It 
could be shown that TAcKLE generates highly reproducible expression profiles with 
down to 2 ng of starting material 199. Additionally, it was demonstrated that the 
correlation of expression ratios obtained with spotted oligonucleotide arrays is higher 
between replicate amplified sample pairs than between amplified and RT-labeled 
sample pairs or replicate RT-labeled sample pairs. Accordingly, one can expect that 
consistent target amplification would also be beneficial, if expression ratios are to be 
compared across platforms. Comparative studies that do not account for this 
consideration might introduce additional systematic bias, resulting in reduced 
agreement between platforms. 
To match the probes from the two platforms, accession numbers provided by 
Affymetrix and Operon were mapped to the current version of the UniGene database. 
Transcript identifiers from the RefSeq collection 221,222 were not chosen for matching 
the platforms, since reference sequences can change through consolidation of the 
database. Recently, Mecham et al. 223 showed that up to 50% of Affymetrix probes do 
not have a matching sequence in the current version of RefSeq. Despite these 
considerations, platform matching by RefSeq identifiers yielded approximately similar 
and partly even improved results in terms of cross platform correlation (9,922 genes 
could be assigned as represented on both platforms, correlations of unfiltered log2-
ratios were r = 0.66 - r = 0.81; data not shown). Evolution of the UniGene database 
(accession numbers that were removed due to misalignment or retraction by their 
submitters; UniGene clusters that were retired as they could be joined or split) and 
the associated loss of cross-references may also explain why we identified less 
genes common to both array types than previously reported by Barczak et al. 173. It 
was also decided against matching by GenBank accession numbers, since 
corresponding probes and probe sets can be annotated by different accession 
numbers of the same UniGene, causing this procedure to exclude large amounts of 
potentially useful information. 
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Considerable variations in the degree of correlation were detected (Fig. 32) when 
comparing unfiltered, log2-transformed expression ratios of individual patients, 
obtained with either GeneChip short oligonucleotide arrays or spotted long 
oligonucleotide arrays,. As reported previously 173,224, these correlations improved 
after the exclusion of probes and probe sets associated with low signal intensities. 
This observation might, at least in part, be attributed to variations in the performance 
of individual array experiments.  
The correlations between expression ratios could further be improved (Table 14) by 
the application of systematic bias adjustment via ‘Distance Weighted Discrimination 
(DWD)’. DWD is an advanced method for the adjustment of various systematic 
differences across microarray experiment subpopulations, including sample source, 
batch and platform effects 178, which facilitates the merging of different data sets. 
DWD uses an approach similar to that of support vector machines (SVM) 225, but 
delivers improved performance in the context of high-dimensional, low sample size 
(HDLSS) data such as those obtained by microarray analyses. Both methods aim at 
finding a hyperplane in high-dimensional space, which separates defined 
subpopulations of data as completely as possible. The essential difference is that, 
while SVM tries to maximize the minimum distance (margin) of all the data to the 
separating plane, DWD works by maximizing the sum of the inverse distances. In this 
way, all data points have an influence on the result (optimized position of the 
hyperplane), and data piling at the margins is avoided, a problem associated with the 
minimum distance criterion of SVM. After determination of the DWD direction vector, 
all data points of each subpopulation are projected onto the direction given by this 
vector. Finally, data points from each subpopulation are shifted in the DWD direction 
by subtracting the DWD direction vector multiplied by their projected means, thereby 
effectively removing systematic variation while preserving any variation in the DWD 
direction not caused by systematic effects. Applied to the data generated in the 
course of this thesis, the DWD approach clearly and consistently improved cross 
platform correlations while shifting the slopes of corresponding regression lines 
towards one (Table 14). The latter effect was minimal in case both data sets had 
been normalized by the same algorithm (vsn), as this procedure not unexpectedly 
yielded slopes closest to one even before DWD. A slope close to one implies that 
genes are more likely to yield similar results (regardless of differential expression) on 
both of the investigated platforms. Further improvements of DWD performance can 
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be anticipated for more extensive data sets, and the method might greatly enhance 
agreement in future comparative studies. 
A goal of this project was to compare reliable measurements from both systems, both 
of which can be regarded as detecting overlapping but different subsets of the actual 
set of differentially expressed genes. This was confirmed by EASE 
overrepresentation analysis 181, which revealed that some of the differentially 
expressed genes could be assigned to the same ‘theme’ on both platforms, whereas 
others were exclusive to one of the platforms (Table 16). On each array system, 
approximately 50 genes were consistently and repeatedly scored as differentially 
expressed, and the intersection of these groups contained 21 common genes 
(Fig. 33a). The majority of genes restricted to one of the platforms showed no 
sufficient degree and/or significance, but at least the same direction of regulated 
expression on the other platform (Fig. 33b). Therefore, it doesn’t matter if a clinical 
study uses Affymetrix or Operon long oligonucleotide arrays, as long as these are 
used consistently and combined with high quality control standards throughout the 
whole investigation.  
For a subset of genes, microarray-derived expression ratios were verified by RQ-
PCR, finding good qualitative agreement between the two array platforms and the 
PCR-based method (Fig. 36).  
It was shown that, overall, expression profiles obtained with either long (Operon) or 
multiple short (Affymetrix) oligonucleotide microarrays display a reasonable 
correlation, with variable concordance of individual genes. Based on patient samples, 
results were obtained that are in good agreement with previous studies utilizing cell 
line-derived RNA. Projecting these findings to a larger series of array experiments, 
one could expect to obtain similar albeit not identical results, concerning, e.g., a 
hierarchical clustering or a gene expression signature, with either of the two 
investigated platforms. On the level of individual genes and quantitative precision, 
however, the results of this study reaffirm that microarrays have to be considered a 
screening technology and that their data should be regarded with caution. This 
should be kept in mind particularly when comparing data from different array 
platforms. Recently, important progress has been made to facilitate this transfer of 
information. Guidelines provided by the ‘Microarray Gene Expression Data Society 
(MGED)’ (http://www.mged.org), which developed the ‘Minimum Information About a 
Microarray Experiment (MIAME)’ specifications 226, assist researchers in the 
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annotation of their microarray experiments. Further improvement is provided by 
public microarray repositories, which facilitate the publication and sharing of properly 
annotated gene expression data. Statistical methods like Distance Weighted 
Discrimination 178 can further improve the comparability of microarray data sets, since 
systematic biases arising from platform-specific parameters, such as measurement 
precision (reproducibility), accuracy (regarding the “true” values), specificity and 
sensitivity or differences in protocol performance, can be properly weighted and 
adjusted accordingly. The utility of future array studies could further improve if the 
‘External RNA Control Consortium (ERCC)’ is successful in its effort to standardize 
controls for the calibration of microarray experiments. But ultimately, meaningful 
comparison, translation and integration of expression data will be impaired as long as 
industrial standards are missing for all stages of the experiment, i.e., the design of 
array probes, the production of the arrays, sample handling, RNA extraction, target 
amplification and target labeling, hybridization, washing, data acquisition, data 
filtering and data normalization. 
 
 
 
4.4 Conclusions 
 
Prediction is very difficult, especially of the future. 
NIELS BOHR 
 
 
In this thesis, a novel procedure (TAcKLE) for the generation of fluorescent, 
antisense-oriented target molecules was successfully conceived, implemented, 
evaluated and employed. It is particularly valuable for applications of spotted 
oligonucleotide microarrays where only limited amounts of RNA source material are 
available. It could be shown that the novel method generates expression profiles of 
exceptional quality and reproducibility. As spotted oligonucleotide arrays are 
becoming increasingly popular and no equally qualified protocols are currently 
available, it is to be expected that the TAcKLE will be widely used in the fields of 
basic biological and biomedical research as well as for biotechnology applications. 
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The protocol has already been used for a large-scale expression profiling study of 
more than 100 primary mamma carcinoma samples obtained by core needle 
biopsies, which could identify a gene expression signature that predicts the patient 
benefit concerning a novel neoadjuvant chemotherapy combining the drugs 
gemcitabine, epirubicine and docetaxel 207. 
As an alternative to target amplification via the TAcKLE protocol, a signal 
amplification method was devised. It uses the principle of rolling circle replication, 
known from the duplication of circular phage genomes or plasmids, to achieve a 
localized amplification of a circular oligonucleotide to enhance the detection of 
hybridization signals. The method is straightforward, cost-efficient and offers the 
compelling theoretical advantage of eliminating sequence-dependent amplification 
bias. Further experimentation will be needed to establish a sufficiently robust 
protocol, but ultimately this new procedure might greatly simplify the way in which 
microarrays are used to assay limited source material. 
Finally, gene expression profiles of HNSCC patients were generated both on spotted 
70-mer oligonucleotide microarrays using the TAcKLE protocol, and on commercial 
microarrays produced by photolithographic in situ synthesis of 25-mer probes 
(Affymetrix). This comparison was particularly important, since spotted 
oligonucleotide arrays had just recently been introduced as an alternative to cDNA 
arrays and the Affymetrix system, which combines attractive advantages from both 
platforms. Like cDNA arrays, spotted oligonucleotide arrays are produced by 
individual research groups, providing a considerable cost advantage. As for the 
Affymetrix platform, their probes are designed to have similar biophysical properties 
and avoid secondary structures as well as repetitive sequences. Additionally, they 
are long enough to allow for a specific analysis via just one probe for each target, 
whereas Affymetrix, due to the reduced specificity of 25-mer sequences, requires 
11 - 16 probes per target. These analyses revealed strong correlations between the 
data sets generated on the platform of spotted 70-mer oligonucleotides and the 
Affymetrix system, and RQ-PCR analysis confirmed the concordance for selected 
genes. There were reproducible differences between the two platforms, though, and 
meaningful comparison and translation of gene expression data will be impaired as 
long as industrial standards are missing for the production and handling of arrays as 
well as for the design of array probes. Both array systems detect overlapping, equally 
large but non-identical subsets of the actual set of differentially expressed genes. 
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Consequently, they are equally qualified for any expression profiling study, as long as 
they are used consistently.  
In conclusion, combining the TAcKLE protocol with spotted oligonucleotide arrays is 
an attractive alterative for transcriptional profiling of limited source material, which 
easily bears comparison with an accepted commercial reference platform.  
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6.1.2 Matching of Oligonucleotide Probe Sequences (alignment.R) 
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6.1.3 Comparison of Operon and Affymetrix GeneChip Data (compare.R) 
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